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ABSTRACT 
The calcium ion (Ca
2+
) is a ubiquitous second messenger that controls intracellular signals that 
trigger various cellular responses including cell proliferation, gene transcription and cell death. 
Intracellular Ca
2+ 
signalling is tightly regulated by the actions of Ca
2+
-transporting proteins 
including Ca
2+ 
channels, Ca
2+ 
exchangers, Ca
2+
-ATPases and their regulators. Evidence suggests 
that deregulation of Ca
2+ 
signalling is associated with several pathophysiological conditions 
including cancer. Altered expression and/or activity of some Ca
2+
 transporters have been 
demonstrated to occur during cancer development and progression. Thus, Ca
2+
 transporters 
represent attractive drug targets for therapeutic intervention.    
    
The work in this thesis is centred on identifying proteins implicated in Ca
2+ 
signalling that represent 
drug targets for breast cancer treatment. This thesis also performed functional assessment of such 
targets in the regulation of Ca
2+
-dependent processes including cell proliferation and cell death in 
breast cancer cells. The first part of this thesis addressed the utility of high throughput siRNA 
screening in combination with high content imaging in a human basal-like breast cancer cell line for 
the identification of potential therapeutic targets which are involved in Ca
2+ 
signalling. Screening of 
an siRNA-based library against Ca
2+ 
signalling modifying proteins revealed 39 possible hits based 
on the pronounced effects on human MDA-MB-231 basal-like breast cancer cells compared to non-
tumorigenic MCF-10A cells. From these hits, eight candidate genes were advanced to target 
validation based on target druggability, plasma membrane localisation and a lack of previous 
assessment in breast cancer cells. These specific selected targets were then assessed in basal breast 
cancer cell lines through the assessment of their mRNA levels and the consequences of their 
silencing and/or pharmacological modulation on Ca
2+ 
signalling, cell viability and cell death. 
 
Of the eight candidate genes, three hits were undetectable by real-time RT-PCR in MDA-MB-231 
cells. CD24 was the first selected candidate gene and was characterised in the human basal-like 
breast cancer cell lines MDA-MB-231 and MDA-MB-468. CD24 mRNA levels were higher (more 
than 800-fold) in MDA-MB-468 compared to MDA-MB-231 cells. Since CD24 has also been 
linked to the chemokine receptor CXCR4 in breast cancer, the functional role of CD24 was 
characterised by examining its effect on CXCL12/CXCR4-mediated Ca
2+ 
signalling. Highly 
metastatic MDA-MB-231 cells displayed more pronounced Ca
2+ 
responses when stimulated with 
CXCL12 (CXCR4 receptor ligand) than poorly metastatic MDA-MB-468 cells. CD24 silencing in 
MDA-MB-468 cells did not alter the nature of ATP-induced Ca
2+ 
transients and did not promote an 
increase in cytosolic free Ca
2+ 
([Ca
2+
]CYT). Real-time RT-PCR showed that CXCR4 expression was 
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higher in MDA-MB-231 than MDA-MB-468 cells. Hence, CXCR4 but not CD24 levels are likely 
responsible for the differences in CXCL12 responsiveness between these two cell lines. CXCR4 
expression was significantly reduced during epidermal growth factor (EGF)-induced epithelial to 
mesenchymal transition (EMT) in MDA-MB-468 cells, indicating that increased CXCR4 is not 
associated with the acquisition of a more mesenchymal phenotype. 
  
This thesis then explored the functional role of another selected target, the Ca
2+ 
permeable ion 
channel TRPV4 in human basal-like breast cancer cells. Real-time RT-PCR analysis revealed that 
TRPV4 was present in both MDA-MB-231 and MDA-MB-468 cells, with higher levels 
(approximately 30-fold) in MDA-MB-468 cells. The functional activity of TRPV4 channels was 
then investigated using a known TRPV4 agonist - GSK1016790A. Consistent with the levels of 
TRPV4 mRNA, TRPV4 activation by GSK1016790A elicited more pronounced increases in 
[Ca
2+
]CYT in MDA-MB-468 compared to MDA-MB-231 cells. GSK1016790A concentration-
response curves revealed a lower EC50 value in MDA-MB-468 cells than MDA-MB-231 cells (3.9 
nM and 76 nM, respectively). Silencing of TRPV4 using siRNA significantly reduced 
GSK1016790A-induced Ca
2+ 
influx in both cell lines, indicating that TRPV4 is a functional Ca
2+ 
entry channel in both MDA-MB-231 and MDA-MB-468 cells.  
 
Pharmacological inhibition of TRPV4 channels using the TRPV4 antagonist, RN 1734 had no 
significant effect on the viable cell number in either MDA-MB-231 or MDA-MB-468 breast cancer 
cells. However, pharmacological activation of TRPV4 channels using GSK1016790A in MDA-
MB-468 cells but not in MDA-MB-231 cells led to a concentration-dependent induction of cell 
death. GSK1016790A-mediated cell death was significantly attenuated in the presence of TRPV4 
siRNA. The mechanism of GSK1016790A-induced cell death in MDA-MB-468 cells was 
independent of caspase, as indicated by the insensitivity to cell death by the caspase inhibitor Z-
VAD-FMK. 
 
The work outlined in this thesis demonstrates the importance of confirmation experiments for 
targets identified by high throughput siRNA screening. These studies have also identified TRPV4 
pharmacological activation as a potential novel mechanism to induce the death of breast cancer cells 
that overexpress this Ca
2+ 
permeable ion channel. 
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CHAPTER 1 : Literature Review 
1.1 Introduction 
The work in this thesis investigates some of the proteins that are involved in Ca
2+ 
signalling which 
may represent potential therapeutic targets for the treatment of breast cancer. This thesis begins 
with a literature review of breast cancer and Ca
2+ 
signalling in mammalian cells. Examples of 
several pathological conditions associated with altered Ca
2+ 
homeostasis are described with an 
emphasis on aberrant expression of Ca
2+ 
signalling-related proteins in different types of tumours 
including breast cancer. The possible use of high throughput small interference RNA (siRNA) 
screening combined with high content imaging as a research tool to identify new therapeutic targets 
for breast cancer therapy is also discussed. The major hypotheses and aims of this PhD thesis are 
outlined at the end of this chapter. 
 
1.1.1 Breast cancer  
World population growth and aging, together with unhealthy lifestyles have markedly increased the 
global burden of cancer (1). Reflective of this is the estimated number of new cancer cases and 
deaths to have occurred in 2012, with 14.1 million cancer cases and 8.2 million cancer deaths 
worldwide (2). Among these cancer cases is breast cancer, which is noted as the most frequent 
cancer among women and accounts for approximately 1.7 million newly diagnosed cancer cases as 
revealed by the International Agency for Research on Cancer (IARC) in 2012 (2). In Australia, 
national statistics have demonstrated that breast cancer is the leading cancer site in females, with a 
total of 13,567 Australian women were diagnosed with breast cancer in 2008 (3). Breast cancer is 
also ranked as the second most common type of cancer-related death after lung cancer in Australian 
women (3). Indeed, breast cancer is a major health problem and conducting research on the 
development of new and effective anti-cancer therapies is of utmost priority. Furthermore, in line 
with this view, the latest world cancer statistics released by IARC also points to the need for putting 
efforts on prevention and control measures for breast cancer (2).  
The breast is made up of lobules (i.e. milk sacks) and ducts (i.e. milk ducts) with surrounding 
structures consisting of fatty and connective tissue (3). Both males and females have breasts, but at 
puberty, the female breast is subjected to profound changes in the morphology and function due to 
hormonal influences (4). Such changes in the female breast are required to perform its primary 
physiological role which is to produce and secrete milk for neonatal needs (4). Breast cancer is 
cancer that originates from the breast tissue when cells in the ducts or lobules undergo abnormal 
and uncontrolled growth (3). Although the cause of breast cancer is unclear (3), a number of risk 
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factors associated with breast cancer have been identified (3,5). These include gender, age, 
geographical variation, family history, cancer-causing lifestyles such as smoking and alcohol 
consumption and others. Known risk factors for breast cancer in women are summarised in Table 
1.1. 
Table ‎1.1: Risk factors for breast cancer. 
Factor High risk group 
Age Elderly 
Geographical location Developed country 
Age at menarche and menopause Early menarche (before age 11) and late menopause (after 
age 54) 
Age at first full pregnancy First child after the age of 35 
Family history of breast cancer on 
either side of the family 
Breast cancer in *first degree or second degree relatives 
when young 
Breast conditions Previous breast disease, such as atypical hyperplasia, 
invasive or pre-invasive breast conditions, dense breast 
tissue 
Diet High intake of saturated fat 
Body weight Being overweight or obese (body mass index > 35) 
increases risk in postmenopausal women 
Alcohol consumption Excessive intake 
Exposure to ionising radiation Abnormal exposure in young females after age 10 
Taking exogenous hormones:  
Oral contraceptives Current use 
Hormone replacement therapy Use for ≥ 10 years 
Diethylstilbestrol Use during pregnancy 
* First degree relatives are parents, children or siblings, and second degree relatives are aunts, 
uncles, grandparents, grandchildren, nieces, nephews or half-siblings. 
Table adapted from references (3,5). 
 
1.1.2 Breast cancer subtypes  
Breast cancer, as described by Sorlie et al (6) is not one disease but rather a heterogeneous disease 
exhibiting distinct molecular subtypes, clinical behaviours and responses to treatments. The use of 
microarray-based gene expression profiling for determining messenger RNA (mRNA) expression 
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levels has enabled gene expression signatures or molecular profiles for breast cancer (6-9). The 
application of this advanced technique has revealed breast cancer molecular subtypes with different 
prognostic outcomes and responsiveness to treatments (6-9). Initial findings by Perou et al (7) 
identified four distinct molecular subtypes, namely normal-like (i.e. breast tumours exhibiting high 
expression of genes characteristic of the basal epithelial cell layer and adipose cells), luminal (i.e. 
breast tumours that are estrogen receptor (ER) positive and can be further divided into two groups: 
luminal A and luminal B (6)), human epidermal growth factor receptor 2 (HER2)-overexpressing 
and basal-like. Subsequent studies using a larger number of breast cancer gene expression datasets 
(6,8) have been able to replicate and validate the previous findings of Perou and colleagues (7). 
Another subtype called the claudin-low has also been recently identified (10), however this subtype 
is still less well-characterised and warrants further research. 
Basal-like breast tumours are associated with the worst clinical outcomes, poor survival, high 
histological grade, high proliferative capacity and aggressive clinical behaviour (11). The basal-like 
subtype is more prevalent among young, premenopausal African American women (11). Gene 
expression profiling performed on a set of 65 tissues of human breast tumours from 42 different 
individuals demonstrated that basal-like breast cancers exhibit high expression of genes 
characteristic of the basal epithelial cell layer, including cytokeratins 5, 6 and 17 (7). Basal-like 
tumours often exhibit low expression of ER, progesterone receptor (PR) and HER2 and therefore, 
most basal breast cancers are triple-negative (ER
-
/PR
-
/HER2
-
) (12). Owing to the lack of expression 
of hormone receptors (ER and PR) and HER2, this particular breast cancer subtype is not eligible 
for hormone-based therapies or HER-2 targeted agents (13). Hence, there is an urgent need to 
develop effective targeted therapies specific for the basal-like subtype. 
 
1.1.3 Breast cancer treatment 
Current treatment modalities available for breast cancer include combinations of surgery and 
postoperative radiation, hormonal therapy, chemotherapy and targeted therapy (14,15). Hormonal 
therapy using tamoxifen, for instance, has long been used to treat women with ER-positive breast 
cancers (16). Results of the International Breast Cancer Study Group Trial 13-93 demonstrated that 
tamoxifen significantly improved treatment outcome in premenopausal patients with ER-positive 
breast tumours (17). Five years of tamoxifen in women with ER-positive breast cancer has been 
reported to decrease the recurrence rate by 39% in the first 10 years and reduce breast cancer 
mortality by about one-third throughout the first 15 years (18). Despite the promising results of 
tamoxifen as a chemopreventive agent in women at high risk of developing breast cancer, the 
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reported adverse side effects associated with the use of tamoxifen appears to reduce patients 
adherence (16).  
HER2-positive breast cancer, which accounts for 25% to 30% of breast cancers (19,20), can be 
therapeutically targeted using a humanised monoclonal antibody directed against HER2 receptor, 
Trastuzumab (21). Trastuzumab in combination with standard chemotherapy decreases the risk of 
death and improves overall survival in women with metastatic breast cancer that overexpressed 
HER2 (21). Lapatinib, a dual tyrosine kinase inhibitor for HER2 and epidermal growth factor 
receptor (EGFR) is another drug for women with HER2-positive advanced breast cancer (22). 
Geyer et al (22) found that a combination of lapatinib and capecitabine - a novel orally administered 
fluoropyrimidine carbamate exhibiting anti-tumor activity (23,24), was superior to capecitabine 
alone in women with HER2-positive advanced breast cancer whose disease progressed on 
trastuzumab. While a number of targeted therapies are available for HER2-enriched breast cancers 
(25), women whose breast cancers are negative for ER, PR, and HER2 receptors (i.e. basal-like or 
triple negative breast cancer) have more limited treatment options and are left without effective 
targeted therapies (13). Hence, much effort is required to improve the specificity and effectiveness 
of treatment strategies to help tailor treatments to specific breast cancer subtypes. This effort may 
involve the identification of alternative drug targets, particularly for the basal-like breast cancer 
subtype. 
Proteins that alter Ca
2+
 signalling may offer new targeted therapy for breast cancer. Evidence 
suggests that some Ca
2+
 signalling-related proteins (such as Ca
2+
 channels and pumps) could 
contribute to the progression of cancer when their expression levels are altered; therefore, these 
proteins are potential drug targets (26,27).  
The next section of this review will provide an overview of Ca
2+
 signalling, Ca
2+
 homeostasis, 
proteins that regulate Ca
2+
 signalling pathways and also the interplay that exists between Ca
2+
  
signalling and cancer.  
 
1.2 Ca
2+
 regulation in cells 
The calcium ion (Ca
2+
) is a highly versatile intracellular signal in the body and modulates a vast 
array of processes (28,29). These Ca
2+
 -modulated processes encompass fertilisation, cell 
proliferation, gene transcription, contraction and secretion, learning and memory, synaptic 
transmission and even cell death via necrosis or apoptosis (28,29). Importantly, these processes are 
all regulated in multiple but specific ways depending on the amplitude, spatial and temporal 
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configuration of the Ca
2+ 
signalling (28,29). It is therefore critical to understand not only how these 
Ca
2+ 
signalling systems work but also how they are maintained and the consequences when these 
systems are disrupted.  
 
1.3 Ca
2+
 homeostasis 
Ca
2+
 is a second messenger that is involved in signal transduction to trigger various cellular 
responses (28,29). Resting cytosolic free Ca
2+ 
([Ca
2+
]CYT) is kept at low levels (approximately 100 
nM) as compared to the extracellular space (approximately 1.2 mM), which creates a concentration 
gradient (~10 000 fold) across the cell membrane (26,29). An increase in this Ca
2+ 
level (roughly 
1000 nM) is able to activate Ca
2+ 
signalling mechanisms and can stimulate a diverse array of 
cellular processes (29).  
Upon stimulation (by means of hormonal stimulation, membrane depolarisation, stretch, 
extracellular agonists, intracellular messengers or other stimuli), Ca
2+ 
-mobilising signals can be 
generated (28-30). The “ON” reactions are activated and Ca2+ is introduced into the cytoplasm 
(either by Ca
2+ 
entry into the cell via specific Ca
2+ 
channels or via Ca
2+ 
release from internal stores 
of Ca
2+ 
such as the endoplasmic/sarcoplasmic reticulum), thereby increasing the concentration of 
Ca
2+ 
in the cells that in turn stimulates many Ca
2+ 
-dependent processes (28-30). The “OFF” 
reactions are accomplished by the actions of various pumps and exchangers that remove Ca
2+ 
from 
the cytoplasm, and thus restore the resting state (28,29). In brief, this mechanism of Ca
2+ 
regulation 
involves many different components that act as functional units. The overall process that occurs in 
the Ca
2+ 
signalling network is simplified in Figure 1.1. 
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Figure ‎1.1: A representative diagram indicating the four functional units of the Ca2+ signalling 
network. Figure adapted from reference (29). 
 
Under normal conditions, intracellular Ca
2+
 levels are tightly regulated to effectively produce 
physiological effects. This Ca
2+ 
homeostatic state is achieved by signalling components recognised 
as the “Ca2+ signalling toolkit”. Some of the signalling components that make up this toolkit 
incorporate several membrane-associated proteins including pumps, channels, exchangers and 
regulators of their activity (28,29).  
The next section in this review will briefly outline some important features of the aforementioned 
membrane-associated proteins and how they functionally correlate with one another to precisely 
control intracellular Ca
2+
 concentration. 
 
1.3.1 Increasing Ca
2+ 
in the cytoplasm: Ca
2+
 channels  
The entry of Ca
2+
 into the cell as a result of an external stimulus or a change in the electrochemical 
gradient across the plasma membrane describes a Ca
2+
 influx event (28). This Ca
2+
 influx is 
facilitated by membrane-bound ion channels, which include the voltage-gated Ca
2+
 channels 
(VGCCs), receptor-operated channels (ROCs) (or ligand-gated channels), second-messenger-
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operated channels (SMOCs), store-operated channels (SOCs) and also the transient receptor 
potential (TRP) ion channel family (28). These channels collectively maintain Ca
2+
 homeostasis, 
and thus regulate Ca
2+ 
-sensitive processes. 
 
1.3.1.1 VGCCs 
As its name implies, VGCCs mediate Ca
2+
 influx upon changes in membrane potential (28,31). 
Mostly expressed in electrically excitable cells such as neurons, muscle and the heart, VGCCs serve 
as the main pathway for Ca
2+
 influx by admitting a small pulse of Ca
2+
, which causes a further 
release of Ca
2+ 
in response to membrane depolarisation (28,32). This mode of action explains an 
important feature of VGCCs that differentiates them from other Ca
2+ 
channels by the ability of 
VGCCs to produce rapid Ca
2+ 
fluxes for controlling fast cellular responses, as in the case of muscle 
contraction and exocytosis at synaptic junctions (28). VGCCs also exert physiological roles in the 
regulation of secretion and gene expression in some cell types (31,33). Biochemical characterisation 
of VGCCs has revealed that these Ca
2+ 
channels are complex proteins consisting of four or five 
different subunits (α1, α2, β, δ and γ), in which the α1 subunit forms the conduction pore (31,33).  
Electrophysiological studies have demonstrated that VGCCs can be classified by the different Ca
2+ 
currents that they mediate, namely the L-, P/Q-, N-, R- and T-type Ca
2+ 
channels (or denoted as 
Cav1.1-1.4 [L-type]; Cav2.1 [P/Q-type]; Cav2.2 [N-type]; Cav2.3 [R-type]; Cav3.1-3.3 [T-type]) 
(31,33). VGCCs are unique in terms of their functional profiles; they can have distinct cellular 
distribution and exhibit specific cellular functions. The reader is directed to the compendium of 
Catterall et al (31), which provides comprehensive information related to the biochemical, 
molecular and genetic properties of VGCCs as well as the physiological functions and 
pharmacological aspects of these voltage-activated Ca
2+ 
channels. Many perturbations that occur in 
the VGCCs (or so-called channelopathies) can have pathological consequences (31,32,34). Indeed, 
channelopathies of VGCCs are associated with various diseases. This topic will be discussed later 
in Section 1.4.3. 
 
1.3.1.2 ROCs/Ligand-gated channels 
ROCs or ligand-gated channels are another class of Ca
2+
 -entry channels that are predominantly 
found in excitable cells (35). The channel-opening mechanism of ROCs involves rapid opening of 
these channels upon direct binding of an extracellular ligand, such as a neurotransmitter or hormone 
(28,29,35). This mode of Ca
2+
 entry can be exemplified by the N-methyl-D-aspartate receptors 
(NMDARs), which are activated by the neurotransmitter glutamate and have been implicated in 
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excitatory synaptic transmission (36). Some members of the transient receptor potential (TRP) ion 
channels superfamily are also ligand-gated Ca
2+ 
channels. An example of this is the non-selective 
cation channel TRPV1 (TRP vanilloid 1), which is stimulated upon binding of capsaicin - an active 
component in ‘hot’ chilli peppers (37). A detailed description of the physiological roles of TRP ion 
channels in facilitating Ca
2+
 influx will be provided in Section 1.3.1.5. 
 
1.3.1.3 SMOCs 
SMOCs are defined as plasma-membrane ion channels that are stimulated upon binding of several 
intracellular small messenger molecules, notably inositol phosphates, cyclic nucleotides (in sensory 
systems) and lipid-derived messengers (such as diacylglycerol and arachidonic acid and its 
metabolites) (28,35). Unlike ROCs, these Ca
2+
 -entry channels are found in some excitable and non-
excitable cells, although they appear to be less widely distributed (35). 
 
1.3.1.4 SOCs 
Store-operated Ca
2+ 
entry (SOCE)
 
(or originally known as capacitative Ca
2+
 entry) serves as the 
principal route for Ca
2+
 influx in response to depletion of intracellular stores in both electrically 
excitable cells (such as neurons) and non-excitable cells (in particular epithelial cells and blood 
cells) (28,35). The term capacitative Ca
2+
 entry can be described as the Ca
2+
 influx stimulated by a 
fall in the Ca
2+
 content of intracellular stores. This Ca
2+
 influx across the plasma membrane 
replenishes empty stores and can result in a sustained increase in the concentration of cytoplasmic 
free Ca
2+ 
(35). This influx itself may control a diverse array of cellular events. SOCs regulate gene 
transcription, exocytosis, the cell cycle and muscle contraction (35). Alterations in SOCs have been 
implicated in a variety of disease states including severe combined immunodeficiency, Alzheimer’s 
disease and acute pancreatitis (35).  
The use of wide-screening RNA interference (RNAi)-based approaches have enabled the 
identification of new proteins necessary for SOCs, namely the stromal interaction molecule 1 
(STIM1) (38), which serves as a Ca
2+
 store sensor that regulates the SOC influx pathway (39) and 
Orai1 (40), which is a plasma-membrane-localised protein and is a critical component of the 
channel pore (41). Orai1 and STIM1 have related isoforms; Orai2 and Orai3 (42-44) and STIM2 
(45), respectively. Although Orai1 and STIM1 have been widely studied as key proteins in 
mediating SOCE, recent studies have begun to explore the functional importance of the other 
related isoforms. For instance, the STIM1 closely-related protein STIM2 has been implicated in the 
regulation of basal endoplasmic reticulum and cytoplasmic Ca
2+ 
concentrations via Orai1 activation 
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(46). Despite very few publications addressing Orai2 compared to Orai1 and Orai3 (47), there is 
recent evidence that Orai2 may function as an endoplasmic reticulum Ca
2+ 
leak channel (48). 
Studies have indicated that Orai3 participates in the proliferation of some cell types including MCF-
7 human breast cancer cells, NCI-H23 and NCI-H460 lung adenocarcinoma cell lines and human 
cervical cancer HeLa cells (49-52). More recently, Orai3 has also been implicated in cardiac 
hypertrophy, where Orai3 interacts with STIM1 in driving constitutive store-independent and store-
operated Ca
2+ 
entries in the adult hypertrophied cardiomyocytes (53).  
 
1.3.1.5 TRP ion channels 
TRP ion channels form a large family consisting of mostly non-selective cation channels that are 
further subdivided into seven subfamilies, namely TRPC (canonical), TRPV (vanilloid), TRPM 
(melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin) and TRPN (54,55). TRP 
subfamilies differ in ion selectivity, activation mechanisms and physiological functions (54). 
Despite these differences, TRP ion channels share a common structural feature referred to as six 
putative transmembrane-spanning domains (TM1-TM6) with a pore-loop linking TM5 and TM6 
and with intracellular carboxy and amino termini (54,55). TRP ion channels have been implicated in 
many cellular functions, such as mediating various sensory modalities (including taste, vision, smell 
and hearing), sensors of heat and pain, modulation of the cell cycle progression and involvement in 
neuronal development and plasticity (54,55). Given the essential roles of TRP ion channels 
particularly in sensory physiology (54), it is therefore not surprising that abnormalities or 
dysfunction in TRP ion channels have been associated with a number of diseases (56). The reader is 
directed to the review of Nilius et al (56), which presents an overview of the involvement of TRP 
ion channels in human diseases including asthma, polycystic kidney disease, hearing loss, thermal 
hyperalgesia and several types of cancers. A better understanding on how TRP ion channels 
contribute to the pathogenesis of human diseases will provide valuable information to facilitate the 
development of new targeted therapies (56). 
 
1.3.2 Restoring‎the‎cell’s‎resting‎state:‎Ca2+ pumps and exchangers 
The recovery process to restore the cell’s resting state occurs under the influence of Ca2+ pumps and 
exchangers such as sarco(endo)plasmic reticulum Ca
2+ 
ATPases (SERCAs), secretory pathway Ca
2+ 
ATPases (SPCAs), plasma membrane Ca
2+ 
ATPases (PMCAs) and Na
+
/Ca
2+
 exchangers (NCXs) 
(28,29). This “OFF” reaction is necessary following the completion of Ca2+ signalling functions and 
involves the removal of Ca
2+ 
from the cytoplasm; this maintains the physiological [Ca
2+
]CYT at low 
concentrations (~100 nM) (28,29). 
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1.3.2.1 SERCAs 
SERCAs are localised to the sarcoplasmic or endoplasmic reticulum membranes and use energy 
derived from the hydrolysis of adenosine-5’-triphosphate (ATP) to actively transport Ca2+ against 
its concentration gradient from the cytosol into the sarco(endo)plasmic reticulum (28,57,58). X-
crystallography has revealed that SERCA has ten putative transmembrane domains and three 
protruding cytoplasmic domains (i.e. the actuator, the phosphorylation and the ATP binding 
domains) (57,59,60). Three basic isoforms of SERCA pumps (SERCA1-3) have been described in 
humans, together with additional splice variants generated from developmental or tissue-specific 
alternative splicing (57-60). SERCA1 is arguably the most studied of all SERCA isoforms and is 
highly expressed in the sarcoplasmic reticulum of fast-twitch skeletal muscle, it is alternatively 
spliced giving rise to two variants: SERCA1a and SERCA1b (58,60). Alternative splicing of the 
SERCA2 gene results in four variants: SERCA2a (predominantly found in cardiac and slow-twitch 
skeletal muscle), SERCA2b (ubiquitously expressed), SERCA2c (first identified in cardiac cells) 
and SERCA2d mRNA (skeletal muscle) (58,60-62). SERCA3 isoforms (SERCA3a-f) are mostly 
expressed in several non-muscle cells including hematopoietic cells, epithelial cells, endothelial 
cells and fibroblasts (58,60). Nevertheless, these SERCA isoforms are highly conserved in their 
primary structure (57,58).  
 
1.3.2.2 SPCAs 
SPCAs are a family of Ca
2+ 
pumps closely related to SERCAs and are usually localised to the Golgi 
(28,60). Two isoforms of the SPCA family have been discovered in the human genome, denoted as 
SPCA1 and SPCA2 with their corresponding genes encoded by ATP2C1 and ATP2C2, respectively 
(28,60). These isoforms exhibit different expression patterns, with SPCA1 being ubiquitously 
expressed (63), while SPCA2 appears to have a more restricted tissue distribution with prominent 
expression in the human brain, testis, gastrointestinal tract, prostate and mammary glands (64,65). 
SPCA is recognised as a critical player in sequestering Ca
2+ 
into the Golgi compartments and 
restoring resting level after cell activation in some cell types (28,60). The essential role of SPCA in 
maintaining the levels of Ca
2+ 
within the Golgi is evident from the effect of mutations in SPCA1, 
which can result in an autosomal dominant skin disorder known as Hailey-Hailey disease 
(28,60,66). This class of Ca
2+ 
pump can also transport manganese ions (Mn
2+
) (67,68). 
 
1.3.2.3 PMCAs 
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PMCAs are a pivotal pump for mediating transmembrane Ca
2+ 
transport and are responsible for the 
active transport of Ca
2+ 
from the cytoplasm to the extracellular space (28,29,59). Structurally, the 
PMCA pump has ten putative transmembrane segments and a protruding cytosolic domain that can 
be divided into four main regions (59). Four basic isoforms of PMCA (PMCA1-4) have been 
identified in mammals and alternative splicing in the primary gene transcripts result in about 30 
splice variants (59). These basic PMCA isoforms display unique expression patterns with PMCA1 
and 4 being widely expressed in animal tissues, whereas PMCA2 and 3 have a more restricted 
tissue distribution (59). Genetic mutations and changes in PMCA isoforms’ expression have been 
connected to several diseases including male infertility, cataracts, cardiac hypertension and 
hypertrophy (69). 
 
1.3.2.4 NCXs 
The NCX is another well-characterised, vital player in maintaining Ca
2+ 
homeostasis by 
transporting one mole of Ca
2+
 in exchange of three moles of sodium (Na
+
), either inward or 
outward,
 
across the plasma membrane depending on the ionic gradients (28,70). NCX is a reversible 
transporter, capable of both extruding and promoting Ca
2+ 
entry. The NCX performs its functions in 
concert with other Ca
2+ 
-selective channels and ATP-driven Ca
2+ 
pumps to carefully fine-tune 
intracellular Ca
2+ 
concentration (70). Three different isoforms of NCX (NCX1-3) have been 
discovered in mammals, which exhibit tissue-specific distribution (28,70). Being the best 
characterised isoform thus far, NCX1 is widely expressed in many tissues including cardiac, 
skeletal and smooth muscles, neurons, kidney and lung. NCX2 and NCX3 on the other hand, are 
only expressed in the brain and skeletal muscle (70). Despite the tissue-specific distribution of the 
NCX isoforms, the functional properties of these three isoforms seem to be very similar (71). 
 
1.3.3 Releasing Ca
2+ 
from internal stores 
The major intracellular Ca
2+ 
store in most cell types is the endoplasmic reticulum or the 
sarcoplasmic reticulum (28,29). These organelles, which possess sophisticated cellular systems, are 
well suited to perform their tasks in releasing Ca
2+ 
from the stores via Ca
2+ 
channels upon 
stimulation by various stimuli (28,29). The key mechanisms responsible for mediating Ca
2+ 
release 
from internal stores include the well-characterised inositol-1,4,5-trisphosphate receptors (IP3Rs) and 
ryanodine receptors (RyRs) (28,29) and also a recently discovered endolysosomal Ca
2+ 
release 
channel, referred to as the two-pore channels (TPCs) (72,73), although this has been the focus of 
recent controversy (74-76). In addition to the aforementioned organelles, mitochondria are also 
intracellular Ca
2+ 
storing organelles implicated in the regulation of Ca
2+ 
signalling (77). The 
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recently identified mitochondrial Ca
2+ 
uniporter (MCU) is discussed at the end of this section 
(78,79). 
 
1.3.3.1 IP3Rs 
Originally purified from rat cerebellum (80), IP3Rs are a family of intracellular Ca
2+ 
release 
channels that are usually located on the endoplasmic reticulum (28,29,81). Named after their 
physiological activator - inositol-1,4,5-trisphosphate (IP3), these Ca
2+ 
-selective cation channels are 
responsible for mobilising Ca
2+ 
from internal stores to participate in a vast array of cellular 
processes including gene transcription, cell proliferation, fluid secretion, contraction and exocytosis 
(81,82). Three isoforms of IP3Rs have been identified in humans, namely the IP3R type 1 (IP3R1), 
IP3R type 2 (IP3R2) and IP3R type 3 (IP3R3) with further diversification as a result of alternative 
splicing and heteroligomerisation among different isoforms (81). Structurally, IP3Rs have been 
shown to assemble in a tetrameric structure of four IP3R molecules, whereby each IP3R protein 
possesses a large cytoplasmic NH2-terminus containing the IP3-binding site, a short COOH-terminal 
region and the predicted six membrane-spanning helices that form the ion-conducting pore of the 
channel (81).  
 
1.3.3.2 RyRs 
RyRs are a family of intracellular Ca
2+
 release channels that are widely expressed in many cell 
types and serve as the principal route for Ca
2+
 release in the sarcoplasmic reticulum of skeletal and 
cardiac muscle cells (28,83). Molecular cloning studies have described three distinct RyR isoforms 
(RyR1-3) encoded by three different genes in mammals that exhibit tissue-specific distribution (83). 
RyR1 is referred to as the skeletal muscle isoform since its expression was first identified in the 
skeletal muscle (84), while the RyR2 gene encodes for the cardiac muscle isoform which is 
expressed in the heart and brain (85). Being the least studied RyR isoform (86), the RyR3 is 
commonly known as the brain isoform and its expression is detected in the brain predominately in 
the corpus striatum, thalamus and hippocampus (87). Various modulators have been found to 
regulate the RyR channel activity; some of these include cytosolic and luminal Ca
2+
, cytosolic ATP, 
redox modifications, calmodulin and calsequestrin (83,86). RyR-mediated Ca
2+ 
release has been 
implicated in cellular events such as striated muscle excitation-contraction coupling, regulation of 
ATP production and the survival of pancreatic β-cells (83,88,89).  
 
1.3.3.3 TPCs 
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TPCs were first identified as new members of the superfamily of voltage-gated Ca
2+
 and Na
+
 ion 
channels based on cloning experiments from rat kidney (72). TPCs appear to share similar 
characteristics with these ion channels except that they possess two homologous domains (i.e. one-
half of the voltage-gated ion channels) comprising two repeats of six transmembrane helices with a 
putative pore in each repeat (72,73). Comparative genomic analysis has discovered three isoforms 
of TPC (TPC1-3) in most animals, with TPC1 and TPC2 being expressed in humans particularly in 
the endosomes and lysosomes, respectively while TPC3 is absent in primates and some rodent 
species (90,91). Although information is still lacking on the physiological significance of TPCs, 
growing evidence suggests that TPCs are a new and ubiquitous class of endolysosomal proteins that 
act as an essential player in mediating Ca
2+
 release from intracellular stores by means of nicotinic 
acid adenine dinucleotide phosphate (NAADP)-mediated Ca
2+
 signalling (73,90,91). However, 
these ion channels are the focus of current controversy. Wang and colleagues (75) recently reported 
that TPC proteins are in fact Na
+
-selective channels activated by phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P2)  when assessed by direct patch-clamp recordings. Another study by Lin-
Moshier et al (76) provided evidence that NAADP may not directly interact with TPCs but bind to 
an accessory protein within a larger TPC complex.  
 
1.3.3.4 MCU 
The MCU was recently discovered as an essential component of the mitochondrial Ca
2+ 
uniporter 
by two independent research groups using innovative strategies through integrative genomics and 
an in silico search of the MitoCarta database (78,79). Functional studies of MCU have revealed that 
it is the channel responsible for the accumulation of Ca
2+ 
in the mitochondrial matrix, since MCU 
silencing in intact and permeabilised cells is associated with reduced mitochondrial Ca
2+ 
uptake 
(78,79) while overexpression of MCU leads to an enhanced matrix Ca
2+ 
concentration (78). Several 
studies have provided evidence for the significance of MCU-mediated mitochondrial Ca
2+ 
uptake in 
some cell types (92-94). Downregulation of the MCU in human colon cancers and cancer-derived 
cells by a cancer-related MCU-targeting microRNA, miR-25, markedly decreases mitochondrial 
Ca
2+ 
uptake and confers resistance to Ca
2+
-dependent apoptosis (95). These findings suggest that 
MCU may be implicated in apoptosis and tumorigenesis; therefore, MCU represents a novel target 
for cancer therapy (95). In the context of breast cancer, MCU expression levels have been shown to 
be upregulated in ER-negative and basal-like breast cancers (96). Curry et al (96) found that MCU 
siRNA-mediated silencing augments ionomycin-initiated cell death in basal-like MDA-MB-231 
breast cancer cells, suggesting that MCU inhibitors may be particularly relevant to sensitise some 
breast cancers to caspase-independent death mechanisms. Recent studies by Hall and co-workers 
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(97) using MDA-MB-231 cells however, have challenged the previous findings by Marchi et al (95) 
who demonstrated the importance of MCU for cell survival in cells derived from cervical, colon and 
prostate cancers. The investigators showed that modulation of MCU activity has minimal effect on 
the survival and sensitivity of MDA-MB-231 cells to therapy-related stresses, indicating that MDA-
MB-231 breast cancer cells may rely on MCU-independent mechanisms for survival. Evidence 
from this study further suggests that targeting MCU may not be relevant for all cancers since not all 
carcinomas may be responsive to MCU modulation (97).      
 
The above text has provided a review of the major components of the “Ca2+ signalling toolkit” that 
are involved in the regulation of Ca
2+ 
signalling. Figure 1.2 depicts some of the aforementioned 
Ca
2+ 
channels, pumps and exchangers that contribute to the strict regulation of Ca
2+ 
homeostasis in 
the cells.  
 
Figure ‎1.2: A schematic diagram illustrating a variety of Ca2+ signalling components that form an 
extensive Ca
2+ 
signalling toolkit to regulate diverse cellular processes. (NCX, Na
+
/Ca
2+
 exchangers; 
PMCA, plasma membrane Ca
2+ 
ATPase; TRP, transient receptor potential; ORAI, an example of 
store-operated Ca
2+ 
channel; IP3R, inositol-1,4,5-trisphosphate receptors; RyR, ryanodine receptors; 
SERCA, sarco(endo)plasmic reticulum Ca
2+ 
ATPase; SPCA, secretory pathway Ca
2+ 
ATPase; TPC, 
two-pore channels. Figure adapted from reference (98). 
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1.3.4 Localised Ca
2+ 
signalling 
In addition to the extensive “Ca2+ signalling toolkit”, the versatility of Ca2+ signalling is also 
attributed to its different spatial and temporal properties (28). One such example is local (or 
spatially-restricted) Ca
2+
 signals which can include Ca
2+
 microdomains at the mouth of channels, 
these local Ca
2+ 
signal events can activate specific downstream targets prior to diffusion into the 
cytoplasm. These local Ca
2+
 signals can be generated by the release of Ca
2+
 from the internal stores 
and also Ca
2+
 entry channels of the plasma membrane (99). Advancement in imaging techniques 
has allowed the visualisation of several types of local Ca
2+
 signals including Ca
2+
 sparks in cardiac 
muscle generated by RyRs in clusters and Ca
2+
 puffs which involve IP3Rs (28,99). Local Ca
2+
 
signals have been implicated in various physiological functions such as the control of 
neurotransmitter release in the pre-synaptic nerve terminals and neuroendocrine cells, activation of 
neuronal growth and gene expression (99,100). Recent evidence has now highlighted the 
importance of assessing local Ca
2+ 
signalling in tumorigenesis (101).  
 
1.3.5 Other proteins implicated in Ca
2+ 
signalling 
There are also many other proteins that play crucial roles in regulating Ca
2+
 signalling. An example 
is the cell surface protein known as the MS4A12 - a sequence homologue of CD20, which has been 
identified as a novel component of a SOC entry mechanism in intestinal cells (102). A genome-
wide data mining approach in combination with functional assays was used to identify targets for 
colon cancer therapy (102). Functional characterisation of MS4A12 demonstrated its importance in 
EGFR signalling (i.e. the major tumour-promoting factor in colon cancer). This further highlights 
the potential therapeutic implication of this recently discovered protein as a new antibody-based 
drug target (102).     
A protein encoded by the gene CCN3 (also termed Cyr61: Cystein rich 61; CTGF: Connective 
tissue growth factor; NOV: Nephroblastoma overexpressed gene; WISP-1, 2 and 3: Wnt-1 induced 
secreted proteins) is a member of the CCN family (CCN1-6) which has been shown to participate in 
many cellular processes including proliferation, differentiation, survival, adhesion and migration 
(103). Although previously recognised as a matricellular protein, CCN3 has now been suggested as 
an adaptive protein that forms multiple physical interactions with different regulatory proteins that 
associate with Ca
2+
 signalling. These regulatory proteins include the calcium-binding extracellular 
matrix glycoprotein fibulin-1C, integrins, transmembrane receptor Notch and calcium binding 
protein S100A4; all of which are dependent upon Ca
2+ 
binding. These findings provide evidence of 
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a link between CCN proteins and Ca
2+
 signalling and that CCN3 regulates intracellular Ca
2+ 
levels 
(103). 
Another example of a protein important in Ca
2+ 
signalling is the scaffold protein AHNAK1, which 
has been demonstrated to be a novel key player in mediating T cell Ca
2+ 
signalling via the L-type 
Ca
2+ 
channels (Cav1.1 channels) (104). AHNAK1 is abundantly expressed by CD4
 
T cells and is 
essential for Ca
2+ 
influx after T cell antigen receptor stimulation to subsequently allow activation 
and proliferation of T cells (104).  
The above examples demonstrate that regulators of Ca
2+ 
signalling go beyond Ca
2+ 
channels and 
pumps. Many of these may play a role in disease states. Indeed, alterations in Ca
2+ 
-dependent 
homeostatic mechanisms have been associated with a growing number of diseases. Therefore, the 
ensuing section of this review will discuss some of the pathological implications of dysregulated 
Ca
2+
 homeostasis. 
 
1.4 Ca
2+
 Dyshomeostasis in disease 
As discussed in Section 1.3, the balance between the “ON” and “OFF” reactions describes Ca2+ 
homeostasis, which serves as an important feature of Ca
2+
 signalling (28). It is imperative for cells 
to keep the Ca
2+
 concentration levels within the normal range by utilising a variety of mechanisms 
to allow for efficient Ca
2+
 -dependent activities in various cell types. The physiological importance 
of the tight regulation of cellular Ca
2+ 
level is highlighted by a plethora of diseases that can occur 
when Ca
2+ 
homeostasis is disrupted. Some of these include heart failure, neurodegenerative 
disorders, channelopathies and also cancers (26,28,34,105). The following sections will discuss 
selected diseases, with the aim of introducing the reader to three different examples of 
pathophysiological conditions associated with disturbed Ca
2+
 homeostasis. The involvement of 
altered Ca
2+
 signalling in cancer and specifically breast cancer will be described in further detail in 
Sections 1.5 and 1.6, respectively. 
 
1.4.1 Heart failure  
The key role of Ca
2+
 signalling in cardiac cells is to attain a synchronised cellular depolarisation and 
movement of intracellular Ca
2+ 
around the cells to activate contractile proteins through a mechanism 
known as the excitation-contraction (EC) coupling (106). Cellular Ca
2+
 mishandling as a result of 
abnormalities of the various components involved in the EC coupling, is the main causative factor 
for contractile dysfunction in heart failure (106,107). These abnormalities could be attributed to 
altered functional expression and/or activity of the aforementioned Ca
2+
 handling proteins, which in 
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turn could result in perturbed Ca
2+
 transients, contractility and arrhythmias in the failing heart (107). 
For example, upregulation of NCX at both the mRNA and protein levels has been reported in end-
stage heart failure, affecting the electrical stability of heart tissue and thereby leading to arrhythmias 
(105); enhanced phosphorylation of RyRs leads to increased sarcoplasmic reticulum Ca
2+ 
leak (107) 
and a functional decline in the activity of SERCA pumps contributes to depressed sarcoplasmic 
reticulum load, which further decreases Ca
2+ 
transient generation and contractile function in heart 
failure (106,107). 
 
1.4.2 Neurodegenerative disorders  
Various types of Ca
2+ 
channels comprising the VGCCs, SMOCs, ligand-gated channels, NMDARs, 
TRP channels as well as the intracellular Ca
2+ 
release channels IP3R and RyR are found in neuronal 
cells (105,108). The deregulation of neuronal Ca
2+ 
homeostasis has been linked to the progression 
of neurodegenerative disorders such as Alzheimer’s disease (AD) (105,108). The main 
characterising features of AD include progressive neuronal death, synaptic degeneration, 
extracellular deposition of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles 
consisting of the hyperphosphorylated forms of the tau protein resulting in memory loss and 
impaired cognitive abilities (109). Although most focus has been directed towards the Aβ and 
hyperphosphorylated tau hypotheses as the main inducers of AD (110), it has been recognised that 
perturbed Ca
2+ 
homeostasis could also be responsible for the disease processes of AD (108-110). 
Khachaturian (111) was the first to propose the Ca
2+ 
hypothesis of AD and brain aging, implicating 
cellular mechanisms for the maintenance of Ca
2+ 
homeostasis in aging and that sustained 
disturbances in Ca
2+ 
homeostasis could cause neuropathological changes associated with AD. 
Considering the critical role of Aβ as a mediator of neuronal degeneration and impaired cognitive 
function in AD (108), Aβ can severely induce neuronal Ca2+ dysregulation via several mechanisms: 
i) Aβ destabilises neuronal Ca2+ homeostasis and increases the vulnerability of neurons to 
excitotoxicity and apoptosis (108,112); ii) Aβ itself forms Ca2+ channels when inserted into bilayer 
membranes, and thus promotes Ca
2+ 
influx into the neurons (110,113); and iii) Aβ aggregation can 
induce oxidative stress by forming free radicals that impair the function of membrane ion and 
glutamate transporters as well as alter mitochondrial function, resulting in neurodegeneration in AD 
brain (109,114). Interested readers are directed to other reviews and the references therein that 
highlight the involvement of Ca
2+ 
in the pathogenesis of AD and possible therapeutic interventions 
for the treatment of AD by exploiting Ca
2+ 
regulation (108,110,115,116). 
 
18 
 
1.4.3 Channelopathies 
Channelopathies are defined as a class of diseases that arise from defective ion channel functions, 
regulation or expression as a result of genetic mutations in genes coding for ion channel subunits or 
their regulatory proteins (117). These channelopathies could be attributed to loss-of-function or 
gain-of-function mutations of the channels (34,56). There is compelling evidence indicating that 
genetic mutations in the VGCCs can influence a broad range of mammalian developmental, 
physiological and behavioural functions (118). Of the ten distinct genes encoding mammalian α1 
subunits (31), five have been linked to several human channelopathies (118). For instance, 
mutations in the CACNA1A gene encoding the P/Q-type Ca
2+ channel α1 subunit (Cav2.1) have been 
associated with three human neurological disorders known as familial hemiplegic migraine, 
episodic ataxia type 2 and spinocerebellar ataxia type 6 (31,118). Given the importance of the L-
type Ca
2+ 
channels (Cav1.1) in the EC coupling in the skeletal muscle (119), two muscle disorders 
known as hypokalemic periodic paralysis and malignant hyperthermia susceptibility have been 
linked to mutations in the CACNA1S gene encoding the Cav1.1 channels (31,118). Mutations in the 
CACNA1H gene (Cav3.2) have been identified to cause childhood absence epilepsy in a Chinese 
population, implicating CACNA1H as a susceptibility gene for absence epilepsy (120). Table 1.2 
provides a summary of the currently known human channelopathies associated with some subtypes 
of the VGCCs. 
 
Table ‎1.2: VGCCs and their associated human channelopathies. 
Channel 
name 
Channel 
subtype 
Gene 
name 
Channelopathy 
L-type 
Cav1.1 CACNA1S 
Hypokalemic periodic paralysis, malignant 
hyperthermia susceptibility 
Cav1.2 CACNA1C Timothy Syndrome 
Cav1.4 CACNA1F 
Incomplete X-linked congenital stationary night 
blindness type 2, X-linked cone-rod dystrophy 
P/Q-type Cav2.1 CACNA1A 
Familial hemiplegic migraine type 1, episodic ataxia 
type 2, spinocerebellar ataxia type 6 
T-type Cav3.2 CACNA1H 
Childhood absence epilepsy, idiopathic generalised 
epilepsy, autism spectrum disorders 
Table adapted from references (31,118). 
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In addition to the diseases associated with the channelopathies of VGCCs, mutations in the 
intracellular Ca
2+ 
release channels have also been reported. Mutations of the gene encoding the 
cardiac isoform RyR2 leads to the development of cardiac arrhythmias, while mutations in the 
skeletal muscle isoform RyR1 are associated with malignant hyperthermia and a rare neuromuscular 
disorder known as central core disease (121). Several hereditary diseases resulting from defective 
TRP channels have also been documented, where mutation in the TRP channel-encoding gene is the 
direct cause for the development of the disease (56,122). Some of the currently known TRP-related 
channelopathies are listed in Table 1.3.  
 
Table ‎1.3: Human diseases related to TRP channelopathies. 
Channel Channelopathy 
Chromosomal location 
(human) 
TRPC6 Focal segmental glomerulosclerosis 11q21-22 
TRPV4 
Brachyolmia type 3 12q24.1 
Spondylometaphyseal dysplasia, 
Kozlowski type 
12q24 
Autosomal dominant metatropic 
dysplasia 
12q24.1 
Congenital distal spinal muscular 
atrophy 
12q24 
Scapuloperoneal hereditary motor 
neuropathy 
12q24 
Charcot–Marie–Tooth disease type 2C 12q24 
TRPM1 
Autosomal recessive congenital 
stationary night blindness 
15q13-q14 
TRPM2 
Guamanian amyotrophic lateral 
sclerosis/parkinsonism dementia 
complex 
21q22.3 
TRPM4 
Progressive familial heart block type 
IB 
19q13.32 
TRPM6 
Hypomagnesemia with secondary 
hypocalcemia 
9q21.13 
TRPM7 
Guamanian amyotrophic lateral 
sclerosis/parkinsonism dementia 
15q21.2 
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complex 
TRPML1 (Mucolipin 1, 
MLN1) 
Mucolipidosis type IV 19p13.3-13.2 
TRPP2 
Autosomal dominant polycystic 
kidney disease 
4q21-23 
Table adapted from references (56,122). 
The above examples provide substantial evidence that impairment of ion channel functions or 
channelopathies are associated with a variety of human disease states. Readers are encouraged to 
consult reviews describing the properties of diverse ion channels and how mutations can 
specifically alter function and result in disease (34,117). 
 
1.5 Ca
2+
 signalling in cancer 
As outlined in Section 1.3, an extensive “Ca2+ signalling toolkit” is involved in regulating Ca2+ 
homeostasis and signalling (28,29). Ca
2+
 signalling can be deficient if changes occur in any of these 
signalling components, thereby resulting in a variety of pathological conditions. In addition to the 
catalogue of human diseases delineated in Section 1.4, Ca
2+
 signalling is also deregulated in various 
cancers (26,123-125). The involvement of Ca
2+
 signalling in carcinogenesis may occur during the 
various stages of cancer development and progression such as malignant transformation of normal 
cells into cancer cells, tumour formation and growth, invasion, migration, angiogenesis and 
metastasis (124-128). A recent review by Hanahan and Weinberg (129) provides an update on the 
six key pathophysiological properties of cancer cells formerly proposed by the same authors a 
decade ago: i) self-sufficiency in growth signals, ii) insensitivity to growth-inhibitory signals, iii) 
resistance towards apoptosis, iv) infinite ability to replicate, v) sustained angiogenesis and vi) tissue 
invasion and metastasis (130). Having appreciated these hallmarks of cancer (129,130), Ca
2+ 
signalling has been implicated in many of these aforementioned signalling processes. For more 
information on the role of Ca
2+ 
signalling in the regulation of cancer-related signalling events, 
readers are referred to appropriate reviews (101,123,131,132). 
Some members of the TRP ion channel family, notably TRPCs, TRPMs and TRPVs appear to play 
significant roles in cancer (133-135). A growing number of studies have assessed the consequences 
of altered TRP ion channels expression levels in proliferation, differentiation, apoptosis, 
angiogenesis, migration and invasion (133-135). The role of TRPM8 in carcinogenesis has been 
well-described (56,133,135,136). First cloned from the human prostate, the TRPM8 cation channel 
is markedly upregulated in prostate cancer and is also expressed in several non-prostatic primary 
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human tumours including those of the breast, colon, lung and skin (137). Results from 
pharmacological activation of TRPM8 and siRNA targeted to TRPM8 suggest that TRPM8-
mediated Ca
2+ 
influx is required for cell survival in androgen-responsive LNCaP prostate cancer 
cells (138). In contrast, studies using androgen-independent prostate cancer PC-3 cells found that 
TRPM8 is not essential for PC-3 cell survival, but rather TRPM8 overexpression results in the 
inhibition of cell proliferation and migration (139).  
The important roles of TRPC6 Ca
2+ 
channels in several types of cancer have also been documented 
(140-145). For example, Shi et al (144) demonstrated that TRPC6 is highly expressed in human 
oesophageal squamous cell carcinoma (OSCC) specimens relative to normal tissues. Further 
functional investigations on the possible role of TRPC6 in OSCC revealed that TRPC6-mediated 
Ca
2+ 
influx is essential for G2/M phase transition and proliferation of human OSCC cells, 
highlighting the potential of targeting TRPC6 for the treatment of OSCC (144). Similar 
observations were made by Zhang and colleagues (140); they reported overexpression of TRPC6 in 
OSCC patients compared to normal tissue. The researchers provided further evidence that 
overexpression of TRPC6 mRNA was associated with poor prognosis in OSCC patients and hence, 
TRPC6 could represent a prospective prognostic biomarker in advanced stage of OSCC (140).     
Since the expression of some members of the TRP ion channels are altered in various cancers, the 
therapeutic potential of TRP ion channels as targets in the treatment of cancers has been highlighted 
(146). The advancement of technology, together with a better understanding of TRP physiology 
holds the promise of identifying alternative therapeutic options for cancer patients.  
Several other Ca
2+ 
pumps and channels (collectively termed as Ca
2+ 
transporters) have been reported 
to exhibit aberrant expression and/or activity in distinct types of cancer, which underlie changes in 
the Ca
2+ 
signalling pathways (26,101). For instance, SERCA3 is markedly downregulated in colon 
cancer (147,148). Isoform-specific upregulation of PMCA has been suggested to significantly 
contribute to the differentiation of colon and gastric cancer cells (149). Readers can find an 
extensive review by Monteith et al (26) and the references therein for more information on altered 
expression and/or activity of classic Ca
2+ 
transporters that are associated with numerous cancers 
(compiled in Table 1.4) and how to exploit these Ca
2+ 
transporters as possible drug targets in 
cancer. The feasibility of many Ca
2+
 transporters to be pharmacologically-modulated offers great 
avenues in the field of therapeutics for cancer (26). In particular, these Ca
2+ 
transporters may be 
targets for some breast cancer subtypes, which is the focus of this PhD thesis and is discussed in 
Section 1.6.  
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Table ‎1.4: Ca
2+ 
pumps and channels displaying aberrant expression in tumours and cancer cell 
lines. 
Channel or 
Pump 
Cancer type investigated 
Changes in 
expression in cancer Refs 
mRNA Protein 
Store-release channels 
IP3R1 Glioblastoma: PTS ↓ ND (150) 
IP3R2 Non-small-cell lung cancer: PTS ↑ ND (151) 
IP3R3 
Gastric cancer: PTS (mRNA only), gastric 
cancer cell lines (malignant ascites derived) 
↑ ↑ (152) 
Glioblastoma: PTS ↑ ND (150) 
Colorectal cancer: PTS ND ↑ (153) 
RyR1 Thyoma: PTS ↓ ND (154) 
Voltage-gated Ca
2+
 channels 
Cav1.2 (L-
type α1C) 
Colon cancer: PTS and cell lines ↑ ND (155) 
Cav1.1 (L-
type Ca
2+
 
channel, 
exons 41 and 
41A) 
Colorectal cancer: PTS and cell lines ↑ ND (156) 
Cav2.3 (R-
type α1E 
Wilms’ tumor: PTS ↑ ND (157) 
Cav3.1 (T-
type α1G) 
Glioma: PTS and cell lines ↑ ND (158) 
Colorectal cancer, colorectal adenoma, gastric 
cancer and acute myeloid leukaemia: PTS and 
cancer cell lines (colon, breast, prostate, lung 
and haematopoietic) 
↓ ND (159) 
Cav3.2 (T-
type α1H) 
Prostate cancer: PTS ↔ ↑ (160,161) 
Cav3.3 (T-
type α1I) 
Colon carcinomas and adenomas: PTS and 
cell lines 
↓ ND (162) 
CACNA2D2 
(regulatory 
subunit of 
voltage-gated 
Lung cancer (non-small cell and small cell): 
PTS and cell lines 
↓ ND (163) 
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channels) 
Transient receptor potential channels 
TRPA1 Fibroblasts and mesenchymal tumor cell lines 
↓ (except 
liposarcoma 
cells) 
ND (164) 
 
TRPM7 
 
 
Breast cancer: PTS ↑ ↑ (165) 
Pancreatic cancer: PTS ↑ ↑ (166) 
TRPM8 
Prostate cancer: PTS ↑ ND (137,167,168) 
Breast cancer, melanoma, colorectal 
adenocarcinoma and lung cancer: PTS 
↑ ND (137) 
Pancreatic cancer: cell lines (mRNA) and 
PTS (protein) 
↑ ↑ (169) 
TRPM1 Melanoma: PTS and cell lines ↓ ND (170,171) 
TRPM2 Prostate cancer: PTS and cell lines ↑ ↑ (172) 
TRPV1 
Bladder cancer (transitional cell carcinoma): 
PTS 
ND ↓ (173) 
Glioma: PTS ↑ ↑ (174) 
Squamous cell carcinoma (tongue) ND ↑ (175) 
Prostate cancer: PTS ↑ ↑ (176) 
TRPV2 
Urothelial carcinoma: PTS ↑ ↑ (177) 
Glioma: PTS, primary cell lines and the 
U87MG cell line 
↓ ↓ (178) 
TRPV6 
Prostate cancer: PTS ↑ ↑ (179,180) 
Breast, ovarian, thyroid, colon cancer: PTS ND ↑ (179) 
Breast cancer: PTS ↑ ↑ (165,179,181) 
TRPC1 
Liver cancer: PTS ↑ ND (145) 
Breast cancer: PTS ↑ ↑ (165) 
TRPC3 
Breast cancer: PTS ↑ ND (182) 
Ovarian cancer: PTS ND ↑ (183) 
TRPC4 
Liver cancer: PTS ↑ ND (145) 
Renal cell carcinoma cell line (P769 cells) 
compared to human renal epithelial cell line 
(HNK) 
↓ ND (184) 
TRPC6 
Haematopoietic transformed mastocyte cell 
line 
↓ ND (185) 
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Breast cancer: PTS and cell lines ↑ ↑ (165,182,186) 
Prostate cancer: PTS and cell lines ND ↑ (143) 
Gastric cancer: PTS ND ↑ (142) 
Liver cancer: PTS ↑ ↑ (145) 
Oesophageal cancer: PTS ↑ ↑ (144) 
Store-operated Ca
2+ 
channels 
ORAI1 Breast cancer: cell lines ↑ ↔ (187,188) 
ORAI3 
Breast cancer: cell lines and PTS ↑, ↔ ↑ (49,187,188) 
Non-small cell lung cancer: PTS and cell lines ↑ ↑ (51) 
Plasma membrane Ca
2+ 
ATPase (PMCA) pumps 
PMCA Skin and lung: SV40 transformed fibroblasts ND ↓ (189) 
PMCA1 
Oral cancer: squamous cell carcinoma, PTS 
and cell lines 
↓ ↓ (190) 
Skin: SV40 transformed fibroblasts ↓ ND (189) 
Breast cancer: cell lines ↑ ND (191) 
PMCA2 
Breast cancer: cell lines (mRNA only) and 
PTS 
↑ ↑ (192,193) 
PMCA4 
Skin: SV40 transformed fibroblasts ↓ ND (189) 
Colon cancer: PTS ↓ ND (194) 
Sarco(endo)plasmic reticulum Ca
2+ 
ATPase (SERCA) pumps 
SERCA2 
Oral cancer: squamous cell carcinoma, PTS 
and cell lines 
↓ ↓ (195) 
Colon and lung cancer: PTS ↓ ND (196) 
Colorectal cancer: PTS ↑ ND (197) 
Thyroid cancer: cell lines ↓ ↓ (198) 
SERCA3 
Colon cancer: PTS and cell lines ND ↓ (147,148) 
Breast cancer: PTS ND ↓ (199) 
Secretory pathway Ca
2+ 
ATPase (SPCA) pumps 
SPCA1 
Cervical carcinoma: squamous cell carcinoma 
↑ in cervical carcinomas 
compared to normal 
epithelial tissue 
(200) 
Breast cancer: basal-like breast cancer cell 
lines and clinical samples 
↑ ND (201) 
SPCA2 Breast cancer: cell lines and PTS ↑ 
↑ in 
MCF-7 
relative 
to MCF-
(202) 
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10A 
PTS = patient tissue samples; ND = not determined; ↑ = upregulation; ↓ = downregulation; ↔ = no 
significant difference. 
Table adapted, with updated data from reference (26). 
 
1.6 Ca
2+
 signalling in breast cancer 
It is clear that Ca
2+ 
homeostasis may have cellular and physiological significance in modulating 
breast epithelial cell proliferation, differentiation and apoptosis during breast development (98). 
Readers are directed to a comprehensive review by Lee et al (98) that presents evidence for the 
contribution of Ca
2+ 
transport and signalling in the mammary gland physiology such as the PMCA 
isoforms, which are not only responsible for maintaining a low resting [Ca
2+
]CYT but these pumps 
also play other possible roles in the breast; the secretion of Ca
2+ 
into milk, the control of cell 
proliferation, differentiation and apoptosis. These authors also discuss the potential implication of 
deregulated Ca
2+ 
homeostasis and signalling in the mammary gland pathophysiology with a primary 
focus on breast cancer (98). Given the essential roles of Ca
2+ 
transporters in controlling Ca
2+ 
homeostasis, deregulation of Ca
2+ 
homeostasis as a result of altered expression of some Ca
2+ 
transporters has been assessed in breast cancer cells (98,191,192).  
Using a panel of breast cancer cell lines, Lee et al (191,192) revealed aberrant expression of PMCA 
isoforms when compared with a normal human breast epithelial cell line. The team showed a 
significant increase in relative PMCA1 mRNA expression in MCF-7 and MDA-MB-231 cells 
compared to normal MCF-10A cells (191). They also reported the upregulation of PMCA2 in some 
breast cancer cell lines with ZR-75-1 breast cancer cell lines showing the highest PMCA2 mRNA 
expression levels (i.e. more than 100-fold) compared to non-tumorigenic 184B5 cells (192). These 
same studies also found a modest downregulation of PMCA4 in breast cancer cell lines relative to 
the 184B5 non-tumorigenic cell line (192). Another study by this team employed anti-sense 
mediated inhibition of PMCA in an ER-positive breast cancer cell line, MCF-7 (203). Reduced 
PMCA expression was associated with changes in cell morphology and profound suppression of 
MCF-7 cell proliferation which involved changes in cell cycle kinetics (203). For this reason, it has 
been deduced that PMCA modulation could have important consequences in regulating the 
proliferation of MCF-7 cells (203). Another Ca
2+ 
pump, SPCA2, is upregulated in luminal-like 
breast cancer cell lines (202). There appears to be a physical interaction between SPCA2 and Orai1 
and a role for this pathway in breast cancer cell tumourigenicity (202).   
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A recent study by Faouzi and colleagues (49) observed overexpression of Orai3 in breast cancer 
tissues and MCF-7 cells in comparison to the normal MCF-10A mammary epithelial cell line. Orai3 
siRNA-mediated knockdown in MCF-7 attenuates cell proliferation in a Ca
2+ 
-dependent manner 
and arrests cell cycle progression at G1 phase (49). This team has also found that downregulating 
Orai3 expression significantly reduces the viability of MCF-7 cells which occurs via apoptotic 
signalling pathways (49). The team concluded that Orai3 plays key roles in regulating cell cycle, 
proliferation and promoting apoptotic resistance in breast cancer cells (49). Subsequent to these 
recently discovered roles of Orai3 in MCF-7 breast cancer cells (49), further work by Faouzi et al 
(50) have provided mechanistic insights into the downstream signalling pathways linking Orai3 
channels to MCF-7 breast cancer cell proliferation, cell cycle progression and survival. The 
researchers demonstrated positive correlation between Orai3 and proto-oncogene c-myc expression 
in breast cancer cells, together with the functional consequences of Orai3 silencing on cell 
proliferation and cell cycle progression in MCF-7 cells (50). 
The involvement of TRP ion channels in breast cancer is also increasingly recognised. Using a 
combination of electrophysiology, molecular and immunohistochemical approaches, Guilbert and 
co-workers (186) found that TRPC6 expression level is functional and significantly elevated in 
breast cancer epithelial cells compared to normal breast tissue. However, there is no correlation 
between TRPC6 levels with tumour grade, ER status and lymph node metastasis (186). A 
subsequent study has also provided evidence for TRPM7 overexpression particularly in high grade 
breast cancer samples (204). Assessments of the functional effects of siRNA-mediated knockdown 
of TRPM7 in MCF-7 cells revealed a reduction in both cell proliferation and intracellular Ca
2+ 
concentration, indicative of a role for TRPM7 in contributing to the proliferative potentiality of 
breast cancer cells (204).  
The increased expression of TRPV6 channels in breast cancer has also been described. Initial 
studies by Zhuang et al (179) showed that TRPV6 (also known as CaT1) expression was 
upregulated in a panel of epithelial tumours including the breast. Subsequent studies by Bolanz and 
colleagues (181) also demonstrated significant upregulation of TRPV6 mRNA expression in breast 
cancer patient samples in comparison to the normal mammary tissue. Using T47D breast cancer cell 
line as a model, the authors found that TRPV6 transcription can be regulated by estrogen, 
progesterone, tamoxifen and 1α,25-dihydroxyvitamin D3. Treatment with TRPV6 siRNA appeared 
to reduce the proliferation rate and calcium uptake in T47D cells, indicating that TRPV6 is 
implicated for the proliferation of breast cancer cells (181). In addition, TRPV6 silencing has also 
been shown to inhibit migration and invasion of MDA-MB-231 breast cancer cells, as well as 
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MCF-7 migration (165). Recent work on TRPV6 has suggested that TRPV6 inhibitors may be 
particularly relevant for treating ER-negative breast cancers, since this cancer type is associated 
with overexpression of TRPV6 channels (205).     
This literature review has provided several examples of Ca
2+ 
transporters with abnormal expression 
levels in breast cancer. Most studies on Ca
2+ 
transporters have focused on altered expression to 
identify new targets for some cancers. However, the functional activity of these Ca
2+ 
transporters in 
breast cancer has not been fully investigated (26). This area of research needs to be addressed since 
the activity of Ca
2+ 
transporters may be altered in the absence of altered expression. Cancer cells 
could remodel or deregulate their Ca
2+ 
signalling via altered localisation of Ca
2+ 
channels as 
exemplified by TRPM8 Ca
2+ 
channel (i.e. plasma membrane versus endoplasmic reticulum 
localisation) (206,207) and mutations in the genes associated with Ca
2+ 
signalling components such 
as SERCA2 (196); however, these aspects are still poorly studied (26,123). Unbiased studies 
assessing specific functional roles of other Ca
2+ 
signalling modifying proteins in breast cancer 
tumourigenesis may help identify new drug targets. This could be achieved using innovative and 
advanced functional studies involving the use of high throughput techniques. This aspect will be 
discussed next. 
 
1.7 Approaches for developing drug targets for breast cancer 
Most research in the field of Ca
2+
 transporters makes use of the overexpression of Ca
2+
 transporters 
to identify therapeutic targets (138,180,192,203). However, there are other options available to 
identify new and novel drug targets for breast cancer therapy. One alternative approach is to employ 
a combination of siRNA screening from a library with high content screening (HCS) and/or high 
throughput screening (HTS). The successful application of siRNA screening coupled with HCS is 
exemplified in a study conducted by Moffat et al (208) whereby lentiviral short hairpin RNA 
(shRNA) libraries were used to help identify key regulators of mitotic progression and proliferation 
in human cancer cells. Moreover, the vital role of STIM1 in Ca
2+ 
signalling was only recognised 
through the use of RNAi-based screening together with several Ca
2+ 
influx assays (38). These 
studies point to the appropriateness of implementing these research tools in pursuit of target 
identification. The next section will briefly discuss some basic theories and applications of the 
aforementioned advanced techniques and relate them to breast cancer research. 
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1.7.1 siRNA screening 
siRNA screening is a robust research method to help identify and validate potential targets based on 
gene function assessment and has been used in functional genomics and drug discovery (209). 
siRNA screening exploits the natural endogenous RNAi pathway by introducing short double-
stranded RNA, otherwise known as siRNA (i.e. 20-23 nucleotides in length), which are potent 
mediators of RNAi to specifically target mRNAs for degradation and hence, silencing their 
expression (210-212). 
High throughput siRNA screening is certainly a powerful experimental method despite the 
complexities that arise from its implementation (such as the need for laboratory automation, 
computing infrastructure, stringent quality control, methods of data analysis and others) 
(209,213,214). The use of specific siRNA reagents designed to target proteins that are known to or 
potentially alter Ca
2+ 
signalling should aid the identification of Ca
2+ 
signalling modifying proteins 
with functional activities in breast cancer cells. Figure 1.3 summarises five main steps that are 
involved in a high throughput siRNA screen campaign. Readers are directed to an article by Kiefer 
et al (209) for further information on each of the steps involved.  
 
Figure ‎1.3: A summary of the high throughput siRNA screening workflow (redrawn from reference 
209). 
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For the purpose of this PhD project, our collaborators in the Diamantina Institute, The University of 
Queensland performed an siRNA screen using inhibitory RNA libraries to screen all known and 
potential Ca
2+ 
signalling-related proteins (including the Ca
2+
 transporters, regulators and oncogenes 
with Ca
2+ 
-binding domains) in the human genome using the tumorigenic MDA-MB-231 breast 
cancer cells and the non-tumorigenic MCF-10A breast cell line (control). Detailed information on 
the screen overview will be presented in Chapter Two of this thesis. 
 
1.7.2 High content screening (HCS) and/or High throughput screening (HTS) 
The sequential steps in the drug discovery pipeline involve target identification and selection, target 
validation, primary screening and candidate optimisation (215). However, productivity of target 
validation and candidate optimisation are major concerns along the pipeline, indicating a need for 
future improvements (215,216). The emergence of automated HCS with computer-based feature 
extraction and data analysis has been valuable in addressing some key bottlenecks particularly 
target validation and lead optimisation in the drug discovery process (215). HCS provides several 
advantages as it gives detailed temporal-spatial dynamic information of cell constituents and 
processes that are crucial for understanding the role of selected targets in cell function as well as 
determining the specificity of lead compounds (215). Assays performed in HCS are physiologically 
relevant and the analysis generates considerably low false-positive and false-negative results (217). 
HCS is regarded as a sophisticated and useful method with potential applications in large-scale cell 
biology (218). The integration of HCS and HTS together with the development of genome-wide 
libraries holds the promise of identifying novel drug targets for the treatment of basal-like breast 
cancer.  
 
1.8 Hypotheses and Aims 
Hypotheses 
 High throughput siRNA screening against siRNA libraries targeting Ca2+ signalling 
modifying proteins will identify drug targets for breast cancer therapy. 
 Expression of Ca2+ signalling modifying proteins identified from siRNA screen are altered 
in breast cancer cells. 
 Functional inhibition of Ca2+ signalling modifying proteins identified from siRNA screen 
will alter Ca
2+ 
signalling, cell proliferation and cell death in breast cancer cells.  
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Aims 
 To select candidate genes identified from an siRNA screen for further characterisation in 
breast cancer cells. 
 To compare the levels of candidate gene mRNA expression in two human basal-like breast 
cancer cell lines. 
 To optimise siRNA-mediated silencing protocols for each candidate gene in human basal-
like breast cancer cell lines and characterise the functional consequences of such silencing 
on Ca
2+ 
signalling, cell proliferation and cell death. 
 To assess the effect of pharmacological modulation (where pharmacological modulators are 
available) of candidate genes in relation to Ca
2+ 
signalling, cell proliferation and cell death. 
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CHAPTER 2 : Assessment of Potential Targets in Basal-like Breast Cancer Cell Lines 
2.1 Introduction 
As introduced in Section 1.7.1 of this PhD thesis, an siRNA-based screen in combination with a 
high content imaging approach was conducted on siRNA libraries targeting 991 unique human 
genes that encode known and predicted Ca
2+ 
transporters including their regulators and proteins 
with Ca
2+ 
binding domains. Through collaboration with The University of Queensland Diamantina 
Institute which is equipped with the ARVEC (Arrayed RetroViral Expression Cloning) facility, the 
screen was performed on human MDA-MB-231 basal-like breast cancer cells and the non-
tumorigenic mammary epithelial cell line, MCF-10A. The screen involved assessment of cell 
viability, proliferation, apoptosis and migration using a Cellomics ArrayScan High Content Imaging 
platform.  
 
Once the screen was performed, the results generated required data normalisation and statistical 
methods to obtain a list of selected hits (209). A number of statistical analysis methods have been 
developed to facilitate the hit selection process from a high throughput RNAi screen (219). 
Choosing appropriate statistical techniques is crucial for RNAi-based screens because they create 
large datasets and also to enable extraction of biological information from the data (209,214,219). 
For example, in a high throughput RNAi screen of pancreatic cancer cells, Henderson et al (220) 
utilised the standard z-score method in multiple assays on the pancreatic cell lines for potential hits 
identification prior to validation. Hits were also defined as those siRNAs that scored positive for the 
phenotype of interest (209). Moffat and colleagues (208) defined a gene as a hit in their screen 
when at least two different shRNAs produced a similar phenotype.  
 
Using Dharmacon siGENOME siRNA reagents, our collaborators helped identify genes as putative 
hits based on phenotypic effects on cell proliferation, viability, cell death and migration in MDA-
MB-231 breast cancer cells as opposed to MCF-10A cells. Bioinformatics tools allowed hit 
identification based on data from several read-outs. These read-outs included the assessment of 
metabolic activity using resazurin assay, adenylate kinase release for evaluating cell death, and cell 
cycle analysis using DAPI staining (for nuclear count and cell cycle) as well as EdU staining to 
determine the percentage of cells in S-phase. Through this siRNA screen, 39 genes were identified 
as possible hits. However, since it is beyond the scope of this PhD thesis to perform extensive 
studies on all 39 hits, candidate genes were selected and prioritised for further assessment. 
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One of the major aspects to be considered for the choice of hits for further study is assessment of 
druggability (221,222). Druggability is a term used to describe the likelihood of a protein to become 
a good drug (222). The druggable genome, originally coined by Hopkins and Groom (222), 
highlights a collection of proteins with known or predicted domains that are amenable to therapeutic 
intervention. These families of proteins consist of G-protein-coupled receptors (GPCRs), ion 
channels, protein kinases, zinc metallopeptidases, serine proteases, nuclear hormone receptors, 
phosphodiesterases and other clinically validated drug targets (222). It is important to note that only 
about 483 proteins have been targeted in current drug therapy, in which GPCRs form the largest 
subgroup (45% of all targets) (216).  
 
Once the hits have been selected, the next step in an RNAi-based screening campaign is validation, 
which generally involves further testing using additional cell lines (209). Target validation is a vital 
step since it can impact on the successful outcome of a high throughput siRNA screen (in addition 
to proper experimental planning and stringent quality control) (209,214). Transcriptional profiles of 
MDA-MB-231 breast cancer cells have indicated that this cell line belongs to the basal-like 
subgroup, which is further subdivided into the Basal A and Basal B gene clusters (223,224). MDA-
MB-231 cells belong to the Basal B subgroup (223,224). The MDA-MB-468 breast cancer cell line 
is also basal-like (223,224). This cell line was originally derived from a pleural effusion of a 51-
year-old woman in 1977 (225) and it was selected from among the 51 commonly used breast cancer 
cell lines (223) as an additional cell line to be examined in this PhD thesis. MDA-MB-468 cells 
exhibit expression profile corresponding to the Basal A subgroup and lack the expression of ER, PR 
and HER2 receptor (223,224). Both MDA-MB-231 and MDA-MB-468 cell lines are well-
characterised and widely used in breast cancer research since they closely represent the features of 
cancer cells in vivo, rendering them a useful resource to help understand the mechanisms of breast 
tumorigenesis (223,224,226). 
 
The following chapter further describes the genes selected from the high throughput siRNA screen 
for confirmation and validation of key proteins modulating Ca
2+ 
signalling in basal-like breast 
cancer cells. Given the massive amount of data generated from the screen and the complexity to 
extract useful information, it is important to verify and validate the putative hits using appropriate 
assays (217).  
 
Specific hypothesis and aims to be addressed in this chapter include: 
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Chapter 2 hypothesis: 
I. High throughput siRNA screening of a targeted library of Ca2+ signalling-related proteins 
will identify relevant target proteins for characterisation as potential drug targets for breast 
cancer treatment. 
Chapter 2 aims: 
I. To select candidate genes identified as hits from an siRNA screen for target validation using 
real-time RT-PCR in MDA-MB-231 breast cancer cells. 
II. To assess the mRNA levels of each candidate gene using real-time RT-PCR in MDA-MB-
231 and MDA-MB-468 breast cancer cells. 
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2.2 Materials and Methods 
2.2.1 Reverse transcription and Real-time RT-PCR 
Isolated RNA from both MDA-MB-231 and MDA-MB-468 breast cancer cell lines was obtained 
from the RNA bank available in our laboratory. The generation of RNA for the RNA bank was 
initially performed using three different passage numbers in triplicates for both cell lines. Both cell 
lines were routinely tested for mycoplasma contamination using the MycoAlert Mycoplasma 
Detection Kit (LT07-218, Lonza). Cell line authentication was performed for both breast cancer cell 
lines at the Queensland Institute of Medical Research (QIMR) using the Promega StemElite™ ID 
Profiling Kit and confirmed based on the short tandem repeat (STR) profiling analysis. Total RNA 
was previously isolated from both cell lines using the RNeasy
®
 Plus Mini Kit (Qiagen) by following 
the manufacturer’s guidelines. Total RNA (1000 ng) was subjected to reverse transcription for the 
synthesis of first strand complementary DNA (cDNA) using Omniscript Reverse Transcriptase kit 
(Qiagen) with random primers and RNase inhibitor (Promega) in a 20 µL reaction volume. The 
reverse transcription mixture was prepared by referring to the manufacturer’s suggestions as 
outlined in Table 2.1. Samples were incubated for 60 minutes at 37°C in a GeneAmp
®
 PCR System 
2400 Thermal Cycler (PerkinElmer).  
 
Table ‎2.1: Reverse transcription reaction components. 
Component Volume per reaction Final concentration 
Master Mix 
10X Buffer RT 2 µL 1X 
dNTP Mix (5 mM each dNTP) 2 µL 0.5 mM each dNTP 
Random primers (100 µM) 2 µL 
10 µM (as recommended by 
Qiagen when using random 
primers) 
RNase inhibitor (10 U/µL), diluted from 
40 U/µL in 1X Buffer RT 
1 µL 
10 U per 20 µL reaction 
Omniscript Reverse Transcriptase 1 µL 4 U per 20 µL reaction 
Template RNA + RNase-free water 12 µL 1000 ng per 20 µL reaction 
Total reaction volume 20 µL  
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To evaluate the expression of genes of interest in both cell lines, each cDNA was subsequently 
assayed by real-time RT-PCR using Assays-on-Demand FAM-MGB primer/probe sets and TaqMan 
Universal PCR Master Mix (Applied Biosystems). A full list of Gene Expression Assays used in 
this chapter is provided in Table 2.2. All real-time RT-PCR amplification contained 25 ng template 
cDNA in a 20 µL PCR reaction mix. For the amplification of 18SrRNA (VIC-MGB primer/probe, 
Applied Biosystems), the cDNA templates were further diluted 1:100 compared to that used for the 
detection of all genes of interest except for TRPC1 (a 1:10 dilution was performed on the cDNA 
templates to probe for 18SrRNA). All amplifications were cycled using universal cycling 
conditions: 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C 
in a StepOnePlus™ Real-Time PCR System Thermal Cycling Block (Applied Biosystems). Gene 
expression was normalised to 18SrRNA (4319413E, Applied Biosystems) and quantified using the 
comparative CT method (relative quantification) as previously described (194). Briefly, threshold 
cycle values (CT) were used to calculate Delta CT (ΔCT) by using a formula of: ΔCT = CT (Target) - CT 
(18SrRNA). A low CT value indicates the transcript is detected at an early time point during the PCR 
cycle, indicating an abundant transcript whereas a high CT value indicates a lower amount of 
transcript is expressed in a tested sample. ΔCT value represents CT for target gene corrected to the 
endogenous reference gene (18SrRNA) and indicates the relative mRNA levels of the 
corresponding target gene. Using the calculated ΔCT value, the delta delta CT (ΔΔCT) value was 
then determined by subtracting to the average ΔCT of an appropriate calibrator to obtain fold change 
of the target gene using the formula 2
-ΔΔCT
 as previously published (227). 
 
Table ‎2.2: List of Applied Biosystems TaqMan Gene Expression Assays. 
Gene Assay ID 
CACNA1C Hs00167681_m1 
CACNA1H Hs00234934_m1 
CD24 Hs02379687_s1 
TACR1 Hs00185530_m1 
TREML1 Hs00698316_m1 
TRPC1 Hs00608195_m1 
TRPM3 Hs00257553_m1 
TRPV4 Hs01099348_m1 
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2.2.2 Statistical analysis 
Statistical analyses were performed using Prism5 (Graph Pad Software version 5.04). The unpaired 
t-test was used to test for statistical significance. P < 0.05 was regarded as statistically significant. 
Unless otherwise specified, results are expressed as mean ± standard error of the mean (SEM).  
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2.3 Results 
2.3.1 Hit identification from the siRNA screen 
 
Table ‎2.3 : List of hits identified by the siRNA screen against Ca2+ signalling modifying proteins in 
MDA-MB-231 breast cancer cells. 
Gene 
ID 
Symbol Description 
1907 EDN2 endothelin 2 
1236 CCR7 chemokine (C-C motif) receptor 7 
4881 NPR1 
natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic 
peptide receptor A) 
10411 RAPGEF3 Rap guanine nucleotide exchange factor (GEF) 3 
6869 TACR1 tachykinin receptor 1 
27032 ATP2C1 ATPase, Ca
2+
 transporting, type 2C, member 1 
624 BDKRB2 bradykinin receptor B2 
147 ADRA1B adrenergic, alpha-1B-, receptor 
925 CD8A CD8a molecule 
934 CD24 CD24 molecule 
6349 CCL3L1 chemokine (C-C motif) ligand 3-like 1 
2811 GP1BA glycoprotein Ib (platelet), alpha polypeptide 
1435 CSF1 colony stimulating factor 1 (macrophage) 
7220 TRPC1 transient receptor potential cation channel, subfamily C, member 1 
2243 FGA fibrinogen alpha chain 
3586 IL10 interleukin 10 
4909 NTF5 neurotrophin 5 (neurotrophin 4/5) 
80036 TRPM3 transient receptor potential cation channel, subfamily M, member 3 
59341 TRPV4 transient receptor potential cation channel, subfamily V, member 4 
10681 GNB5 guanine nucleotide binding protein (G protein), beta 5 
115019 SLC26A9 solute carrier family 26, member 9 
340205 TREML1 triggering receptor expressed on myeloid cells-like 1 
7070 THY1 Thy-1 cell surface antigen 
1667 DEFA1 defensin, alpha 1 
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3811 KIR3DL1 
killer cell immunoglobulin-like receptor, three domains, long 
cytoplasmic tail, 1 
1670 DEFA5 defensin, alpha 5, Paneth cell-specific 
10914 PAPOLA poly(A) polymerase alpha 
112 ADCY6 adenylate cyclase 6 
1734 DIO2 deiodinase, iodothyronine, type II 
1965 EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 
5270 SERPINE2 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 2 
6286 S100P S100 calcium binding protein P 
10204 NUTF2 nuclear transport factor 2 
521 ATP5I ATP synthase, H
+
 transporting, mitochondrial Fo complex, subunit E 
2353 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 
6588 SLN sarcolipin 
2155 F7 coagulation factor VII (serum prothrombin conversion accelerator) 
775 CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit 
8912 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit 
 
2.3.2 Selection of candidate genes from the siRNA screen for target validation in MDA-MB-
231 breast cancer cells 
From the 39 hits shown in Table 2.3, eight genes (referred to as candidate genes) were short-listed 
for target selection before being advanced for target validation. The hits were narrowed down into 
eight candidate genes by consideration of criteria related to druggability (221,222). Priority was 
given to those genes that have not previously been studied or largely unexplored in the context of 
breast cancer. Plasma membrane localisation was an important determining factor for the candidacy 
of potential targets since these proteins are attractive targets for drug therapy (228). Genes that 
represented druggable targets such as GPCRs, ion channels, receptors and enzymes (216,222,228) 
were also prioritised. Known targets were not selected for this study, for example, ATP2C1 
(encodes for SPCA1) which has been shown to play a key role in regulating the processing of a 
protein implicated in tumour progression called insulin-like growth factor receptor (IGF1R) in 
MDA-MB-231 basal breast cancer cells (201). The eight candidate genes selected were CACNA1C, 
CACNA1H, TREML1, TACR1, CD24, TRPC1, TRPM3 and TRPV4 (Table 2.4).  
 
2.3.2.1 CACNA1C: L-type voltage-dependent Ca
2+ 
channel 
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CACNA1C which encodes for the alpha 1C subunit of the L-type voltage-gated Ca
2+ 
channel is also 
known as the cardiac or smooth muscle L-type Ca
2+ 
channel (31). Despite evidence for the 
upregulation of CACNA1C during the maintenance phase of methotrexate-induced senescence in 
human colorectal cancer C85 cells (229), there are no studies to date, to investigate the possible 
involvement of this Ca
2+
 channel in breast cancer. CACNA1C was therefore chosen as a candidate 
gene for further assessment. 
 
2.3.2.2 CACNA1H: T-type voltage-dependent Ca
2+ 
channel 
The T-type voltage-gated Ca
2+ 
channel alpha 1H subunit (CACNA1H) is implicated in many 
physiological processes including the control of repetitive firing, hormone (e.g. aldosterone and 
cortisol) secretion, and regulating smooth muscle contraction and proliferation (31). It is 
increasingly recognised that CACNA1H is implicated in the development of several cancers such as 
prostate (160), ovarian cancer (230) and very recently human glioblastoma (231). However, studies 
assessing the potential role of CACNA1H in breast cancer are limited (232-234).     
 
2.3.2.3 TREML1: Triggering receptor expressed on myeloid cells-like 1 
The triggering receptor expressed on myeloid cells-like 1 (TREML1) or also known as the TREM-
like transcript-1 (TLT1) is a member of the TREM family (235,236).  TREML1 has been reported as 
a putative inhibitory receptor which regulates the signalling of the TREM family (237) and 
represents a new costimulatory immunoreceptor which enhances Ca
2+
 signalling in an SHP2-
dependent manner (238). Thus far, no studies have explored the possible association of TREML1 
with breast cancer or other cancer types. TREML1 was therefore selected as a candidate gene.   
 
2.3.2.4 TACR1: Tachykinin receptor 1 
TACR1 encodes for tachykinin receptor 1 (or sometimes referred to as neurokinin 1) which belongs 
to the tachykinin receptor family (239). TACR1 is a GPCR widely expressed in various cell types, 
including the central and peripheral nervous systems (239). Although the roles of TACR1 have been 
evaluated in breast cancer (240-242) and other cancer types (243,244), it is of interest to extend our 
current knowledge on how TACR1 regulates Ca
2+
 signalling in basal-like breast cancer and 
specifically affects cancer-related pathways such as cell proliferation and cell death. Given evidence 
which suggests the potential therapeutic effect of peripheral tachykinin receptor antagonists in 
several diseases (245) and the recognised roles of neurokinin-1 receptor in the microenvironment of 
inflammation and cancer (246), it is possible that TACR1 will emerge as a new drug target with 
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therapeutic benefits in breast cancer. To address this, TACR1 was selected as a candidate gene in 
this study. 
 
2.3.2.5 TRPM3: Transient receptor potential melastatin 3  
TRPM3 is one of the eight members of the TRPM family (54). Phylogenetically, TRPM3 is the 
closest relative to TRPM1 (54) – a Ca2+ permeable channel which has been proposed as a tumor-
suppressor in melanoma (170). Using two-dimensional gel electrophoresis combined with mass 
spectrometry, TRPM3 has been identified as a protein upregulated in squamous cervical cancer 
(247). Gene expression profiling has revealed a significant upregulation of TRPM3 in human 
choroid plexus tumors (248). However, there have been no studies on the contribution of TRPM3 in 
breast cancer. To address this, TRPM3 was selected as a candidate gene.  
 
2.3.2.6 CD24: CD24 molecule 
CD24 is a mucin-type glycoprotein which exclusively binds to P-selectin on human carcinoma cells 
(249). The binding of CD24 to P-selectin has been shown to be important for mediating P-selectin 
dependent rolling of breast cancer cells in cancer metastasis (250). It is increasingly recognised that 
CD24 plays a pivotal role in several human malignancies such as the breast, ovary and prostate 
(251-253). However, the potential involvement of CD24 in the regulation of Ca
2+ 
signalling in 
breast cancer has not been addressed. For this reason, CD24 was selected as a candidate gene for 
further study.   
 
2.3.2.7 TRPC1: Transient receptor potential canonical 1 
TRPC1 is a member of the TRPC family, which is ubiquitously expressed in many types of animal 
cells (54,254). TRPC1 is involved in a diverse array of physiological processes including the control 
of cellular processes such as proliferation (255), apoptosis (256,257) and cell division (258). 
Altered expression of TRPC1 has been reported in various cancers (135,259-261). The role of 
TRPC1 has also been documented in the context of breast cancer, but most of these studies focused 
on breast cancer cells of the luminal subtype (165,262,263). Given limited studies on TRPC1 in 
basal-like breast cancer cells, TRPC1 was also selected as a candidate gene.   
 
2.3.2.8 TRPV4: Transient receptor potential vanilloid 4 
TRPV4 is a member of the TRPV ion channel family with permeability for both Ca
2+ 
and Na
+
 (264). 
TRPV4 is implicated in physiological processes such as osmoregulation, mechanosensation and 
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thermoregulation (54,265-267). TRPV4 is polymodal, since it is responsive to multiple stimuli such 
as heat, cell swelling, phorbol esters and arachidonic acid (54,267). Although only a few studies 
have addressed the link between TRPV4 and cancer (268,269), this does not exclude the possibility 
for the involvement of TRPV4 in cancer progression. Apart from few studies on TRPV4 in breast 
cancer (270-272), this area of research is still not well explored. TRPV4 was therefore selected as a 
candidate gene.  
 
2.3.3 Assessment of mRNA levels of candidate genes in MDA-MB-231 breast cancer cells 
Initial experiments assessed whether these eight candidate genes were expressed in our MDA-MB-
231 cells before commencing downstream experiments. Table 2.4 shows the detection and relative 
quantification of the candidate genes in MDA-MB-231 breast cancer cells. Five candidate genes 
(i.e. CD24, TACR1, TRPC1, TRPM3 and TRPV4) were expressed at variable levels in this cell line 
whereas the remaining three genes (i.e. CACNA1C, CACNA1H and TREML1) were not detected. 
Three candidate genes (i.e. CD24, TRPC1 and TRPV4) were then selected for further 
characterisation in basal-like breast cancer cells. 
 
Table ‎2.4: Candidate genes mRNA levels in MDA-MB-231 breast cancer cells, assessed 
quantitatively with real-time RT-PCR and displayed as average ΔCT values ± standard deviation 
(S.D.) (n = 3). ΔCT value indicates a target gene expression levels. A lower ΔCT value means higher 
expression levels or vice versa. 
Gene Amplification in MDA-MB-231 cells Average Delta CT ± S.D. 
CACNA1C Not detected - 
CACNA1H Not detected - 
TREML1 Not detected - 
TACR1 Detected 13.925 ± 0.089 
TRPM3 Detected 12.059 ± 0.224 
CD24 Detected 4.066 ± 3.201 
TRPC1 Detected 0.770 ± 2.382 
TRPV4 Detected 9.230 ± 0.865 
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2.3.4 Assessment of the mRNA levels of three candidate genes in two basal-like breast 
cancer cell lines 
According to the real-time RT-PCR analysis shown in Table 2.4, three candidate genes were 
expressed at substantial levels in our MDA-MB-231 breast cancer cells. These were CD24, TRPC1 
and TRPV4 as the average ΔCT values were among the lowest compared to the other genes assessed. 
Given that these genes were present and abundant in MDA-MB-231 cells, the next experiment 
examined whether or not these candidate genes were expressed in an additional basal-like breast 
cancer cell line, i.e. MDA-MB-468 cells. To allow for comparison of mRNA expression levels for 
each candidate gene between MDA-MB-231 and MDA-MB-468 breast cancer cells, real-time RT-
PCR was carried out using three different biological replicates derived from three different passage 
numbers for both cell lines, as described in the methods section.     
 
2.3.4.1 CD24 mRNA expression levels in MDA-MB-231 and MDA-MB-468 breast cancer 
cells 
This study sought to compare relative CD24 mRNA expression levels between MDA-MB-231 and 
MDA-MB-468 basal-like breast cancer cell lines using real-time RT-PCR. MDA-MB-468 cells 
exhibited significantly higher levels of CD24 (approximately more than 800-fold) in comparison to 
MDA-MB-231 cells (Figure 2.1).  
 
2.3.4.2 TRPC1 mRNA expression levels in MDA-MB-231 and MDA-MB-468 breast cancer 
cells 
The expression levels of TRPC1 were evaluated in MDA-MB-231 and MDA-MB-468 basal-like 
breast cancer cell lines. Real-time RT-PCR analysis revealed that TRPC1 was highly expressed in 
MDA-MB-231 cells (approximately more than 200-fold) compared to MDA-MB-468 cells (Figure 
2.2). 
 
2.3.4.3 TRPV4 mRNA expression levels in MDA-MB-231 and MDA-MB-468 breast cancer 
cells 
Since the role of TRPV4 in breast cancer has not been extensively investigated, the present study 
sought to characterise TRPV4 expression between MDA-MB-231 and MDA-MB-468 breast cancer 
cells. Assessment of the relative TRPV4 mRNA expression levels in both cell lines indicated that 
MDA-MB-468 cells displayed significantly higher levels of TRPV4 (approximately 30-fold higher) 
as opposed to MDA-MB-231 cells (Figure 2.3). 
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Figure ‎2.1: Relative CD24 mRNA levels in MDA-MB-231 and MDA-MB-468 basal-like breast 
cancer cell lines normalised to 18S ribosomal RNA (-ΔCT). CD24 mRNA levels were quantified 
using real-time RT-PCR. Results are pooled from three independent experiments, shown as mean ± 
SEM (n = 3). Statistical analysis was performed using an unpaired t-test; * denotes P < 0.05. 
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Figure ‎2.2: Relative TRPC1 mRNA levels in MDA-MB-231 and MDA-MB-468 basal-like breast 
cancer cell lines normalised to 18S ribosomal RNA (-ΔCT). TRPC1 mRNA levels were quantified 
using real-time RT-PCR. Results are pooled from three independent experiments, shown as mean ± 
SEM (n = 3). Statistical analysis was performed using an unpaired t-test; * denotes P < 0.05. 
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Figure ‎2.3: Relative TRPV4 mRNA levels in MDA-MB-231 and MDA-MB-468 basal-like breast 
cancer cell lines normalised to 18S ribosomal RNA (-ΔCT). TRPV4 mRNA levels were quantified 
using real-time RT-PCR. Results are pooled from three independent experiments, shown as mean ± 
SEM (n = 3). Statistical analysis was performed using an unpaired t-test; ** denotes P < 0.01. 
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2.4 Discussion 
Work presented in this chapter highlights the use of high throughput siRNA-based screening in 
combination with high content imaging to determine Ca
2+ 
regulating proteins with therapeutic 
potential as new drug candidates for the treatment of basal-like breast cancer. The screen yielded 39 
hits. The criteria used for identification of potential hits were based on greater effects on cell 
viability, proliferation, cell death and migration of human MDA-MB-231 basal-like breast cancer 
cells compared to MCF-10A cells. The list of hits was then condensed into eight candidate genes 
worthy of further investigation. These eight candidate genes consisting of CACNA1C, CACNA1H, 
TREML1, TACR1, CD24, TRPC1, TRPM3 and TRPV4 were selected by considering a number of 
criteria as stated in Section 2.3.2. These criteria include the targets druggability, plasma membrane 
localisation and targets that have not been assessed or extensively studied in the context of breast 
cancer. 
 
Initial expression analysis using real-time RT-PCR demonstrated that mRNA for five out of eight 
candidate genes (i.e. CD24, TACR1, TRPC1, TRPM3 and TRPV4) were detected in MDA-MB-231 
breast cancer cells. The remaining three genes (i.e. CACNA1C, CACNA1H and TREML1) had 
mRNA which was absent in this cell line. This observation is not surprising and might be explained 
by several reasons. One of the reasons is related to the inherent nature of siRNA technology, known 
as off-target effects (214). The off-target effects can be defined as any observed phenotypic change 
which is not due to silencing of the targeted mRNA (i.e. target-gene specific) (214,219,273). The 
first evidence for the off-target effects was documented by Jackson et al (273) using gene 
expression profiling. The authors found that different siRNAs designed to the same target exhibited 
unique expression patterns which implied siRNA-specific rather than target-specific signatures 
(273). Considerable efforts have been directed towards identifying the source of unwanted off-
target effects. Several studies have reported a number of mechanisms contributing to the occurrence 
of off-target effects associated with RNAi-based screens including short sequence complementarity 
to the so-called ‘seed region’ of the siRNA, the method of siRNA delivery into the cells and 
activation of the interferon-response pathway (214,274,275). Off-target effects could also result in 
false positive hits which are commonly identified during the first stage of large-scale screens (214). 
False positive hits can also occur due to the mechanism of RNAi action which often requires longer 
time-points (i.e. generally 48 – 72 hours) to produce maximal effect in the cells, thereby allowing 
the cell culture and environmental variation to affect the phenotypes of interest, and hence leading 
to more variable phenotypes in the screens (219). Therefore, in an attempt to minimise off-target 
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effects, all siRNAs used in the present study were Dharmacon ON-TARGET plus SMARTpools, 
consisting of a pool of four siRNA sequences targeting the same gene. These siRNAs are rationally 
designed to have dual strand modification and their design uses an algorithm to minimise seed 
region matches, thereby reducing off-target effects (276,277).  
 
The absence of some candidate genes in our study model could also be due to different phenotypes 
of MDA-MB-231 breast cancer cells across different laboratories. Most breast cancer cells have 
been cultured for many years by multiple groups which can cause heterogeneity of phenotype in 
those breast cancer cells. Heterogeneity has been described as a common characteristic of breast 
tumours (278). For instance, MCF-7 cells which are widely studied in breast cancer research, have 
been found to exhibit extensive heterogeneity at both the genomic and RNA expression levels 
(278). Another breast cancer cell line, T47D has also been reported to show heterogeneity in 
progesterone receptor levels and DNA content among the clonal derivatives (279). In addition, 
breast cancer cell lines could also undergo specific genotype or phenotype alterations as a 
consequence of long term culture (226,280). Therefore, it is possible that the same breast cancer cell 
line which is maintained with various growth conditions in different laboratories may display 
different molecular characteristics, thus making inter-laboratory comparisons of data more difficult 
(226,280). 
 
Inappropriate handling and practice of cell culture techniques may potentially cause cell line cross-
contamination (280,281) which can also contribute to the variability of data obtained from different 
laboratories. To address this issue, our laboratory periodically performs cell line authentication 
using a reliable and reproducible technique known as the STR profiling (282). This is crucial to 
eliminate possible cross-contamination between cell lines and ensure the authenticity of each cell 
line (282) throughout the period of studies. Assessment of mycoplasma contamination (280) and 
morphological characteristics are also regularly assessed for all breast cancer cell lines available in 
our laboratory as additional quality control measures to avoid using contaminated and false cell 
lines. Hence, it is unlikely that targets may have been missed due to incorrect cell lines being used 
or mycoplasma contamination. 
 
It is important to confirm and validate siRNA screening hits to distinguish between the “true 
positives” from false positives prior to subsequent experiments. The issues pertaining to off-target 
effects and false positive hits further signify the necessity to perform secondary screening to 
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validate the findings obtained from first stage screening in order to maximise the reliability of 
RNAi screens (214,283).  
 
Following the real-time RT-PCR data for the assessment of expression levels of each candidate 
gene in our MDA-MB-231 breast cancer cells, three genes (CD24, TRPC1 and TRPV4) were 
proceeded to the next phase. To ascertain if these candidate genes were also expressed in other 
basal-like breast cancer cells, real-time RT-PCR analysis was performed for each gene in MDA-
MB-468 breast cancer cells. Differential transcription of all three candidate genes was observed 
between MDA-MB-231 and MDA-MB-468 breast cancer cells. This finding provides a starting 
point for further series of investigations of their likelihood as drug candidates for treating breast 
cancer. 
 
In conclusion, the results in this chapter collectively illustrate the suitability of using high 
throughput RNAi-based screening combined with high content imaging in the pursuit of finding 
novel and new targets for breast cancer therapy. In addition, the data presented in this chapter 
provide further evidence for the importance of validating potential hits before detailed studies are 
performed.     
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2.5 Conclusion 
This chapter describes a set of genes selected from an siRNA screen and the confirmation of their 
expression levels in two models of basal-like breast cancer cell lines. Given the mRNA levels of 
CD24 and TRPV4 in both study models, these two genes were chosen for subsequent functional 
studies. Functional characterisation of TRPC1 was not pursued in this thesis because TRPC1 was 
studied by other groups and by another member of the CSICRL during my candidature (284).  
 
The characterisation of CD24 is presented in Chapter Three of this thesis. Work on TRPV4 in 
MDA-MB-231 and MDA-MB-468 breast cancer cells are described in Chapters Four and Five, 
respectively. 
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CHAPTER 3 : Characterisation of CD24 and Its Potential Role in Regulating 
CXCL12/CXCR4-mediated Ca
2+
 Signalling in Basal-like Breast Cancer Cells 
3.1 Introduction  
The work presented in this chapter describes the characterisation of CD24 as one of the candidate 
genes identified from high throughput siRNA screening. This chapter also explores the potential 
role of CD24 in the regulation of Ca
2+ 
signalling mediated by CXCL12/CXCR4 interaction using 
two human basal-like breast cancer cell lines (MDA-MB-468 and MDA-MB-231).  
 
Chemokines are a superfamily of small (approximately 8 to 14 kDa) molecules that mediate many 
cellular functions through the activation of GPCRs (285,286). In addition to their well-established 
role in the regulation of the immune system (285,286), chemokines and their respective receptors 
are also linked to metastasis of cancers such as osteosarcomas (287), neuroblastomas (288) and 
those of the prostate (289) and breast (290,291). In breast cancer cells, the chemokine receptors 
CXCR4 and CCR7 have been reported to be upregulated compared to normal mammary epithelial 
cells (290). The increased expression of CXCL12, the ligand for CXCR4 (292), in the most 
common sites of breast cancer metastasis, further implicates an important role for CXCR4/CXCL12 
signalling in the development of metastatic disease (290).  
 
Several studies have demonstrated that upregulation of CXCR4 is associated with poor clinical 
outcomes in breast cancer patients (293-295). CXCL12 interacts with CXCR4 to initiate numerous 
cellular processes important in various aspects of tumour progression including migration, 
proliferation and gene transcription (296); however the exact signalling mechanisms involved are 
not fully understood. The response to CXCL12 activation of CXCR4 in some cells is the release of 
Ca
2+ 
from internal stores (296). Ca
2+ 
signalling has been associated with processes important in 
metastasis including migration and invasion (131,297) as well as the induction of a more invasive 
phenotype via epithelial to mesenchymal transition (EMT) (298). EMT is a process whereby 
epithelial cells undergo conversion to a mesenchymal (invasive) phenotype (299). The induction of 
EMT can occur via multiple stimuli (300), one of which is by treatment with epidermal growth 
factor (EGF) (301,302).   
 
The nature of responses to CXCL12 via CXCR4 activation has been reported to vary between cell 
types (296) and could be due to differences in the level of CXCR4 regulators such as CD24 (303). 
CD24 is a small highly glycosylated protein that is anchored to the membrane via a glycosyl 
51 
 
phosphatidylinositol lipid anchor (304). CD24 expression has been implicated in various human 
malignancies, including those of the breast, ovary and prostate, and it has prognostic significance 
(251-253). In the context of breast cancer, CD24 has received great interest since its discovery as a 
breast tumour stem cell marker, together with its counterpart, CD44 (305). 
Schabath et al (303) demonstrated that basal-like MDA-MB-231 breast cancer cells with low CD24 
expression, showed augmented CXCL12/CXCR4-mediated cell migration and enhanced tumour 
growth compared to MDA-MB-231 overexpressing CD24, suggesting that CD24 expression levels 
negatively affect CXCL12/CXCR4-mediated cell migration and tumour growth in breast cancer 
cells. However, the possible role of CD24 in the regulation of CXCL12/CXCR4-mediated Ca
2+
 
signalling in breast cancer cells was not assessed. In this thesis, the role of CD24 in the regulation 
of CXCL12/CXCR4-induced Ca
2+
 release in basal-like breast cancer cells is explored. 
The specific hypotheses and aims assessed in this chapter are: 
 
Chapter 3 hypotheses: 
I. CXCL12/CXCR4-mediated Ca2+ signalling is different in MDA-MB-231 and MDA-MB-
468 breast cancer cells. 
II. CD24 silencing alters agonist-mediated Ca2+ signalling responses in basal-like breast cancer 
cells. 
III. Induction of EMT by EGF in MDA-MB-468 breast cancer cells is associated with changes 
in CXCR4 receptor expression levels. 
Chapter 3 aims: 
I. To assess CXCL12-induced intracellular Ca2+ transients in MDA-MB-231 and MDA-MB-
468 breast cancer cells. 
II. To compare the mRNA levels of CD24 and CXCR4 in MDA-MB-231 and MDA-MB-468 
breast cancer cells. 
III. To evaluate the functional consequences of CD24 silencing on agonist-mediated Ca2+ 
signalling using a purinergic receptor activator (ATP) and a CXCR4 receptor ligand 
(CXCL12) in MDA-MB-468 breast cancer cells. 
IV. To investigate changes in CXCR4 mRNA levels during EGF-induced EMT in MDA-MB-
468 breast cancer cells.  
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3.2 Materials and Methods 
3.2.1 Materials 
Recombinant human CXCL12 (350-NS-010) was purchased from R&D Systems. ATP disodium 
salt hydrate was purchased from Sigma-Aldrich. The Dharmacon ON-TARGET plus SMARTpool 
CD24 siRNA (L-187156-00-0005) and control ON-TARGET plus Non-Targeting pool siRNA (D-
001810-10-05) were obtained from Dharmacon RNAi Technologies.  
 
3.2.2 Cell Culture 
The human basal-like breast cancer cell lines MDA-MB-231 (American Type Culture Collection, 
ATCC) and MDA-MB-468 (a kind gift from Dr Chanel Smart from University of Queensland 
Centre for Clinical Research) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, 
D6546) (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich), L-
glutamine (4 mM) (Invitrogen), penicillin 100 U/mL and streptomycin 100 µg/mL (Invitrogen). 
Cells were grown in a humidified incubator (37°C, 5% CO2) and routinely screened for 
mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (LT07-218, Lonza). 
For consistency, the maximum passage number for the cultured cells was nine for all experiments. 
 
3.2.3 Intracellular Ca
2+
 measurement 
For Ca
2+
 measurements, MDA-MB-231 (7.5 X 10
3 
cells per well) or MDA-MB-468 (1.5 X 10
4 
cells 
per well) cells were seeded in a 96-well CellBIND plate (Corning) in antibiotic-free media. At 24 
hours post-plating, the FBS concentration was reduced to 8% and where appropriate cells were 
treated with CD24 siRNA or non-targeting siRNA. Total RNA was isolated 24 hours post-
transfection to confirm mRNA knockdown of CD24, using real-time RT-PCR, prior to Ca
2+ 
assays 
(refer to Section 3.2.4 for method). At 72 hours post-treatment, Ca
2+ 
assays were performed using 
the fluorescence imaging plate reader FLIPR
TETRA 
(Molecular Devices) with a wash protocol (194). 
Transfection medium was removed and cells were loaded with culture medium containing Ca
2+ 
-
sensitive dye Fluo-4 AM (4 µM) (Molecular Probes, Invitrogen) and incubated in a humidified 
incubator (37°C, 5% CO2) for 30 minutes. Loading solution was replaced with physiological salt 
solution (PSS; 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4, 5 mM NaHCO3, 
140 mM NaCl, 11.5 mM glucose and 1.8 mM CaCl2) for 15 minutes at room temperature to 
equilibrate the cells. The preparation of PSS was described in Appendix V. The PSS pH (adjusted 
to pH 7.2) was set and measured under the conditions at which the PSS was used. The PSS (pH 7.2) 
was removed and cells were washed twice with PSS containing bovine serum albumin (BSA, 0.3%) 
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prior to measurement of intracellular Ca
2+
. Fluo-4 loaded cells were excited at 470-495 nm and 
emission assessed at 515-575 nm over an 800 seconds period. Relative [Ca
2+
]CYT was determined in 
the presence of approximate maximal and sub-maximal concentrations of ATP (100 µM and 0.6 
µM) and CXCL12 (100 ng/mL and 300 ng/mL). Data were acquired using ScreenWorks™ 
Software (Molecular Devices) and are presented as response over baseline (response/baseline) 
which is a measure of relative [Ca
2+
]CYT. Response/baseline has no units, as the unit is a ratio. Peak 
relative [Ca
2+
]CYT was determined by the maximum relative fluorescence (response/baseline) value 
achieved during the duration of the exposure to ATP and CXCL12 (800 seconds). 
 
3.2.4 RNA isolation and Real-time RT-PCR 
Total RNA was isolated using a RNeasy
®
 Plus Mini Kit (Qiagen), reverse-transcription reactions 
were carried out using a Omniscript Reverse Transcriptase kit (Qiagen) with random primers and 
RNase inhibitor (Promega) as recommended by the manufacturer. The real-time RT-PCR was 
conducted using Assays-on-Demand FAM-MGB primer/probe sets and TaqMan Universal PCR 
Master Mix (Applied Biosystems). Assays included human CD24 (Hs02379687_s1), human 
CXCR4 (Hs00237052_m1) and the endogenous control 18SrRNA (4319413E, VIC-MGB 
primer/probe). All amplifications were performed using universal cycling conditions in a 
StepOnePlus™ Real-Time PCR System Thermal Cycling Block (Applied Biosystems). Data were 
normalised to 18SrRNA and analysed using the comparative CT method (194).  
 
3.2.5 Silencing of CD24 expression 
MDA-MB-468 cells (1.5 X 10
4 
cells per well) were seeded in a 96-well plate in antibiotic-free 
media. Cells were then incubated with Dharmacon ON-TARGET plus SMARTpool CD24 siRNA 
(100 nM) or control ON-TARGET plus Non-Targeting pool siRNA as per the manufacturer’s 
guidelines. DharmaFECT 4 transfection reagent was used at a volume of 0.4 µL per well (100 µL 
total volume). Total RNA was isolated 24 hours post-transfection using the RNeasy
®
 Plus Mini kit 
(Qiagen). Knockdown of CD24 relative to non-targeting siRNA control was confirmed using real-
time RT-PCR (Applied Biosystems). 
 
3.2.6 EGF treatment to induce EMT  
For induction of EMT, MDA-MB-468 cells were plated into a 6-well plate and serum-starved (0.5% 
FBS) for 24 hours prior to treatment with EGF (50 ng/mL) (Sigma-Aldrich) as described previously 
(298,301). Total RNA was isolated at 48 hours post-EGF treatment and subjected to reverse-
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transcription followed by real-time RT-PCR as described in Section 3.2.4 for quantification of 
changes in CXCR4 expression. 
 
3.2.7 Statistical analysis 
Statistical analyses were performed using Prism5 (Graph Pad Software version 5.04). Results are 
expressed as mean ± SEM from the specified number of independent experiments. The statistical 
tests used are stated in each figure legend. 
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3.3 Results  
3.3.1 Characterisation of CXCL12-induced intracellular Ca
2+
 transients in breast cancer 
cells  
The present study sought to characterise CXCL12-induced intracellular Ca
2+
 transients in two 
different basal-like breast cancer cell lines MDA-MB-231 (Basal B) and MDA-MB-468 (Basal A). 
A dose-dependent significant increase in [Ca
2+
]CYT was observed following CXCL12 stimulation in 
MDA-MB-231 breast cancer cells (Figure 3.1A and B). However, no increase in [Ca
2+
]CYT was 
observed in MDA-MB-468 cells treated with CXCL12 (Figure 3.1C). 
 
3.3.2 Effect of CD24 siRNA-mediated silencing in MDA-MB-468 cells on ATP-induced Ca
2+
 
transients at sub-maximum and maximum concentrations 
CD24 has been reported to regulate the function of CXCR4, a cognate receptor for CXCL12 in pre-
B lymphocytes and breast cancer cells (303). Given the significantly elevated levels of CD24 in 
MDA-MB-468 cells compared to MDA-MB-231 cells (as assessed quantitatively using real-time 
RT-PCR in Section 2.3.4.1 of this thesis, Figure 2.1), studies were carried out to test the hypothesis 
that the non-responsiveness of MDA-MB-468 cells to CXCL12-mediated increases in [Ca
2+
]CYT in 
Figure 3.1C may be due to CD24 attenuating the Ca
2+
 signalling via CXCR4. CD24 siRNA 
significantly reduced the level of CD24 mRNA when compared with non-targeting siRNA (NT 
siRNA) in MDA-MB-468 cells (Figure 3.2). To first assess if CD24 silencing may produce non-
specific effects on Ca
2+ 
signalling, the effect of ATP-mediated Ca
2+ 
signalling was first assessed. 
CD24 siRNA did not alter the nature of ATP-induced Ca
2+
 transients or the peak relative [Ca
2+
]CYT 
at both sub-maximum (Figure 3.3A and B) and maximum ATP concentrations (Figure 3.3C and D). 
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Figure ‎3.1: Effect of CXCL12 stimulation on [Ca2+]CYT in MDA-MB-231 and MDA-MB-468 
breast cancer cells. (A) Representative [Ca
2+
]CYT transients with 100 ng/mL and 300 ng/mL 
CXCL12 in MDA-MB-231 breast cancer cells. (B) Each bar represents the response (depicted as 
relative [Ca
2+
]CYT) to either 100 ng/mL CXCL12 or 300 ng/mL CXCL12 in MDA-MB-231 breast 
cancer cells as indicated (mean ± SEM (n = 3), from three independent experiments. (C) 
Representative [Ca
2+
]CYT transients with 100 ng/mL and 300 ng/mL CXCL12 in MDA-MB-468 
breast cancer cells. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparison test; ** denotes P < 0.01. 
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Figure ‎3.2: Silencing of CD24 in MDA-MB-468 cells. Cells were plated in 96-well plates and 
CD24 expression was inhibited using Dharmacon ON-TARGET Plus SMARTpool siRNA. Total 
RNA was isolated 24 hours post-transfection and knockdown of CD24 relative to the non-targeting 
siRNA (NT siRNA) control was confirmed using real-time RT-PCR. Each bar represents mean ± 
SEM (n = 4, from four independent experiments). Statistical analysis was performed using an 
unpaired t-test; **** denotes P < 0.0001 compared to the NT siRNA control. 
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Figure ‎3.3: Effect of CD24 siRNA-mediated silencing on ATP-induced Ca2+ transients in MDA-
MB-468 cells. (A) Representative ATP-induced Ca
2+
 transients in the presence or absence of CD24 
siRNA-mediated knockdown in MDA-MB-468 breast cancer cells. (B) Each bar represents the 
response (depicted as relative [Ca
2+
]CYT) to 0.6 µM ATP. Each bar represents mean ± SEM (n = 3), 
from three independent experiments. (C) Representative ATP-induced Ca
2+
 transients in the 
presence or absence of CD24 siRNA-mediated knockdown in MDA-MB-468 breast cancer cells. 
(D) Each bar represents the response (depicted as relative [Ca
2+
]CYT) to 100 µM ATP. Each bar 
represents mean ± SEM (n = 3), from three independent experiments. Statistical analysis was 
performed using an unpaired t-test (P > 0.05). 
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3.3.3 Effect of CD24 siRNA-mediated silencing on CXCL12-induced increases in [Ca
2+
]CYT 
in MDA-MB-468 cells 
Given reports of CD24-mediated attenuation of CXCR4-mediated cell migration and tumour 
growth in MDA-MB-231 cells (303), the present study further explored if CD24 silencing could 
restore CXCL12-induced increases in [Ca
2+
]CYT in MDA-MB-468 breast cancer cells. CD24 
silencing did not promote CXCL12-induced increases in [Ca
2+
]CYT in MDA-MB-468 cells (Figure 
3.4), suggesting that differences in CD24 levels are not responsible for the differences in CXCL12-
mediated Ca
2+
 signalling between MDA-MB-468 and MDA-MB-231 breast cancer cells. 
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Figure ‎3.4: Consequences of CD24 siRNA-mediated silencing on CXCL12-induced Ca2+ 
signalling in MDA-MB-468 breast cancer cells. Representative Ca
2+
 responses in the presence or 
absence of CD24 siRNA-mediated knockdown in MDA-MB-468 breast cancer cells.  
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3.3.4 CXCR4 mRNA expression levels in MDA-MB-468 and MDA-MB-231 cells 
Differences in CXCL12-mediated increases in [Ca
2+
]CYT between MDA-MB-468 and MDA-MB-
231 cells could also be due to differences in CXCR4 levels. CXCR4 mRNA levels were therefore 
compared in these two cell lines. CXCR4 mRNA was significantly higher in MDA-MB-231 cells as 
compared to MDA-MB-468 cells (Figure 3.5). 
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Figure ‎3.5: Relative CXCR4 mRNA levels in MDA-MB-231 and MDA-MB-468 basal-like breast 
cancer cell lines. CXCR4 mRNA levels were quantified using real-time RT-PCR relative to 18S 
ribosomal RNA (-ΔCT). Results are from three independent experiments, (n = 3) and are shown as 
mean ± SEM. Statistical analysis was performed using an unpaired t-test; ** denotes P < 0.01. 
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3.3.5 CXCR4 mRNA expression levels in EGF-induced EMT in MDA-MB-468 cells 
EGF-mediated EMT in MDA-MB-468 breast cancer cells is associated with the expression of 
mesenchymal proteins such as those expressed endogenously in MDA-MB-231 cells (e.g. vimentin) 
(306). Since the endogenous CXCR4 mRNA expression levels were significantly higher in MDA-
MB-231 cells (mesenchymal marker rich) than in MDA-MB-468 cells (mesenchymal marker poor) 
(306,307), the ability of the EMT inducer EGF to increase CXCR4 mRNA levels was assessed in 
MDA-MB-468 cells. However, induction of EMT in MDA-MB-468 cells with EGF decreased 
CXCR4 mRNA levels (Figure 3.6). This finding suggests that increases in CXCR4 mRNA in 
MDA-MB-231 cells are not related to the acquisition of a more mesenchymal phenotype. 
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Figure ‎3.6: Relative CXCR4 mRNA levels in EGF-induced EMT (48 hours post-EGF treatment) in 
MDA-MB-468 breast cancer cells. CXCR4 mRNA levels were quantified using real-time RT-PCR 
relative to 18S ribosomal RNA and expressed as fold change (2
-ΔΔCT
). Results are from three 
independent experiments, (n = 3) and are shown as mean ± SEM. Statistical analysis was performed 
using an unpaired t-test; * denotes P < 0.05. 
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3.4 Discussion 
These studies identified distinct CXCL12-induced Ca
2+
 responses between two basal-like breast 
cancer cell lines, - MDA-MB-231 and MDA-MB-468 cells. CXCL12-mediated Ca
2+ 
responses were 
only observed in MDA-MB-231 breast cancer cells while these agonist-mediated Ca
2+ 
responses 
were absent in MDA-MB-468 cells. Of note, the initial increase in relative [Ca
2+
]CYT  observed prior 
to CXCL12 stimulation in MDA-MB-468 cells may be due to addition artefacts introduced by the 
rapid fluid addition (308) during the dispensing of the agonist onto the cells. CXCL12/CXCR4-
mediated Ca
2+
 signalling has been reported to be enhanced in metastatic breast cancer cell lines 
such as MDA-MB-231 and BT-549 compared to non-metastatic cell lines (309). The results 
obtained from the present study extend these findings since CXCL12-induced increases in [Ca
2+
]CYT 
were more pronounced in the more metastatic MDA-MB-231 cell line compared to the less 
metastatic MDA-MB-468 cell line.  
 
The potential cause of the differential CXCL12-induced Ca
2+ 
signalling between MDA-MB-231 
and MDA-MB-468 basal-like breast cancer cell lines was explored by comparing the mRNA 
expression levels of CD24, a known negative regulator of CXCR4 function in breast cancer cells 
(303). CD24 mRNA was indeed higher in the poorly metastatic MDA-MB-468 cells in comparison 
to the highly metastatic MDA-MB-231 cells. The differential CD24 expression observed in the 
present study is in agreement with previous work by Schindelmann et al (310) which although did 
not involve the assessment of MDA-MB-468 breast cancer cells, did report that CD24 mRNA 
levels are higher in non-invasive breast cancer cell lines compared to invasive breast cancer cell 
lines. 
 
ATP is a major extracellular messenger that mediates Ca
2+
 signalling in various cell types including 
astrocytes, microglial cells and human prostate cancer cells (311-313). The effect of CD24 siRNA-
mediated knockdown on ATP-mediated Ca
2+
 signalling was investigated in MDA-MB-468 breast 
cancer cells. No alteration was observed in the nature of ATP-induced Ca
2+
 transients or the peak 
relative [Ca
2+
]CYT achieved when CD24 was silenced in MDA-MB-468 cells. The absence of an 
effect of CD24 downregulation on ATP-induced Ca
2+ 
transients suggests that CD24 does not play 
an important role as a regulator of global Ca
2+ 
signalling in MDA-MB-468 cells. Of note, addition 
of sub-maximal concentration of ATP (0.6 µM) in MDA-MB-468 cells was associated with a 
plateau phase of [Ca
2+
]CYT. The plateau phase of [Ca
2+
]CYT could either be due to: 1. influx of Ca
2+ 
through plasma membrane channels (since the cells were incubated in PSS containing 1.8 mM Ca
2+ 
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as described in Section 3.2.3 and in the absence of extracellular Ca
2+ 
chelator BAPTA) or 2. 
spontaneous Ca
2+
 oscillations which have been reported to be a defining feature of this cell line 
(284). 
 
Although CD24, a negative regulator of CXCR4 (303), was elevated in MDA-MB-468 cells, 
inhibition of CD24 expression failed to promote increases in [Ca
2+
]CYT after CXCL12 stimulation in 
MDA-MB-468 cells. The inability of CD24 silencing to restore CXCL12-induced increases in 
[Ca
2+
]CYT suggests that inhibiting CD24 to ‘mirror’ its expression levels in MDA-MB-231 cells 
does not allow the less metastatic MDA-MB-468 cells to acquire the same Ca
2+ 
phenotype as of the 
more metastatic MDA-MB-231 cells. Taken together, these data also suggest that the absence of 
Ca
2+
 responses in MDA-MB-468 cells is not related to differences in CD24 mRNA levels. Instead 
the differences in MDA-MB-231 and MDA-MB-468 [Ca
2+
]CYT responses to CXCL12 may be 
related to divergent CXCR4 expression levels, which were higher in MDA-MB-231 cells compared 
to MDA-MB-468 cells. These findings are in accordance with previous results demonstrating high 
CXCR4 expression in invasive MDA-MB-231 cells compared to non-invasive MDA-MB-468 cells 
when assessed using Northern blotting (314). A large tissue microarray study of clinical breast 
tissue samples identified that CXCR4 receptor is expressed in many invasive breast cancers and that 
its expression correlates with tumour aggressiveness and patient survival (315). My observation of 
significantly reduced CXCR4 mRNA levels and CXCL12 [Ca
2+
]CYT responses in MDA-MB-468 
cells leads to the hypothesis that differences in Ca
2+
 responses may, in part, contribute to 
differences in invasive properties of breast cancer cells. 
 
To determine if differences in CXCR4 levels between MDA-MB-468 and MDA-MB-231 cells are 
associated with the more invasive mesenchymal phenotype, CXCR4 mRNA levels were assessed in 
an in vitro model of EMT. CXCR4 mRNA levels decreased with EGF treatment, indicating that the 
high levels of CXCR4 mRNA in MDA-MB-231 cells are unlikely to be the consequence of a more 
mesenchymal state. These findings are in contrast to observations in ovarian cancer cells where 
CXCR4 expression is upregulated by EGF (316), suggesting that the regulation of CXCR4 may be 
cancer cell type specific.  
 
In conclusion, although there are significant differences in expression levels of the CXCR4 negative 
regulator CD24 between MDA-MB-231 and MDA-MB-468 cells, this difference is not responsible 
for the augmented [Ca
2+
]CYT responses to the CXCR4 activator CXCL12 in MDA-MB-231 cells 
compared to MDA-MB-468 cells. Given the lack of potentiation of CXCL12-induced Ca
2+ 
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responses through the reduction of CD24 expression levels in MDA-MB-468 cells, future studies 
assessing the effect of CD24 induced overexpression on CXCL12-induced Ca
2+ 
release in MDA-
MB-231 cells are now required. Such studies would explore further the possible regulatory role of 
CD24 on CXCL12/CXCR4-mediated Ca
2+ 
signalling in breast cancer cells. Calcium signalling 
results obtained from such studies would be valuable and should be correlated with the 
aforementioned work of Schabath et al (303) who investigated the role of CD24 in 
CXCL12/CXCR4 proliferative and migration responses in MDA-MB-231 cells with endogenously 
low CD24 levels and MDA-MB-231 cells overexpressing CD24.  
 
Further studies are also required to determine if the enhanced [Ca
2+
]CYT responses to CXCL12 in 
the MDA-MB-231 breast cancer cell line compared to MDA-MB-468 cells contributes to the 
greater metastatic potential of this cell line. In addition to CXCL12/CXCR4-mediated Ca
2+ 
signalling, it is also noteworthy to assess and compare basal [Ca
2+
]CYT levels between these two 
phenotypically different breast cancer cell lines. However, the use of nonratiometric Ca
2+ 
indicator 
Fluo-4 in the present study did not allow accurate calibration of intracellular Ca
2+ 
concentration 
which is required for the assessment of basal levels of intracellular Ca
2+ 
(317). Previous studies 
from our laboratory have reported that MDA-MB-468 cells exhibit greater non-stimulated Ca
2+ 
influx compared to MDA-MB-231 cells (284). Although this finding has provided an insight into 
the different characteristics that exist between MDA-MB-468 and MDA-MB-231 cells, future 
studies should use ratiometric dyes to allow for more accurate comparison of Ca
2+ 
regulation in 
these two breast cancer cell lines (317), particularly for the assessment of basal intracellular Ca
2+ 
concentration.     
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3.5 Conclusion 
In this chapter, key experiments were conducted to characterise CD24 in breast cancer by assessing 
the nature of Ca
2+ 
signalling responses in the context of CXCL12/CXCR4 interaction. CXCL12 
stimulation elicited more pronounced increases in [Ca
2+
]CYT in MDA-MB-231 cells compared to 
MDA-MB-468 cells. Given evidence for the negative regulation of CXCR4 function by CD24 in 
breast cancer cells, the mRNA expression level of CD24 was investigated in both breast cancer cell 
lines. CD24 mRNA was higher in MDA-MB-468 cells than MDA-MB-231 cells. Despite the 
significant upregulation of CD24 in MDA-MB-468 cells, silencing of CD24 had no profound effect 
on CXCL12-mediated Ca
2+ 
responses in this cell line. These findings indicate that CD24 is not a 
regulator of Ca
2+ 
signalling in breast cancer cells.  
CXCR4 mRNA expression was analysed in both breast cancer cell lines to ascertain if CXCR4 
levels may contribute to the regulation of Ca
2+ 
responses. Real-time RT-PCR confirmed a 
significant upregulation of endogenous CXCR4 in MDA-MB-231 cells in comparison to MDA-
MB-468 cells. This finding suggests that CXCR4 expression, but not CD24 expression, may in part 
contribute to the divergent CXCL12-activated Ca
2+ 
signalling in MDA-MB-231 and MDA-MB-468 
cells. Further analysis of CXCR4 mRNA expression during EGF-induced EMT in MDA-MB-468 
cells showed a significant downregulation of the CXCR4 receptor levels, indicating that increased 
CXCR4 mRNA expression is not associated with the acquisition of a mesenchymal phenotype.  
The following two chapters of this thesis focus on the characterisation of another selected hit from 
the siRNA screen – the Ca2+ permeable ion channel TRPV4 in MDA-MB-231 and MDA-MB-468 
basal-like breast cancer cells. 
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CHAPTER 4 : Characterisation of TRPV4 Channels in MDA-MB-231 Breast Cancer Cells 
4.1 Introduction 
The TRP protein superfamily is composed of a large group of cation channels with diversity and 
versatility in ion selectivity, mechanisms of activation and functions (54). The TRP superfamily is 
categorised into seven main subfamilies. Among these subfamilies is the TRPV subfamily, 
consisting of six distinct members (TRPV1-6) (54). One common feature of TRP channels is 
polymodal activation – a characteristic of being responsive to several types of different stimuli 
(54,56). TRPV4 is polymodal since this channel can be activated by diverse stimuli both physical 
(heat, changes in extracellular osmolarity, mechanical stress, cell swelling) (264-266,318) and 
chemical (arachidonic acid, anandamide, phorbol esters) (319,320). Unlike TRPV5 and TRPV6 
channels which exhibit high selectivity for Ca
2+
 (permeability ratio PCa/PNa exceeding 100) (321), 
TRPV4 is permeable to both Ca
2+ 
and Na
+ 
with a PCa/PNa value of 6 (264). Expression of TRPV4 
has been documented in many cell types, predominantly in epithelial cell types (272,322-324). 
TRPV4 is expressed in a wide range of tissues such as lung, kidney, liver, heart, brain, urinary 
bladder and salivary gland (264,267,325-329). TRPV4 has been reported to participate in 
osmoregulation, mechanosensation, cell volume regulation and thermoregulation (54,265-267,330).  
 
4.1.1 Structure of TRPV4 
The predicted structure of TRPV4 is similar to that of other TRP channels with intracellular N- and 
C-termini, containing six transmembrane-spanning domains (TM1-TM6) and a hydrophobic pore 
forming region between TM5 and TM6 (55,267). TRPV4 possesses at least three ankyrin (ANK) 
repeat domains in its cytosolic N terminus (264,267). These ANK repeats, which are described as 
modular protein domains, mediate specific protein-protein interactions (331) and are required for 
oligomerisation of TRPV4 (332). As identified from screening the expressed-sequence tag (EST) 
database, TRPV4 consists of 871 amino acid (aa) residues (264,267). Based on sequence homology, 
TRPV4 is a close relative to TRPV1 and TRPV2 since it displays approximately 40 percent 
sequence identity (55,264). A schematic diagram of the TRPV4 structure is illustrated in Figure 4.1. 
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Figure ‎4.1: Putative structure of TRPV4 channels showing the six transmembrane-spanning 
domains (TM), pore region, cytoplasmic N- and C- termini and ankyrin (ANK) repeats. Figure 
adapted from reference (55). 
 
4.1.2 TRPV4 alternative splicing 
Alternative pre-mRNA splicing is a process of genetic regulation which contributes to protein 
diversity (333). Several splice variants encoding different isoforms have been recognised within the 
TRP superfamily and TRPV4 is no exception (334). Thus far, five different TRPV4 transcript 
variants have been reported in human airways epithelial cell lines (332). These splice variants are 
referred to as TRPV4-A and TRPV4-B (Δ384-444 aa) and the newly discovered TRPV4-C (Δ237-
284 aa), TRPV4-D (Δ27-61 aa) and TRPV4-E (Δ237-284 and Δ384-444 aa). TRPV4-A, encoding 
the full-length isoform is responsive to various stimuli (332,335). TRPV4-B lacks exon number 7, 
TRPV4-C lacks exon 5, TRPV4-D has a short deletion inside exon 2 and TRPV4-E is a result of 
double alternative splicing lacking exons 5 and 7 (332). Functional analysis of TRPV4 variants 
reveals that only TRPV4-A and TRPV4-D produce Ca
2+ 
responses upon stimulation with different 
TRPV4 activators, owing to their cell surface expression. In contrast, the remaining three variants 
are not functional, presumably due to the lack of parts of the ANK domains and oligomerisation and 
thus, these variants are retained in the endoplasmic reticulum (332). Hence, the characterisation of 
TRPV4 in breast cancer cells should include assessment of TRPV4 channel activity.  
 
4.1.3 Pharmacological modulators of TRPV4 
Some of the known small molecule modulators of TRPV4 are outlined in Table 4.1. The reported 
agonists and antagonists of TRPV4 have been comprehensively reviewed elsewhere (336-338).  
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Table ‎4.1: List of pharmacological modulators of TRPV4. 
TRPV4 
modulators 
Compound name Description 
Potency 
(EC50/IC50) 
Refs 
Activators 
4α-phorbol 12,13-
didecanoate (4α-
PDD) 
A selective TRPV4 
activator which directly 
interacts with the 
channel 
200 - 400 nM (319,338) 
Bisandrographolide 
A (BAA) 
An active compound in 
the extract of 
Andrographis 
paniculata used in 
traditional Chinese 
medicine 
0.79 - 0.95 µM (339) 
RN 1747 
Identified from a 
focused screen of 
commercial ortho- and 
para-substituted aryl 
sulphonamides 
0.77 µM (340) 
GSK1016790A 
Discovered in 2008 
from a small molecule 
screen 
2.1 nM (325) 
Inhibitors 
RN 1734 
Identified from the 
same focused library as 
RN 1747 
2.3 µM (340) 
HC067047 
Discovered in a high-
throughput screen as a 
potent and selective 
TRPV4 antagonist 
48 nM (341) 
GSK2193874 
Identified from a small 
molecule screen and 
chemical optimisation 
as a selective and orally 
active TRPV4 blocker 
40 - 50 nM (342) 
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For the purpose of this PhD thesis, the TRPV4 activator GSK1016790A (325) and the TRPV4 
inhibitor RN 1734 (340) were used to functionally characterise TRPV4 in basal-like breast cancer 
cells. GSK1016790A was selected in the present study because this compound exhibits higher 
agonist potency (300-fold greater) (325) than the non-selective TRPV4 activator 4α-PDD (319). 
Given the ability of RN 1734 to fully antagonise ligand-gated and hypotonicity-induced activation 
of TRPV4 as well as its selectivity for TRPV4 channels (340), this compound was also chosen to 
probe the role of TRPV4 in breast cancer cells.  
 
4.1.4 TRPV4 and interacting proteins 
4.1.4.1 PACSIN 3 
From a yeast two-hybrid screen, the PACSINs have been identified as TRPV4-binding partners 
(343). The PACSINs are a family of phosphoproteins comprised of three isoforms (PACSIN 1-3) 
which are important in synaptic vesicular membrane trafficking and endocytosis (344,345). 
Cuajungco et al (343) showed that PACSIN 3 specifically interacts with TRPV4 at the N-terminal 
proline-rich domain of TRPV4. The functional interaction between TRPV4 and PACSIN 3 has been 
demonstrated to inhibit the endocytosis and alter the subcellular distribution of TRPV4 channels 
(343). A subsequent study provided further evidence for the role of PACSIN 3 as an auxiliary 
protein of TRPV4 that modulates TRPV4 activation in a stimulus-specific manner (346).     
 
4.1.4.2 MAP7 
Using a yeast two-hybrid approach, MAP7 which encodes for microtubule-associated protein 7 was 
found to interact with TRPV4 both in vitro and in vivo (347). The interaction site between MAP7 
and TRPV4 involves the C terminus of TRPV4 within residues 798 and 809. Co-expression of 
MAP7 and TRPV4 leads to the redistribution of TRPV4 toward the plasma membrane, thereby 
increasing the expression levels of TRPV4 at the plasma membrane (347). 
 
4.1.4.3 IP3 receptor 
Another reported protein partner of TRPV4 is the IP3 receptor (348). Coimmunoprecipitation assays 
by Fernandes et al (348) revealed a physical interaction between TRPV4 and IP3R3 which 
sensitised TRPV4 to the mechano- and osmotransducing messenger 5’-6’-epoxyeicosatrienoic acid 
(EET). The IP3R3-interaction site is localised to the C terminus of TRPV4 and appears to overlap 
with the previously identified calmodulin (CaM)-binding site (349,350). 
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4.1.5 TRPV4 and cancer 
The involvement of TRPV4 in cancer has not been extensively assessed. However, TRPV channels 
in general have been implicated in the regulation of processes such as proliferation, apoptosis, 
angiogenesis, migration and invasion during tumour progression (269). Recent studies have begun 
to suggest a role for TRPV4 in some types of cancer. Vriens and colleagues (268) demonstrated 
functional expression of TRPV4 in human hepatoblastoma HepG2 cells. The authors evaluated the 
functionality of TRPV4 in HepG2 cells using several stimuli including 4α-PDD, arachidonic acid, 
hypotonic stress and heat activation. These stimuli (all previously reported to activate TRPV4) led 
to an increase in intracellular Ca
2+
, suggesting that TRPV4 is a functional Ca
2+ 
entry channel in 
HepG2 cells (268). However, the effect of TRPV4 on Ca
2+
-dependent cellular processes such as cell 
proliferation and cell death were not assessed in studies using HepG2 cells.  
 
The first evidence to associate TRPV4 with breast cancer is presented in a recent publication by 
Friorio Pla et al (270) who identified the pivotal role of TRPV4 in mediating arachidonic acid-
induced migration of breast tumour-derived endothelial cells (BTEC). When compared with 
‘normal’ endothelial cells (HMVEC), the endogenous expression of TRPV4 was significantly 
greater in BTEC. Consistent with the levels of TRPV4 expression, stimulation with the TRPV4 
activator 4α-PDD elicited more pronounced increases in [Ca2+]CYT in BTEC than HMVEC cells, 
demonstrating that TRPV4 is functional in both cell types (270). Inhibition of TRPV4 using the 
non-specific TRPV4 antagonist ruthenium red (319) and shRNA abolished arachidonic acid-
induced BTEC migration. These results demonstrated the role of TRPV4 in the migration of BTEC. 
Friorio Pla et al (270) highlighted the potential of TRPV4 as a novel drug target for breast tumours 
in the context of angiogenesis. However, the study was limited since no assessment was performed 
on the effect of TRPV4 activation on cell proliferation and cell death. Furthermore, the potential 
expression of TRPV4 in breast cancer cells was not assessed. 
 
As outlined in Section 2.3 of this thesis, high throughput siRNA screening with the MDA-MB-231 
breast cancer cell line using siRNAs targeting Ca
2+ 
signalling modifying proteins identified TRPV4 
as a positive hit. Despite the established roles of other TRP channels (such as TRPV6) in some 
breast cancers (165,179,181,205,351-353), the role of TRPV4 in breast cancer remains poorly 
understood. Section 2.3.4.3 evaluated the mRNA levels of TRPV4 in two different basal-like breast 
cancer cells and found the presence of TRPV4 mRNA in MDA-MB-231 and MDA-MB-468 breast 
cancer cells. Chapters Four and Five of this thesis characterise the potential role of TRPV4 in the 
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regulation of Ca
2+
 signalling and Ca
2+
-dependent cancer-related pathways including cell 
proliferation and cell death in breast cancer cells. 
 
Specific hypotheses and aims to be addressed in this chapter are: 
 
Chapter 4 hypotheses: 
I. TRPV4 is a functional Ca2+ channel in MDA-MB-231 basal-like breast cancer cells. 
II. Pharmacological modulation of TRPV4 alters cell viability and cell death in MDA-MB-231 
basal-like breast cancer cells. 
Chapter 4 aims: 
I. To assess the functional activity of TRPV4 channels using a pharmacological activator of 
TRPV4 in MDA-MB-231 breast cancer cells. 
II. To silence TRPV4 expression using siRNA and to investigate the functional consequences 
on Ca
2+ 
signalling mediated by a TRPV4 activator in MDA-MB-231 breast cancer cells. 
III. To assess the effect of a TRPV4 pharmacological inhibitor on viable cell number in MDA-
MB-231 breast cancer cells. 
IV. To evaluate the effect of a TRPV4 pharmacological activator on viable cell number and cell 
death in MDA-MB-231 breast cancer cells.  
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4.2 Materials and Methods 
4.2.1 Materials 
GSK1016790A, dimethyl sulfoxide (DMSO) and ATP disodium salt hydrate were purchased from 
Sigma-Aldrich. RN 1734 was purchased from Tocris Bioscience. Hoechst 33342 (10 mg/mL) and 
propidium iodide (1 mg/mL) were obtained from Invitrogen. ABT-263 was purchased from 
Selleckchem. 
 
4.2.2 Cell culture for MDA-MB-231 breast cancer cells 
The human MDA-MB-231 breast cancer cell line (ATCC) was routinely subcultured at a split ratio 
of 1:4. Cells were grown in high glucose DMEM (D6546) (Sigma-Aldrich) supplemented with 10% 
FBS (Sigma-Aldrich) and 4 mM L-glutamine (Invitrogen). Cells were maintained in a humidified 
incubator (37°C, 5% CO2) and routinely screened for mycoplasma contamination using the 
MycoAlert Mycoplasma Detection Kit (LT07-218, Lonza). Cultured cells were passaged less than 
nine times for all experiments.   
 
4.2.3 Intracellular Ca
2+ 
measurement 
For intracellular Ca
2+
 measurements, MDA-MB-231 cells (7.5 X 10
3 
cells per well) were plated into 
a 96-well CellBIND plate (Corning) in antibiotic-free media. At 24 hours post-plating, the FBS 
concentration was reduced to 8% and where appropriate, cells were treated with TRPV4 siRNA or 
non-targeting siRNA. Total RNA was isolated 24 hours post-transfection to confirm mRNA 
knockdown of TRPV4 prior to Ca
2+ 
assays (refer to Section 4.2.5 for details). At 72 hours post-
treatment, Ca
2+ 
assays were performed using the FLIPR
TETRA 
(Molecular Devices) as previously 
described in Section 3.2.3. Data were acquired using ScreenWorks™ Software (Molecular Devices) 
and are presented as response/baseline as a relative measure of cytosolic free Ca
2+ 
([Ca
2+
]CYT). 
Response/baseline has no units, as the unit is a ratio. Peak relative [Ca
2+
]CYT was determined by 
recording the maximum relative fluorescence (response/baseline) value achieved during the 
duration of the exposure to activator (800 seconds). Rate of rise in [Ca
2+
]CYT was assessed between 
20 seconds to 80 seconds after addition of the activator. For rate, units are response/baseline.s
-1
. 
Area under the curve was calculated between 20 seconds and 200 seconds after addition of the 
activator and corrected by subtracting the area calculated from ScreenWorks 2.0 Software with the 
area from a theoretical non-response. Both parameters (rate of rise in [Ca
2+
]CYT and area under the 
curve) were analysed using ScreenWorks 2.0 Software and Microsoft Excel. 
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4.2.4 Silencing of TRPV4 expression  
MDA-MB-231 cells were seeded at 7.5 X 10
3 
cells per well in a 96-well plate in antibiotic-free 
media and allowed to adhere overnight. Dharmacon ON-TARGET plus SMARTpool siRNAs 
(Dharmacon) were used at a final concentration of 100 nM. DharmaFECT 4 transfection reagent 
was used at a volume of 0.1 µL per well (100 µL total volume). Cells were incubated with 
Dharmacon ON-TARGET plus SMARTpool TRPV4 siRNA (L-004195-00-0005) or control ON-
TARGET plus Non-Targeting pool siRNA (D-001810-10-05) according to the guidelines provided 
by the manufacturer. TRPV4 mRNA silencing was confirmed at 24 hours post-siRNA by real-time 
RT-PCR (refer to Section 4.2.5 for method) (Applied Biosystems). Data were normalised to 
18SrRNA and analysed using the comparative CT method (194).  
 
4.2.5 RNA isolation and Real-time RT-PCR 
MDA-MB-231 cells were plated at 7.5 X 10
3 
cells per well in a 96-well plate in antibiotic-free 
media and siRNA-transfected. Following siRNA transfection (24 hours), total RNA was isolated 
using a RNeasy
®
 Plus Mini Kit (Qiagen) and reverse-transcription reactions were carried out using 
a Omniscript Reverse Transcriptase kit (Qiagen) with random primers and RNase inhibitor 
(Promega) under standard conditions described by the manufacturer. Samples were incubated in a 
GeneAmp
®
 PCR System 2400 Thermal Cycler (PerkinElmer) at 37°C for 60 minutes. The PCR step 
was then conducted using Assays-on-Demand FAM-MGB primer/probe sets and TaqMan 
Universal PCR Master Mix (Applied Biosystems). Assays included human TRPV4 
(Hs01099348_m1) and the endogenous control 18SrRNA (4319413E, VIC-MGB primer/probe). As 
specified by the manufacturer, the assay used for detecting TRPV4 expression is the most 
recommended primer/probe set for standard gene expression experiments and it recognises all five 
TRPV4 splice variants (332). All amplifications were performed using universal cycling conditions: 
10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C in a 
StepOnePlus™ Real-Time PCR System Thermal Cycling Block (Applied Biosystems). Data 
analyses were performed using the comparative CT method (relative quantification) as described 
previously (194).  
 
4.2.6 Relative viable cell number assay  
Viable cell number was approximated using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) (Promega) following the manufacturer’s protocol. The following agents 
were used in this assay: GSK1016790A (Sigma-Aldrich) and RN 1734 (Tocris Bioscience). 
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GSK1016790A was added to the cells to a final concentration of 1-, 10- or 100 nM whereas RN 
1734 was added to a final concentration of 1-, 10- or 100 µM. These concentrations were selected 
based on published EC50 (325,354) and IC50 (340) values for these compounds and concentrations 
used by other investigators (355-357). MDA-MB-231 cells were seeded in 96-well plates at 4.0 X 
10
3 
cells per well and incubated for 24 hours. The medium was then replaced with fresh medium 
with or without the drugs and cells were cultured for five or seven days. Throughout the incubation 
period, the medium was replenished with fresh reagents every two days except for the day of an 
MTS assay (day 5 and day 7). An MTS assay for viable cell number was performed at the time 
points stated in the results by adding 20 µl of CellTiter 96® AQueous One Solution Reagent into each 
well and incubating the plate for 2 hours at 37°C in a humidified, 5% CO2 atmosphere. Following 
incubation, the absorbance in each well was determined at 490 nm using a BioRad iMark
TM 
Microplate Reader (Bio-Rad Laboratories).  
 
4.2.7 High content imaging assay for cell death 
MDA-MB-231 cells (5.0 X 10
3 
cells per well) were plated in a 96-well imaging plate (BD 
Biosciences) in antibiotic-free media and incubated overnight. Concentration of FBS was reduced 
to 8% 24 hours post-plating to mimic siRNA transfection. After 72 hours, media was removed and 
cells were treated with GSK1016790A (Sigma-Aldrich), ABT-263 (Selleckchem), or DMSO for 48 
hours in phenol-red free DMEM containing 8% FBS. All drug concentrations were expressed as the 
final concentration in the cells and specified in the figures. The final concentration of DMSO in 
each well for all treatment groups was maintained at 0.13% throughout the experimental conditions. 
Cells were then stained with Hoechst 33342 (10 µg/mL, Invitrogen) and propidium iodide (1 
µg/mL, Invitrogen) for 15 minutes at 37°C prior to imaging. Cell imaging was performed using an 
ImageXpress micro automated epifluorescence microscope (Molecular Devices Corporation) as 
previously published (358). Percentage of propidium iodide positive cells and total cell number 
were determined using the multi-wavelength cell scoring application module (MetaXpress version 
3.1.0.83; Molecular Devices). 
 
4.2.8 Statistical analysis 
Statistical analyses were performed using Prism5 (Graph Pad Software version 5.04). The statistical 
tests used in this chapter are indicated in each figure legend. The EC50 calculation was performed 
using a nonlinear regression analysis in Prism5. Results are expressed as mean ± SEM.  
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4.3 Results 
4.3.1 Assessment of TRPV4 channels in MDA-MB-231 breast cancer cells 
To determine if the mRNA levels of TRPV4 is associated with a functional Ca
2+ 
permeable ion 
channel in MDA-MB-231 cells, intracellular Ca
2+
 was assessed in response to GSK1016790A 
stimulation – a potent and specific TRPV4 agonist (325), using the fluorescence Ca2+ sensor dye 
Fluo-4. Stimulation with 100 nM GSK1016790A induced a slow Ca
2+ 
response as evident from a 
sustained elevation of intracellular free Ca
2+ 
(Figure 4.2A). This Ca
2+ 
response was less than that of 
intracellular Ca
2+ 
increases when the same cell line was activated with 100 µM of the purinergic 
receptor activator ATP (201) (Figure 4.2A). To ascertain the potency of GSK1016790A on TRPV4 
channels, a concentration-response curve was performed in MDA-MB-231 cells. A concentration-
response curve of GSK1016790A showed an EC50 of 76 nM (Figure 4.2B). Taken together, these 
findings reveal that TRPV4 is a functional Ca
2+ 
entry channel in MDA-MB-231 cells.    
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Figure ‎4.2: (A) Effect of GSK1016790A (100 nM) stimulation on relative [Ca2+]CYT in MDA-MB-
231 cells. Representative Ca
2+
 traces showing average of three different wells from a single 
experiment shown as response/baseline. Stimulation with 100 µM ATP was used as a positive 
control for the assay. (B) Concentration-response curve for GSK1016790A in MDA-MB-231 cells. 
Results are pooled from four independent experiments, (n = 4) and are shown as the mean ± SEM. 
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4.3.2 TRPV4 siRNA-mediated silencing in MDA-MB-231 breast cancer cells 
To establish the functional role of TRPV4 channels in MDA-MB-231 breast cancer cells, TRPV4 
expression was inhibited using siRNA. Silencing of TRPV4 was achieved in this cell line. TRPV4 
siRNA significantly reduced TRPV4 mRNA levels when compared to the non-targeting siRNA 
(NT siRNA) control (Figure 4.3). 
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Figure ‎4.3: TRPV4 silencing in MDA-MB-231 breast cancer cells. Cells were plated in a 96-well 
plate and TRPV4 expression was inhibited using Dharmacon ON-TARGET Plus SMARTpool 
siRNA. Total RNA was isolated at 24 hours post-transfection and knockdown of TRPV4 relative to 
the non-targeting siRNA (NT siRNA) control was confirmed using real-time RT-PCR. Each bar 
represents the mean ± SEM (n = 3). Statistical analysis was performed using an unpaired t-test; ** 
denotes P < 0.01 compared to the NT siRNA control. 
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4.3.3 Effect of TRPV4 siRNA-mediated silencing on GSK1016790A-induced Ca
2+ 
influx in 
MDA-MB-231 breast cancer cells 
To assess the functional consequences of TRPV4 siRNA-mediated silencing on Ca
2+ 
signalling, 
MDA-MB-231 breast cancer cells were activated with 1 µM GSK1016790A in the presence or 
absence of TRPV4 siRNA. GSK1016790A-induced Ca
2+ 
influx was markedly inhibited by TRPV4-
specific siRNA in MDA-MB-231 cells (Figure 4.4A). TRPV4 silencing also altered the nature of 
Ca
2+ 
responses, with a decreased rate of rise in [Ca
2+
]CYT and area under the curve in MDA-MB-231 
cells in response to GSK1016790A stimulation (Figure 4.4A, B and C). 
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Figure ‎4.4: Effect of TRPV4 siRNA-mediated knockdown on GSK1016790A-induced Ca2+ 
signalling responses in MDA-MB-231 breast cancer cells. (A) Representative GSK1016790A (1 
µM)-induced Ca
2+ 
influx in the presence or absence of TRPV4 siRNA-mediated knockdown in 
MDA-MB-231 cells. Ca
2+
 traces are shown as the average of three different wells from a single 
experiment and depicted as response/baseline. Bar graphs show (B) rate of rise in [Ca
2+
]CYT 
calculated between 20 s and 80 s and (C) area under the curve determined between 20 s and 200 s. 
Results are pooled from three independent experiments, (n = 3) and are shown as the mean ± SEM. 
Statistical analysis was performed using a paired t-test; * denotes P < 0.05. 
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4.3.4 Effect of RN 1734 on cell viability in MDA-MB-231 breast cancer cells 
The potential role of TRPV4 channels in cell proliferation was explored by evaluating the effect of 
RN 1734 – a recently reported selective TRPV4 antagonist (340) on the viability of MDA-MB-231 
breast cancer cells using an MTS assay. Low concentrations of RN 1734 (i.e. 0 -, 1 - and 10 µM) 
did not cause a significant alteration in the absorbance at 490 nm (A490) (an approximation of 
viable cells in culture, whereby the relationship between cell number and absorbance value is 
linear) in MDA-MB-231 cells at either time point (Figure 4.5A and B). This observation suggests 
that TRPV4 channels do not play a key role in regulating cell proliferation, at least in MDA-MB-
231 cells. This finding also indicates that pharmacological inhibition of TRPV4 is not anti-
proliferative at relevant concentrations of RN 1734. However, cytotoxicity was detected when cells 
were treated with 100 µM RN 1734, as demonstrated by a significant reduction in the A490 reading 
(Figure 4.5A and B). This concentration is well above the reported IC50 for this compound (2.3 µM) 
(340). 
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Figure ‎4.5: Effect of RN 1734 on relative viable cell numbers in MDA-MB-231 breast cancer cells 
as determined by an MTS assay. Cells were treated with various concentrations of RN 1734 for up 
to 7 days. Viable cell number was approximated using an MTS assay as described in the methods 
section. Viability results are depicted as absorbance at 490 nm. (A and B) Bar graphs show the 
treatment of MDA-MB-231 cells for 5 days (A) or 7 days (B) with RN 1734. Results are pooled 
from three independent experiments, (n = 3) and are shown as mean ± SEM. Statistical analysis was 
performed using a one-way ANOVA with Tukey’s multiple comparison test; *** denotes P < 
0.0001 compared to control. 
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4.3.5 Effect of GSK1016790A on viable cell number in MDA-MB-231 breast cancer cells 
To further assess the possible role of TRPV4 in regulating cell proliferation of MDA-MB-231 
breast cancer cells, different concentrations of GSK1016790A were applied, ranging from 0 nM to 
100 nM. TRPV4 activation using various concentrations of GSK1016790A in MDA-MB-231 cells 
produced no change on cellular viability at either time point tested (Figure 4.6A and B). This 
finding indicates that TRPV4 activation does not affect cell proliferation in MDA-MB-231 cells. 
The absence of effects of TRPV4 activation by GSK1016790A on MDA-MB-231 viable cell 
numbers also suggests that GSK1016790A does not promote cell death in this cell line. 
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Figure ‎4.6: Effect of GSK1016790A treatment on relative viable cell number in MDA-MB-231 
breast cancer cells as determined by an MTS assay. Cultured cells were treated with various 
concentrations of GSK1016790A for up to 7 days. Viability was assessed using an MTS assay as 
described in the methods section. Results are depicted as absorbance at 490 nm.  (A and B) Bar 
graphs show the treatment of MDA-MB-231 cells for 5 days (A) or 7 days (B) with GSK1016790A. 
Results are pooled from three independent experiments, (n = 3) and are shown as the mean ± SEM. 
Statistical analysis was performed using a one-way ANOVA with Tukey’s multiple comparison 
test. 
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4.3.6 Effect of GSK1016790A stimulation at sub-maximum and maximum concentrations on 
cell death in MDA-MB-231 breast cancer cells 
To provide an insight into the effect of activating TRPV4 channels on cell death in MDA-MB-231 
cells, treatment with sub-maximum (30 nM) and maximum (1 µM) concentrations of 
GSK1016790A were carried out. Pharmacological activation of TRPV4 channels using 
GSK1016790A at both concentrations failed to promote cell death in MDA-MB-231 cells (Figure 
4.7A and B) as indicated by a lack of change in membrane permeability when assessed by 
propidium iodide staining. Cell death was also examined in the presence of the potent Bcl-2 family 
inhibitor - ABT-263 (359), either alone or in combination with GSK1016790A in MDA-MB-231 
cells. Single treatment of ABT-263 significantly induced cell death in MDA-MB-231 cells 
compared to control as indicated by an increase in the percentage of propidium iodide positive cells 
(Figure 4.7A and B). GSK1016790A did not augment ABT-263-mediated cell death in MDA-MB-
231 cells (Figure 4.7A and B). The effect of TRPV4 activation using GSK1016790A on cell 
viability was also assessed by cell enumeration analysis. No significant alteration in total cell 
number was observed when MDA-MB-231 cells were treated with GSK1016790A at both sub-
maximum and maximum concentrations in comparison to control (Figure 4.7C and D).  
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Figure ‎4.7: Effect of ABT-263 and GSK1016790A for 48 hours on cell death in MDA-MB-231 
breast cancer cells. (A and B) Bar graphs show the percentage of propidium iodide positive cells in 
response to 3 µM ABT-263 and/or 30 nM GSK1016790A (A) and/or 1 µM GSK1016790A (B) in 
MDA-MB-231 cells. Results are pooled from three independent experiments, (n = 3) and are shown 
as the mean ± SEM. Statistical analysis was performed using a one-way ANOVA with Tukey’s 
multiple comparison test; ** denotes P < 0.01. (C and D) Bar graphs show the average of total cell 
number in response to 30 nM GSK1016790A (C) or 1 µM GSK1016790A (D) compared to DMSO 
control in MDA-MB-231 cells. Results are pooled from three independent experiments, (n = 3) and 
are shown as the mean ± SEM. Statistical analysis was performed using an unpaired t-test. 
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4.4 Discussion 
The key findings outlined in this chapter relate to the identification of a functional TRPV4 channel 
in MDA-MB-231 breast cancer cells. This is the first study to demonstrate TRPV4 as a Ca
2+ 
entry 
channel in MDA-MB-231 cells, which was evidenced by a slow and sustained increase in Ca
2+ 
influx elicited by the TRPV4 activator GSK1016790A. An evaluation of the potency of 
GSK1016790A in increasing intracellular Ca
2+ 
in MDA-MB-231 cells revealed an EC50 value of 76 
nM – a concentration which was higher than the previously reported EC50 of 2.1 nM in human 
embryonic kidney HEK293 cells expressing TRPV4 channels (325). The observed differing values 
for GSK1016790A between both cell lines could possibly be explained by differential TRPV4 
expression levels in both model systems and also the methods for assessing TRPV4-mediated Ca
2+ 
influx, which was a FLIPR
TETRA
 Ca
2+
 assay with the non-ratiometric Fluo-4 dye in the current study 
and a FlexStation with the ratiometric Fura-2 dye in studies using HEK293 cells.  
 
In the present study, MDA-MB-231 cells showed greater responsiveness to ATP-evoked Ca
2+ 
signalling compared to GSK1016790A-activated Ca
2+ 
influx. The difference in the magnitude of 
agonist-mediated Ca
2+ 
responses may be attributable to the difference in expression levels of both 
ATP-activated purinergic receptors and TRPV4 in MDA-MB-231 cells. Analysis of the expression 
profile of a panel of purinergic receptors (consisting of P2X and P2Y receptors) (360,361) and 
comparison to the levels of TRPV4 expression in MDA-MB-231 cells could be useful to further 
explore this possibility.  
 
Inhibition of the Ca
2+
 response to GSK1016790A (exhibited as a decreased rate of rise in [Ca
2+
]CYT 
and area under the curve) by TRPV4 siRNA treatment, provides further evidence that TRPV4 is a 
functional channel in MDA-MB-231 cells. This observation could also indicate that TRPV4 is one 
of the molecular candidates which provides a Ca
2+ 
entry pathway in MDA-MB-231 cells. Given that 
MDA-MB-231 cells exhibit GSK1016790A-induced Ca
2+ 
influx that is sensitive to TRPV4 
silencing, this finding may also suggest that TRPV4-mediated Ca
2+ 
influx is a feature of some 
basal-like breast cancer cells.  
 
Several reports on the involvement of TRPV4 in cell proliferation (329,362-364) prompted an 
investigation as to whether TRPV4 is implicated in regulating the proliferation of human MDA-
MB-231 breast cancer cells. In the present study, exposure of MDA-MB-231 cells to RN 1734 at a 
concentration range from 0 µM to 10 µM showed no significant change on cell viability at days 5 
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and 7, as assessed by an MTS assay. The absence of effect of RN 1734 treatment on the viability of 
MDA-MB-231 cells at this concentration range (0 µM to 10 µM) is unlikely due to its interaction or 
binding with other proteins since studies by Dragoni et al (365) using human circulating endothelial 
progenitor cells (EPCs) found that RN 1734 could inhibit EPC proliferation in the presence of 
culture medium supplemented with growth factors and serum. In contrast, 100 µM RN 1734 
significantly decreased cell viability which is most likely due to a non-specific cytotoxic effect. 
Activating TRPV4 using various concentrations of GSK1016790A did not alter cell proliferation in 
MDA-MB-231 cells. These results suggest that TRPV4 pharmacological modulators are unlikely to 
be useful as regulators of cell proliferation for breast cancer cells which have TRPV4 expression 
levels similar to that of MDA-MB-231 cells. 
 
The cytotoxicity observed at 100 µM RN 1734 indicates that this compound may inhibit and/or 
activate other ion channels at such high concentration. Indeed, characterisation of the selectivity of 
RN 1734 across a panel of other TRP channels revealed that this compound also showed activity on 
closely related ion channels including TRPV1, TRPV3 and TRPM8 (340). Future studies could 
determine the specificity of RN 1734 by characterising the potency and efficacy of this compound 
using MTS assays on cell lines that do not endogenously express TRPV4 channels, such as 
HEK293 (366) and HeLa cells (367). Results obtained from MTS assays of studies treating 
HEK293 or HeLa cells with RN 1734 using the concentration used here in MDA-MB-231 cells are 
required to show that the effects of 100 µM RN 1734 are unrelated to TRPV4. 
 
Intracellular Ca
2+ 
signalling is critical for an array of biological processes encompassing cell 
proliferation, fertilisation, development and cell death via necrosis or apoptosis (29,368). Some 
TRP channels have been associated with cell survival and death (369). A study by Ryskamp et al 
(370) provided evidence for the role of TRPV4 in modulating apoptosis in mouse retinal ganglion 
cells (RGCs). The researchers showed that prolonged exposure to GSK1016790A caused significant 
cell death of isolated RGCs, corresponding to the cytotoxic effect from sustained activation of 
TRPV4 channels which subsequently led to the initiation of cell death pathways (370). 
Pharmacological activation of overexpressed specific ion channels has been proposed as a 
therapeutic strategy to induce cancer cell death via apoptosis and necrosis (26,134). Based on the 
reasons outlined above, the present study sought to further explore if pharmacological activation of 
TRPV4 in MDA-MB-231 breast cancer cells could affect Ca
2+ 
-dependent cell death.  
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Application of GSK1016790A did not induce cell death in MDA-MB-231 cells. This finding is also 
consistent with the MTS assays where no pronounced changes in cell viability were observed as a 
result of GSK1016790A treatment in MDA-MB-231 cells. Quantification of total cell number 
indicated no significant effect on cell number following TRPV4 activation by GSK1016790A in 
MDA-MB-231 cells. The Ca
2+ 
influx associated with GSK1016790A appears to be insufficient to 
initiate cell death pathways in MDA-MB-231 breast cancer cells. Furthermore, when 
GSK1016790A was used in combination with the Bcl-2 inhibitor ABT-263 in MDA-MB-231 cells, 
there was no significant difference in the percentage of propidium iodide positive cells compared to 
Bcl-2 inhibitor alone. A recent publication highlighted the role of a specific isoform of the plasma 
membrane Ca
2+ 
ATPase pump, PMCA4 in augmenting ABT-263-induced apoptosis when this 
pump was silenced in MDA-MB-231 cells (358). The investigators concluded that some PMCA 
isoforms could be exploited as potential targets to improve the effectiveness of some therapies in 
cancer cells (358). However, the work presented in this chapter indicates that it is unlikely that a 
similar approach would be appropriate for TRPV4 activators for breast cancers that have similar 
TRPV4 expression levels as MDA-MB-231 cells. Nevertheless, given the potentiation of ABT-263-
mediated apoptosis as a result of reduced PMCA4 expression in MDA-MB-231 cells (358), future 
studies could investigate the consequences of combining PMCA inhibition and TRPV4 activation.  
As PMCA4 silencing has been shown to markedly increase agonist-induced peak [Ca
2+
]CYT  in HT-
29 human colon cancer cells (194), PMCA4 downregulation may also increase [Ca
2+
]CYT and 
compromise PMCA-mediated Ca
2+ 
efflux in MDA-MB-231 cells. This effect, coupled to a further 
increase in Ca
2+ 
influx as a result of TRPV4 activation may lead to Ca
2+ 
overload sufficient for the 
initiation of cell death pathways in MDA-MB-231 cells. However, further investigations are 
warranted to test this hypothesis and determine whether PMCA inhibition together with TRPV4 
activation would alter the sensitivity of MDA-MB-231 cells to apoptotic stimuli.       
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4.5 Conclusion 
In conclusion, the work described in this chapter represents the first demonstration of a functional 
TRPV4 in MDA-MB-231 basal-like breast cancer cells. Selective activation of TRPV4 channels 
with GSK1016790A evoked Ca
2+ 
responses in MDA-MB-231 cells. This agonist-mediated Ca
2+ 
influx was sensitive to TRPV4 silencing. Despite the functional expression of TRPV4 channels in 
MDA-MB-231 cells, modulation of these channels either by inhibition or activation using specific 
pharmacological modulators did not affect cell proliferation. Moreover, pharmacological activation 
of TRPV4 with a specific TRPV4 activator did not induce cell death in MDA-MB-231 breast 
cancer cells. 
 
Chapter Five characterises TRPV4 in another basal-like breast cancer cell line, MDA-MB-468 cells. 
As depicted in Figure 2.3 of this thesis, MDA-MB-468 cells have a higher endogenous level of 
TRPV4 as compared to MDA-MB-231 cells. It is therefore appropriate to now understand the 
functional role of TRPV4 in a cell line that exhibits a pronounced upregulation of this ion channel. 
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CHAPTER 5 : Characterisation of TRPV4 Channels in MDA-MB-468 Breast Cancer Cells 
5.1 Introduction 
Section 2.3.1 of this thesis identified TRPV4 as a potential therapeutic target using an siRNA 
screen. As previously stated in Chapter Two, two models of human basal-like breast cancer cell 
lines were selected to assess the functional role of TRPV4 in breast cancer cells, MDA-MB-231 and 
MDA-MB-468 cells. Both cell lines have been transcriptionally categorised as basal-like breast 
cancer subtype (223,224) and exhibit different metastatic potential. MDA-MB-231 cells display 
greater metastatic potential than MDA-MB-468 cells (371). 
 
Real-time RT-PCR data presented in Section 2.3.4.3 indicated that TRPV4 mRNA levels are higher 
in MDA-MB-468 cells (approximately 30-fold higher) compared to MDA-MB-231 cells. Chapter 
Four of this thesis functionally characterised TRPV4 in MDA-MB-231 cells. Pharmacological 
activation of TRPV4 in MDA-MB-231 cells using GSK1016790A increased intracellular Ca
2+ 
which was significantly reduced with siRNA-mediated TRPV4 silencing. Pharmacological 
modulation of TRPV4 using an inhibitor or activator showed no significant effect on MDA-MB-
231 viable cell numbers. In this chapter, TRPV4 will be assessed in the other basal-like breast 
cancer cell line used in these studies, MDA-MB-468 cells, which have high levels of TRPV4 
mRNA. 
 
Specific hypotheses and aims for this chapter are: 
 
Chapter 5 hypotheses: 
I. TRPV4 is a Ca2+ entry channel in MDA-MB-468 basal-like breast cancer cells. 
II. MDA-MB-468 basal-like breast cancer cells are sensitive to TRPV4 pharmacological 
modulators. 
Chapter 5 aims: 
I. To assess TRPV4 channel function in MDA-MB-468 breast cancer cells using a 
pharmacological activator of TRPV4. 
II. To silence TRPV4 using siRNA and to define the effects of TRPV4 silencing on TRPV4 
activator-mediated Ca
2+ 
increases in MDA-MB-468 breast cancer cells. 
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III. To assess the effect of a TRPV4 pharmacological inhibitor on MDA-MB-468 breast cancer 
viable cell number. 
IV. To evaluate the effects of a TRPV4 pharmacological activator on MDA-MB-468 breast 
cancer viable cell number and cell death. 
V. To assess possible mechanisms for cell death induced by a TRPV4 pharmacological 
activator in MDA-MB-468 breast cancer cells. 
VI. To assess the effects of TRPV4 siRNA on TRPV4 pharmacological activator-mediated cell 
death in MDA-MB-468 cells.  
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5.2 Materials and Methods 
5.2.1 Materials 
GSK1016790A, DMSO and ATP disodium salt hydrate were purchased from Sigma-Aldrich. RN 
1734 was purchased from Tocris Bioscience. Hoechst 33342 (10 mg/mL) and propidium iodide (1 
mg/mL) were obtained from Invitrogen. Z-VAD-fluoromethylketone (Z-VAD-FMK) was obtained 
from Enzo Life Sciences.  
 
5.2.2 Cell culture for MDA-MB-468 breast cancer cells 
The human MDA-MB-468 breast cancer cell line was kindly provided by Dr Chanel Smart 
(University of Queensland Centre for Clinical Research). Cells were grown in high glucose DMEM 
(D6546) (Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich) and 4 mM L-glutamine 
(Invitrogen). Cells were subcultured at a split ratio between 2:10 and 3:10. Cell culture medium was 
renewed every second day. Cells were maintained in a humidified incubator (37°C, 5% CO2) and 
routinely screened for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit 
(LT07-218, Lonza). The cultured cells were only used up to passage nine for all experiments. 
 
5.2.3 Intracellular Ca
2+ 
measurement 
For the measurement of intracellular Ca
2+
 in MDA-MB-468 cells, cells were seeded at 1.5 X 10
4 
cells per well in a 96-well CellBIND plate (Corning) in antibiotic-free media. At 24 hours post-
plating, the concentration of FBS was reduced to 8% and where appropriate, cells were transfected 
with TRPV4 siRNA or non-targeting siRNA. Total RNA was isolated 24 hours post-transfection 
and mRNA knockdown of TRPV4 was checked prior to Ca
2+ 
assays (see Section 4.2.5 for method). 
At 72 hours post-treatment, Ca
2+ 
assays were performed using the FLIPR
TETRA 
(Molecular Devices) 
with a no-wash dye PBX Ca
2+ 
Assay Kit (BD Biosciences). Transfection medium was removed and 
replaced with a PBX signal enhancer dye loading solution (100 µL total volume) consisting of PSS 
with Ca
2+ 
(1.8 mM), PBX signal enhancer (5%, BD Biosciences), Fluo-4 AM (2 µM, Invitrogen) 
and probenecid (500 µM, Sigma-Aldrich). Fluo-4 loaded cells were incubated in a humidified 
incubator (5% CO2) at 37°C for 1 hour. Cells were then allowed to equilibrate to room temperature 
for 15 minutes before the dye loading solution was replaced with a replacement solution (100 µL 
total volume) containing PSS with Ca
2+ 
(1.8 mM), PBX signal enhancer (5%) and probenecid (500 
µM) prior to FLIPR Ca
2+ 
assays. Cells were excited at 470-495 nm and emission assessed at 515-
575 nm. Data were acquired using ScreenWorks™ Software (Molecular Devices) and are presented 
as response/baseline as a relative measure of cytosolic free Ca
2+ 
([Ca
2+
]CYT). Response/baseline has 
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no units, as the unit is a ratio. Peak relative [Ca
2+
]CYT was determined by recording the maximum 
relative fluorescence (response/baseline) value achieved during the duration of the exposure to 
activator (800 seconds). Rate of rise in [Ca
2+
]CYT was assessed between 20 seconds to 40 seconds 
after activator addition. For rate, units are response/baseline.s
-1
. Area under the curve was 
calculated between 20 seconds and 200 seconds after activator addition and corrected by subtracting 
the area calculated from ScreenWorks 2.0 Software with the area from a theoretical non-response. 
Both parameters (rate of rise in [Ca
2+
]CYT and area under the curve) were analysed using 
ScreenWorks 2.0 Software and Microsoft Excel. 
 
5.2.4 Silencing of TRPV4 expression  
MDA-MB-468 cells (1.5 X 10
4 
cells per well) were seeded in a 96-well plate in antibiotic-free 
media. Cells were then incubated with Dharmacon ON-TARGET plus SMARTpool TRPV4 siRNA 
(100 nM) or control ON-TARGET plus Non-Targeting pool siRNA as per the manufacturer’s 
specifications. DharmaFECT 4 transfection reagent was used at a volume of 0.2 µL per well (100 
µL total volume). Total RNA was isolated 24 hours post-transfection using the RNeasy
®
 Plus Mini 
kit (Qiagen). TRPV4 mRNA silencing was confirmed at 24 hours post-siRNA as previously 
described in Section 4.2.4. 
 
5.2.5 RNA isolation and Real-time RT-PCR 
MDA-MB-468 cells were plated at 1.5 X 10
4 
cells per well in a 96-well plate in antibiotic-free 
media and treated with siRNA. Following siRNA transfection (24 hours), total RNA was isolated 
using a Qiagen RNeasy
®
 Plus Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA 
was reverse-transcribed using a Omniscript Reverse Transcriptase kit (Qiagen) and subsequently 
amplified using Assays-on-Demand FAM-MGB primer/probe sets and TaqMan Universal PCR 
Master Mix (Applied Biosystems) as detailed in Section 4.2.5. 
 
5.2.6 Relative viable cell number assay  
The CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega) was used for 
the assessment of relative viable cell number. The following drugs were used in this assay: 
GSK1016790A (Sigma-Aldrich) and RN 1734 (Tocris Bioscience). GSK1016790A was added to 
the designated wells to a final concentration of 1-, 10- or 100 nM whereas RN 1734 was added to a 
final concentration of 1-, 10- or 100 µM. MDA-MB-468 cells were seeded in 96-well plates at 6.0 
X 10
3 
cells per well and incubated for 24 hours. The medium was then replaced with fresh medium 
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with or without the drugs being tested and cells were cultured over a five-day or a seven-day period. 
Throughout the incubation period, the medium was replenished with fresh reagents every two days 
except for the day of an MTS assay (day 5 and day 7). At the desired time point, an MTS assay was 
performed as previously described in Section 4.2.6. 
 
5.2.7 High content imaging assay for cell death 
MDA-MB-468 cells (1.0 X 10
4 
cells per well) were plated in a 96-well imaging plate (BD 
Biosciences) in antibiotic-free media. The FBS concentration was reduced to 8% 24 hours post-
plating and where appropriate, cells were transfected with TRPV4 siRNA or non-targeting siRNA. 
After 72 hours, media was removed and cells were treated with GSK1016790A (Sigma-Aldrich), Z-
VAD-FMK (Enzo Life Sciences), or DMSO for 48 hours in phenol-red free DMEM containing 8% 
FBS. All drug concentrations were expressed as the final concentration in the cells and specified in 
the figures. For experiments involving the caspase inhibitor Z-VAD-FMK, this drug was added to 
the cells at a final concentration of 50 µM and incubated for 1 hour at 37°C before the addition of 
GSK1016790A. Control cells were treated with DMSO at the same concentration as test cells. The 
final concentration of DMSO for each treatment group was maintained between 0.15% and 0.3%. 
For the evaluation of cell death, live cells were stained with Hoechst 33342 (10 µg/mL, Invitrogen) 
and propidium iodide (1 µg/mL, Invitrogen) for 15 minutes at 37°C. Following staining, imaging 
was conducted using an ImageXpress micro automated epifluorescence microscope (Molecular 
Devices Corporation) as previously published (358). Parameters of interest (percentage of 
propidium iodide positive cells and total cell number) were analysed as previously stated in Section 
4.2.7. 
 
5.2.8 Statistical analysis 
Statistical analyses were performed using Prism5 (Graph Pad Software version 5.04). The statistical 
tests used in this chapter are described in the figure legends. The EC50 calculation was performed 
using a nonlinear regression analysis in Prism5. The average ΔCT values calculated from the real-
time RT-PCR data are given as mean ± S.D. Results are shown as mean ± SEM from the specified 
number of independent experiments. 
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5.3 Results 
5.3.1 Assessment of TRPV4 channels in MDA-MB-468 breast cancer cells 
As depicted in Figure 2.3 of this thesis, TRPV4 was significantly overexpressed in MDA-MB-468 
breast cancer cells compared to MDA-MB-231 breast cancer cells. The functional activity of 
TRPV4 channels in MDA-MB-468 cells was initially assessed by measuring intracellular cytosolic 
free Ca
2+ 
in response to the TRPV4 pharmacological activator GSK1016790A (325). Stimulation 
with 100 nM GSK1016790A elicited a rapid, robust and sustained Ca
2+ 
influx, indicating that 
MDA-MB-468 cells express functional TRPV4 channels (Figure 5.1A). This increase in 
intracellular Ca
2+ 
following GSK1016790A treatment was greater than that of intracellular cytosolic 
free Ca
2+ 
increases when the same cell line was exposed to 100 µM ATP (Figure 5.1A). This result 
was in contrast to MDA-MB-231 cells where ATP induced higher increases in intracellular free 
Ca
2+ 
than GSK1016790A. A concentration-response curve of GSK1016790A in MDA-MB-468 
cells revealed an EC50 of approximately 3.9 nM (Figure 5.1B). These results indicate that TRPV4 
channels are functional in MDA-MB-468 breast cancer cells.  
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Figure ‎5.1: (A) Effect of GSK1016790A (100 nM) stimulation on relative [Ca2+]CYT in MDA-MB-
468 cells. Representative Ca
2+
 traces showing average of three different wells from a single 
experiment shown as response/baseline. Stimulation with 100 µM ATP was used as a positive 
control for the assay. (B) Concentration-response curve for GSK1016790A in MDA-MB-468 cells. 
Results are pooled from four independent experiments, (n = 4) and are shown as the mean ± SEM. 
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5.3.2 TRPV4 siRNA-mediated knockdown in MDA-MB-468 breast cancer cells 
To assess if GSK1016790A-mediated increases in cytosolic free Ca
2+ 
in MDA-MB-468 cells are 
mediated by TRPV4, TRPV4 was silenced using siRNA. TRPV4 siRNA significantly reduced 
TRPV4 mRNA levels when compared to the non-targeting siRNA (NT siRNA) control (Figure 
5.2). However, it should be noted that at this degree of knockdown (approximately 81%) the level 
of TRPV4 expression is still higher in MDA-MB-468 cells compared to MDA-MB-231 cells, with 
MDA-MB-468 cells displaying an average ΔCT value of 7.367 ± 0.402 (n = 3) while MDA-MB-231 
cells resulting in an average ΔCT value of 18.503 ± 5.676 (n = 3). As described in Section 2.3.3 of 
this thesis, the ΔCT value represents a target gene expression levels with a lower ΔCT value 
indicating higher expression levels or vice versa. 
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Figure ‎5.2: TRPV4 siRNA-mediated silencing in MDA-MB-468 breast cancer cells. Cells were 
plated in a 96-well plate and TRPV4 expression was inhibited using Dharmacon ON-TARGET Plus 
SMARTpool siRNA. Total RNA was isolated at 24 hours post-transfection and knockdown of 
TRPV4 relative to the non-targeting siRNA (NT siRNA) control was confirmed using real-time RT-
PCR. Each bar represents the mean ± SEM (n = 3). Statistical analysis was performed using an 
unpaired t-test; **** denotes P < 0.0001 compared to the NT siRNA control. 
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5.3.3 Effect of TRPV4 siRNA-mediated knockdown on GSK1016790A-induced Ca
2+ 
influx 
in MDA-MB-468 breast cancer cells 
To assess the dependence of GSK1016790A-induced Ca
2+ 
influx in MDA-MB-468 cells on TRPV4, 
cells were treated with 30 nM GSK1016790A in the presence or absence of TRPV4 siRNA. 
Compared with NT siRNA, the GSK1016790A-induced Ca
2+ 
influx was decreased by TRPV4 
siRNA in MDA-MB-468 cells (Figure 5.3A). Both the rate of rise in [Ca
2+
]CYT and area under the 
curve were significantly decreased by TRPV4 siRNA treatment (Figure 5.3B and C).  
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Figure ‎5.3: Effect of TRPV4 siRNA-mediated silencing on GSK1016790A-induced Ca2+ signalling 
responses in MDA-MB-468 breast cancer cells. (A) Representative GSK1016790A (30 nM)-
induced Ca
2+ 
influx in the presence or absence of TRPV4 siRNA-mediated knockdown in MDA-
MB-468 cells. Ca
2+
 traces are shown as the average of three different wells from a single 
experiment and depicted as response/baseline. Bar graphs show (B) rate of rise in [Ca
2+
]CYT 
calculated between 20 s and 40 s and (C) area under the curve determined between 20 s and 200 s. 
Results are pooled from five independent experiments, (n = 5) and are shown as the mean ± SEM. 
Statistical analysis was performed using a paired t-test; * denotes P < 0.05 and *** denotes P < 
0.001. 
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5.3.4 Effect of RN 1734 on viable cell number in MDA-MB-468 breast cancer cells 
Recent studies in other model systems (such as endothelial cells and smooth muscle cells) indicate 
that TRPV4 is involved in regulating cell proliferation in some cell types (329,362-364). The 
present study sought to examine if TRPV4 participates in the proliferation of MDA-MB-468 breast 
cancer cells using the TRPV4 antagonist, RN 1734 with a reported IC50 of 2.3 µM (340). An MTS 
assay of MDA-MB-468 cells treated with relevant concentrations of RN 1734 (i.e. 1 µM and 10 
µM) showed no significant effect on A490 at 5 days and 7 days (Figure 5.4A and B). This 
observation suggests that pharmacological inhibition of TRPV4 channels may not reduce the 
proliferation of MDA-MB-468 cells. However, very high concentrations of RN 1734 (100 µM) 
appeared to be cytotoxic, most probably as a result of non-specific cytotoxic effect of this TRPV4 
antagonist (Figure 5.4A and B). 
106 
 
 
Figure ‎5.4: Effect of RN 1734 on relative MDA-MB-468 viable cell number as determined by an 
MTS assay. Cells were treated with various concentrations of RN 1734 for up to 7 days. Relative 
viable cell number was analysed using an MTS assay as described in the methods section through 
absorbance at 490 nm. (A and B) Bar graphs show the treatment of MDA-MB-468 cells over 5 
days (A) or 7 days (B) with RN 1734. Results are pooled from three independent experiments, (n = 
3) and are shown as the mean ± SEM. Statistical analysis was performed using a one-way ANOVA 
with Tukey’s multiple comparison test; *** denotes P < 0.0001 and ** denotes P < 0.01 compared 
to control. 
107 
 
5.3.5 Effect of GSK1016790A on cell viability in MDA-MB-468 breast cancer cells 
To evaluate the potential for TRPV4 activation to regulate the viability of MDA-MB-468 cells, an 
MTS assay was carried out using various concentrations of GSK1016790A. Compared to the 
control, all concentrations of GSK1016790A tested decreased viability of MDA-MB-468 cells at 
both time points (5 and 7 days), with the calculated IC50 values estimated as 2.189 nM and 2.166 
nM at days 5 and 7, respectively. A pronounced decrease in the viability of MDA-MB-468 cells 
was observed at both 10 nM and 100 nM GSK1016790A, as indicated by a significant reduction in 
the A490 reading (Figure 5.5A and B). This observation implies that GSK1016790A could be an 
inducer of cell death in this cell line. 
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Figure ‎5.5: Effect of GSK1016790A on viability of MDA-MB-468 breast cancer cells as 
determined by an MTS assay. Cells were treated with various concentrations of GSK1016790A for 
up to 7 days. Relative viable cell number was analysed by an MTS assay as described in the 
methods section and results are depicted as absorbance at 490 nm.  (A and B) Bar graphs show the 
treatment of MDA-MB-468 cells over 5 days (A) or 7 days (B) with GSK1016790A. Results are 
pooled from three independent experiments, (n = 3) and are shown as the mean ± SEM. Statistical 
analysis was performed using a one-way ANOVA with Tukey’s multiple comparison test; ** 
denotes P < 0.01 compared to control. 
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5.3.6 Effect of GSK1016790A stimulation at sub-maximum and maximum concentrations on 
cell death in MDA-MB-468 breast cancer cells 
To explore the possible involvement of TRPV4 in the regulation of cell death, MDA-MB-468 cells 
were exposed to sub-maximal (1 nM) and maximal (30 nM) concentrations of GSK1016790A as 
assessed through increases in free cytosolic Ca
2+ 
(Figure 5.1B). Pharmacological activation of 
TRPV4 using GSK1016790A at both concentrations led to a significant increase in the percentage 
of propidium iodide positive cells, and thus induced death in MDA-MB-468 cells (Figure 5.6A and 
B). Cell enumeration analysis was also performed to further explore the effect of TRPV4 activation 
on cell viability. The data from total nuclear count analysis was in agreement with that obtained 
from the MTS assay, in which GSK1016790A treatment significantly reduced total cell number in a 
concentration-dependent manner (Figure 5.6C and D). Collectively, these findings demonstrate that 
GSK1016790A reduces total cell number and evokes a concentration-dependent cell death in MDA-
MB-468 cells.  
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Figure ‎5.6: Effect of GSK1016790A for 48 hours on cell death in MDA-MB-468 breast cancer 
cells. (A and B) Bar graphs show the percentage of propidium iodide positive cells in response to 1 
nM GSK1016790A (A) or 30 nM GSK1016790A (B) in MDA-MB-468 cells. Results are pooled 
from three independent experiments, (n = 3) and are shown as the mean ± SEM. Statistical analysis 
was performed using an unpaired t-test; ** denotes P < 0.01 and * denotes P < 0.05. (C and D) Bar 
graphs show the average of total cell number in response to 1 nM GSK1016790A (C) or 30 nM 
GSK1016790A (D) compared to DMSO control in MDA-MB-468 cells. Results are pooled from 
three independent experiments, (n = 3) and are shown as the mean ± SEM. Statistical analysis was 
performed using an unpaired t-test; *** denotes P < 0.0001 and ** denotes P < 0.01 compared to 
control. 
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5.3.7 Effect of the caspase inhibitor Z-VAD-FMK on GSK1016790A-induced cell death in 
MDA-MB-468 breast cancer cells 
To probe for possible mechanisms of induction of death by GSK1016790A in MDA-MB-468 cells, 
a specific broad-spectrum caspase inhibitor Z-VAD-FMK (372) was added either alone or in 
combination with GSK1016790A. Addition of GSK1016790A again increased the proportion of 
propidium iodide positive cells. The combination of Z-VAD-FMK and GSK1016790A however, 
had no significant influence on the percentage of propidium iodide positive cells when compared to 
GSK1016790A alone. Therefore, Z-VAD-FMK itself did not significantly block GSK1016790A-
induced cell death in MDA-MB-468 cells (Figure 5.7). Taken together, these results suggest that 
GSK1016790A-induced cell death in MDA-MB-468 cells occurs independently of caspase 
activation and hence, may be via a necrotic rather than an apoptotic mechanism (373). 
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Figure ‎5.7: Effect of the caspase inhibitor Z-VAD-FMK on GSK1016790A-induced cell death in 
MDA-MB-468 cells. Bar graph shows the percentage of propidium iodide positive cells treated with 
GSK1016790A and/or Z-VAD-FMK in MDA-MB-468 cells. Results are pooled from three 
independent experiments, (n = 3) and are shown as the mean ± SEM. Statistical analysis was 
performed using repeated measures two-way ANOVA, followed by Bonferroni post-hoc analysis; P 
> 0.05. 
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5.3.8 Effect of TRPV4 siRNA-mediated silencing on GSK1016790A-induced cell death in 
MDA-MB-468 breast cancer cells 
To demonstrate that TRPV4 channels mediate GSK1016790A-induced cell death in MDA-MB-468 
cells, cells were exposed to GSK1016790A (30 nM) in the presence or absence of TRPV4-specific 
siRNA. Consistent with a decrease in Ca
2+ 
influx as a result of TRPV4 siRNA (Figure 5.3A), 
TRPV4 silencing significantly attenuated GSK1016790A-induced cell death in MDA-MB-468 cells 
(Figure 5.8). This observation demonstrates that the induction of cell death by GSK1016790A in 
MDA-MB-468 cells is TRPV4-mediated.  
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Figure ‎5.8: Effect of TRPV4 silencing on GSK1016790A-induced cell death in MDA-MB-468 
breast cancer cells. Bar graph shows the percentage of propidium iodide positive cells treated with 
GSK1016790A in the presence or absence of TRPV4 siRNA-mediated knockdown in MDA-MB-
468 cells. Results are pooled from three independent experiments, (n = 3) and are shown as the 
mean ± SEM. Statistical analysis was performed using a paired t-test; * denotes P < 0.05. 
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5.4 Discussion 
Work presented in this chapter provides several new findings regarding the functional role of the 
TRPV4 channel in human MDA-MB-468 basal-like breast cancer cells. The present study provides 
the first evidence for the expression of a functional TRPV4 as a Ca
2+ 
entry channel in MDA-MB-
468 breast cancer cells. The functional activity of TRPV4 in MDA-MB-468 breast cancer cells was 
clearly demonstrated by the rapid, robust and sustained intracellular Ca
2+ 
elevation in response to 
the TRPV4 activator GSK1016790A. This GSK1016790A-mediated Ca
2+ 
influx was more 
pronounced in MDA-MB-468 cells compared to MDA-MB-231 cells (see Section 4.3.1, Figure 
4.2A) presumably due to the substantial difference in TRPV4 expression levels between these cell 
lines (as assessed by mRNA levels). Using FLIPR Ca
2+ 
assays to generate a GSK1016790A 
concentration-response curve, MDA-MB-468 cells showed an EC50 of approximately 3.9 nM. This 
EC50 value appears to correspond to that of HEK293 cells – ectopically expressing TRPV4 channels 
(325), albeit slightly higher. In contrast, MDA-MB-231 cells, which have lower levels of TRPV4 
mRNA, displayed a higher EC50 value (76 nM) than MDA-MB-468 cells. The observed variability 
in both the responsiveness to GSK1016790A and EC50 value may be due to the different levels of 
TRPV4 expression between the two different basal-like breast cancer cell lines. Indeed, a similar 
observation was reported in a recent study by Alenmyr and colleagues (324) who assessed the role 
of TRPV4 in human native airway epithelial cells. Using two bronchial epithelial cell lines; 16HBE 
and BEAS2B as well as HEK293 cells with inducible human TRPV4 expression, the researchers 
demonstrated that all three cell lines differentially expressed TRPV4, with TRPV4-expressing 
HEK293 cells exhibiting the highest TRPV4 mRNA expression followed by BEAS2B and 16HBE 
cells (324). GSK1016790A concentration-response curves for these cell lines revealed an EC50 of 
0.64 nM in TRPV4-expressing HEK293 cells, 2.1 nM in BEAS2B cells and 56 nM in 16HBE cells 
(324), indicating that TRPV4 expression levels do affect the EC50 for GSK1016790A. The 
researchers found that BEAS2B cells which expressed more TRPV4 than 16HBE cells were more 
sensitive to TRPV4 activation as assessed by fluorometric calcium imaging (324). The data 
presented in this thesis provide further evidence that TRPV4 mRNA levels can predict sensitivity to 
GSK1016790A-induced Ca
2+ 
signalling.  
 
In the present study, TRPV4 silencing in MDA-MB-468 cells significantly reduced 
GSK1016790A-induced Ca
2+ 
influx. These results suggest that GSK1016790A-induced Ca
2+ 
signalling is sensitive to TRPV4 silencing and that TRPV4-mediated Ca
2+ 
influx is a feature of 
some breast cancer cells. The modest reduction in Ca
2+ 
influx when TRPV4 was silenced in MDA-
MB-468 cells is in contrast to that of MDA-MB-231 cells. As shown in Figure 4.4A of this thesis, 
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TRPV4 silencing markedly decreased GSK1016790A-induced Ca
2+ 
influx in MDA-MB-231 cells. 
This observation may be explained by the degree of TRPV4 knockdown achieved in both cell lines 
during the experiments. Given the substantial expression of TRPV4 in MDA-MB-468 cells 
(approximately 30-fold higher than MDA-MB-231 cells), there is still more functional TRPV4 
channels expressed in MDA-MB-468 cells with approximately 81% knockdown of TRPV4 in 
comparison to MDA-MB-231 cells. Thus, the remaining TRPV4 channels after siRNA-mediated 
silencing could still mediate Ca
2+ 
entry in MDA-MB-468 cells. However, the significant reduction 
in GSK1016790A-mediated Ca
2+ 
influx by TRPV4 siRNA is further evidence that Ca
2+ 
influx 
induced by GSK1016790A is mediated by TRPV4. 
 
Recent evidence from independent studies supports a role for TRPV4 in the regulation of cell 
proliferation in several cell types including human esophageal epithelial cells (364), brain capillary 
endothelial cells (329) and pulmonary arterial smooth muscle cells (374). However, the role of 
TRPV4 in cell proliferation of breast cancer cells is presently unknown. To address this gap in 
knowledge, the effect of pharmacological modulation of TRPV4 on viable cell number was 
examined using an MTS assay. Similar to the results obtained when RN 1734 was applied to MDA-
MB-231 cells (see Section 4.3.4, Figure 4.5), low concentrations of this drug did not alter the 
MDA-MB-468 viable cell numbers, indicating that pharmacological inhibition of TRPV4 is not 
anti-proliferative in this cell line. A high concentration of RN 1734 (100 µM) appears to be 
cytotoxic. This cytotoxicity is most probably due to non-specific cytotoxic effect of RN 1734 as 
previously discussed in Section 4.4 of this thesis. Application of the TRPV4 activator, 
GSK1016790A decreased the viability of MDA-MB-468 cells at both time points tested (i.e. days 5 
and 7), with the estimated IC50 values of 2.189 nM and 2.166 nM, respectively. These values appear 
to correspond to that of EC50 value determined for the GSK1016790A-induced rise of [Ca
2+
]CYT 
(i.e. approximately 3.9 nM), albeit slightly lower. Taken together, these results suggest that 
GSK1016790A could promote cell death in MDA-MB-468 cells. 
 
To clarify that the decrease in viable cell number was due to induction of cell death, the effect of 
TRPV4 activation was assessed using high content imaging. Exposure of MDA-MB-468 cells to 
both sub-maximal and maximal concentrations of GSK1016790A significantly induced cell death 
as illustrated by a significant increase in the percentage of propidium iodide positive cells. 
Additional analysis using total cell count provided further support that GSK1016790A reduces 
viable cell number in MDA-MB-468 cells. Collectively, these findings demonstrate that TRPV4 
activation by GSK1016790A is capable of inducing cell death in MDA-MB-468 cells. To determine 
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the nature of cell death induced by GSK1016790A in MDA-MB-468 cells, a pan-caspase inhibitor, 
Z-VAD-FMK (372) was used. GSK1016790A-induced cell death was not affected by Z-VAD-
FMK, indicating that the mechanism of death induction in MDA-MB-468 cells is caspase-
independent. Two major pathways of cell death are apoptosis and necrosis (373,375). Apoptosis is a 
type of regulated (or programmed) cell death and is characterised by morphological changes such as 
membrane blebbing, nuclear shrinking and budding as well as DNA fragmentation (373,376). 
Necrosis, on the other hand, is a form of cell death with distinct morphological features to that of 
apoptosis, leading to cell destruction through the release of cytosolic constituents into the 
extracellular medium, which can be associated with an inflammatory response (375). Since 
GSK1016790A-induced cell death in MDA-MB-468 cells did not involve the activation of 
caspases; a family of cysteine-dependent aspartate-directed proteases that serve as the central 
executioners during the induction of apoptosis (373,376), it can be deduced that death induction by 
GSK1016790A in MDA-MB-468 cells may occur via a necrotic mechanism under the conditions 
used here. To confirm the involvement of TRPV4 in mediating cell death in MDA-MB-468 cells, 
cells were transfected with TRPV4 siRNA and subjected to cell death assays. Knockdown of 
TRPV4 with siRNA significantly attenuated GSK1016790A-induced cell death in MDA-MB-468 
cells compared to the control. Although data from the present study indicated that GSK1016790A-
induced cell death in MDA-MB-468 cells occurred in the absence of caspase participation, the 
precise nature of the death pathway mediated by TRPV4 activation in this particular cell line 
remains to be determined. One potential mechanism may involve a mitochondrial intermembrane 
flavoprotein, apoptosis-inducing factor (AIF) which has been implicated in the regulation of 
caspase-independent cell death (377). In response to certain apoptotic stimuli, AIF translocates from 
the mitochondria into the nucleus, where it interacts with DNA and mediates caspase-independent 
peripheral type of chromatin condensation (377). Apart from caspases, cell death could also be 
triggered by proteolytic damage by several other proteases including lysosomal and proteosomal 
proteases, granzyme B and matrix metalloproteinases (378). Indeed, recent evidence has provided a 
link between matrix metalloproteinases (MMPs) and TRPV4 activation in the context of lung injury 
(379). Studies by Villalta et al (379) found that activation of TRPV4 by GSK1016790A leads to an 
upregulation of active MMP2 and MMP9 isoforms, together with reduced expression of 
endogenous tissue inhibitor of metalloproteinases (TIMP) 2 in the mouse lung, which subsequently 
mediates TRPV4-induced lung injury. The researchers postulated that TRPV4-mediated Ca
2+ 
entry 
is required for increased MMP2 and MMP9 activity and thus promotes proteolytic activity by these 
gelatinase MMPs to result in lung injury (379). Hence, the possible role of MMPs and other 
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proteases in the TRPV4-mediated cell death in MDA-MB-468 cells should not be neglected and 
should be the focus of future studies. 
 
A previous study on mouse RGCs reported that sustained TRPV4 activation by GSK1016790A is 
associated with dose-dependent apoptotic cell death (370). Alenmyr et al (324) showed that 
treatment with 1 nM and 10 nM GSK1016790A for 20 minutes on human primary nasal ciliated 
epithelial cells which highly express TRPV4, led to a cessation of ciliary beating associated with the 
development of membrane blebs and eventually cell death. The authors proposed that the most 
likely explanation for these unexpected findings could be attributed to intracellular Ca
2+ 
overload 
(324). Using the mouse pancreatic beta cell line MIN6, Casas et al (380) found that TRPV4 
knockdown significantly inhibited intracellular Ca
2+ 
rises induced by human islet amyloid 
polypeptide (hIAPP) and prevented MIN6 cells from the induction of the endoplasmic reticulum 
stress and apoptosis. These results suggest a possible role for TRPV4 in hIAPP-induced beta cell 
cytotoxicity (380). No studies have been done to elucidate the role of TRPV4 in the regulation of 
cell death in breast cancer cells. Thus, the results presented in this chapter extend the current 
knowledge on the contribution of TRPV4-mediated Ca
2+ 
signalling in regulating cell death. 
 
The significant induction of cell death in response to GSK1016790A stimulation in MDA-MB-468 
cells may have therapeutic implications because it suggests that breast cancer cells with increased 
TRPV4 expression levels could be pharmacologically targeted via TRPV4 activation. TRPV4 
activation has been proposed as a therapeutic approach for the treatment of polycystic kidney 
disease (362) and rheumatoid arthritis (381). The ability of nanomolar concentrations of 
GSK1016790A to induce MDA-MB-468 cell death is particularly encouraging in terms of potential 
future clinical use.  
 
Our group and others have highlighted a rational approach for targeting an aberrantly expressed 
Ca
2+ 
channel in a cancer cell by means of induction of cell death (26,134). This strategy can be 
achieved by activating an overexpressed Ca
2+ 
channel in the targeted cancer cells using a specific 
activator to elicit a sustained increase in Ca
2+ 
entry that in turn triggers cell death via apoptosis or 
necrosis (26,134). The potential of targeting an overexpressed Ca
2+ 
channel by pharmaceutical 
intervention has been proposed for a member of the melastatin TRP subfamily, TRPM8 in the 
context of prostate cancer (382). The menthol-activated TRPM8 is upregulated in prostate cancer 
compared to the normal prostate epithelial cells (137). Studies by Zhang and Barritt (138) 
demonstrated that pharmacological blockade of TRPM8 using capsazepine and inhibition of 
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TRPM8 expression reduced the viability of androgen-sensitive LNCaP prostate cancer cells. 
Furthermore, sustained activation of TRPM8 by menthol significantly evoked apoptotic cell death 
in LNCaP cells, presumably by excessive Ca
2+ 
influx (138). Given that activation of an 
overexpressed Ca
2+ 
channel can be exploited to provoke cancer cell death through a sustained 
increase in [Ca
2+
]CYT (26,134,382), one could speculate that a similar approach could be employed 
for TRPV4 channels in some breast cancers. Although TRPV4 possesses moderate Ca
2+ 
selectivity 
compared to TRPV5 and TRPV6 (321), the present study shows that selective activation of 
overexpressed TRPV4 channels in MDA-MB-468 cells is effective and sufficient to initiate cell 
death.  
 
The significant overexpression of TRPV4 renders this channel a plausible target for follow up in in 
vivo studies. Given TRPV4 is overexpressed in MDA-MB-468 breast cancer cells, future in vivo 
studies should investigate the effect of systemic administration of GSK1016790A on cell death and 
tumour growth in MDA-MB-468 breast cancer xenograft models. The feasibility of using human 
tumour xenograft models for evaluating the efficacy of GSK1016790A as an anti-cancer drug lies in 
the fact that these models can provide predictive indications for the activity of the tested drugs in 
humans (383). However, it is noteworthy that inappropriate systemic activation of TRPV4 using 
GSK1016790A at 0.3 mg/kg in three species (mouse, rat and dog) leads to catastrophic circulatory 
collapse associated with endothelial failure (354). Despite the detrimental effect of GSK1016790A 
at a lethal dose of 0.3 mg/kg (354), another study on cholangiocytes in an animal model of 
polycystic kidney disease tested the effect of GSK1016790A on cyst growth using a sublethal dose 
of 0.01 mg/kg (362). The investigators found that at this lower dose, administration of 
GSK1016790A resulted in a significant decrease in kidney cystic areas and fibrosis (362). 
Importantly, no evidence of cardiac failure was reported at lower doses (362); thereby indicating 
that the use of GSK1016790A at a lower dose is feasible in animal studies.  
 
Future studies should also evaluate TRPV4 expression in a wider bank of breast cancer cell lines 
including those derived from normal breast tissue to elucidate if TRPV4 overexpression is a 
characterising feature of specific breast cancer subtypes. Assessment of TRPV4 expression in breast 
cancer clinical samples using microarrays (384,385) could also be employed to further determine if 
TRPV4 expression is associated with specific breast cancer subtypes and correlates with prognosis. 
Further analysis to define the underlying mechanism for TRPV4 mRNA overexpression in some 
breast cancers would also be valuable, as recently performed for TRPV6 channels (205). 
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5.5 Conclusion 
In summary, the results presented in this chapter showed for the first time that MDA-MB-468 cells 
highly express functional TRPV4 channels. This conclusion is derived from the following lines of 
evidence: 1. pharmacological activation of TRPV4 channels using GSK1016790A in MDA-MB-
468 cells produced sustained elevations of [Ca
2+
]CYT; 2. GSK1016790A-induced Ca
2+ 
influx was 
reduced in the presence of TRPV4 siRNA; and 3. TRPV4-mediated Ca
2+ 
influx induced cell death 
via a caspase-independent mechanism. Collectively, evidence from the present study supports the 
rationale for targeting TRPV4 activation to induce breast cancer cell death in cancers that 
overexpress TRPV4 channels.  
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CHAPTER 6 : Overall Discussion and Conclusions 
6.1 Summary 
Intracellular Ca
2+ 
regulates a diverse array of physiological processes in virtually all cell types, 
starting from the beginning of life at fertilisation until the end of cell life through apoptosis or 
necrosis (386). Unlike other second messenger molecules, Ca
2+ 
cannot be metabolised and thus, 
cells must maintain a homeostatic state of intracellular Ca
2+ 
level to ensure proper signalling 
function (28,387). This precise regulation of intracellular Ca
2+ 
level is achieved by the concerted 
actions of numerous signalling components collectively known as the Ca
2+ 
signalling toolkit, 
consisting of Ca
2+ 
channels, pumps, exchangers, Ca
2+ 
-binding proteins and regulators of their 
activity (28,29). Altered expression and/or activity of these Ca
2+ 
signalling components is 
increasingly recognised as a characterising feature of some cancers, including breast cancer 
(26,101,132). Moreover, proteins that modify Ca
2+ 
signalling have been proposed as prospective 
targets for breast cancer therapy. 
 
6.1.1 High throughput siRNA screening in conjunction with high content imaging allows for 
the identification of Ca
2+ 
signalling modifying proteins as potential therapeutic targets for 
breast cancer  
The major aim of this thesis was to utilise high throughput siRNA screening in combination with 
high content imaging to screen for Ca
2+ 
signalling modifying proteins with therapeutic potential for 
basal-like breast cancers. The findings presented in this thesis suggest that a combined approach of 
high throughput siRNA screening and high content imaging is suitable for facilitating the 
identification of new drug targets for breast cancer. From the screen, a total of 39 genes were 
classified as putative hits with profound effects on human MDA-MB-231 breast cancer cells 
relative to non-malignant human MCF-10A cells. These putative hits were then condensed to eight 
candidate genes and later finalised into three candidate genes (namely CD24, TRPC1 and TRPV4), 
two of which were assessed in this thesis (CD24 and TRPV4). Using MDA-MB-231 and MDA-
MB-468 basal-like breast cancer cell lines as study models, the present study found that mRNA for 
all three candidate genes was present in both basal-like breast cancer cell lines, although at different 
levels. Quantitative assessment of mRNA levels showed that both CD24 and TRPV4 were enriched 
in MDA-MB-468 cells while TRPC1 was significantly upregulated in MDA-MB-231 cells. These 
initial data provided a basis for pursuing these candidate genes for further functional 
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characterisation in basal-like breast cancer cell lines, with an emphasis on their possible role in Ca
2+ 
signalling and cancer-related pathways. 
 
The second major aim of this thesis involved the functional assessment of specific targets identified 
from the siRNA screen. Chapter Three of this thesis assessed CD24, a negative regulator of 
CXCL12 signalling in basal breast cancer cells. CD24-siRNA mediated silencing had no effect on 
CXCL12/CXCR4-mediated Ca
2+ 
signalling in basal-like breast cancer cells. However, recent 
studies now provide some evidence for the therapeutic potential of CD24 in HER2-positive breast 
cancers (388) which could be explored in future studies involving Ca
2+ 
signalling. Chapters Four 
and Five present results of the characterisation of TRPV4 in both MDA-MB-231 and MDA-MB-
468 basal-like breast cancer cells which became the focus of this research. 
 
6.1.2 Pharmacological targeting of TRPV4 offers potential therapeutic strategy for breast 
cancer treatment 
The results from this thesis showed for the first time that TRPV4 channels are differentially 
expressed in MDA-MB-231 and MDA-MB-468 basal-like breast cancer cell lines, as determined 
quantitatively using the real-time RT-PCR. TRPV4 mRNA levels were found to be higher in MDA-
MB-468 cells compared to MDA-MB-231 cells. The main findings of this functional 
characterisation using the TRPV4 activator GSK1016790A are summarised in Table 6.1. 
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Table ‎6.1: Summary of the characterisation of TRPV4 channels in MDA-MB-468 and MDA-MB-
231 basal-like breast cancer cell lines. 
 MDA-MB-468 MDA-MB-231 
TRPV4 mRNA levels High Low 
GSK1016790A-induced Ca
2+ 
influx 
High Low 
GSK1016790A concentration-
response curve 
EC50 = 3.9 nM EC50 = 76 nM 
Effect of TRPV4 siRNA on Ca
2+ 
signalling 
Decreased Ca
2+ 
influx 
induced by GSK1016790A 
Decreased Ca
2+ 
influx 
induced by GSK1016790A 
GSK1016790A and cell death Induction of cell death No effect 
Mechanism of cell death Caspase-independent Not applicable 
Effect of TRPV4 siRNA on 
GSK1016790A-induced cell 
death 
Attenuation of cell death Not applicable 
 
Basal-like breast cancers are associated with poor prognosis (11) and currently, there are no long 
term molecularly targeted therapies available for this specific breast cancer subtype, with current 
therapy involving standard chemotherapy regimens (13). Evidence from the present study where 
TRPV4 pharmacological activation using GSK1016790A leads to a caspase-independent cell death 
in MDA-MB-468 cells with high levels of TRPV4 is significant, as this suggests that TRPV4 may 
be a promising drug target for the treatment of basal-like breast cancers overexpressing TRPV4 
channels. This work adds breast cancer to several other diseases such as inflammatory bowel 
disease, neuropathic pain, obesity and type 2 diabetes (389-391) where pharmacological targeting of 
TRPV4 holds therapeutic promise.  
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6.1.3 Conclusions 
Collectively, the findings presented throughout this thesis lead to the following conclusions: 
 Combination of high throughput siRNA screening and high content imaging is a suitable 
research tool for identifying novel and new potential drug candidates for breast cancer 
therapy; however, it is crucial to validate potential hits before performing detailed 
characterisation studies. 
 CXCL12, a natural ligand for the CXCR4 receptor, induces greater Ca2+ responses in more 
metastatic MDA-MB-231 cells compared to less metastatic MDA-MB-468 cells. 
 Differences between MDA-MB-231 and MDA-MB-468 cells in CXCL12-mediated Ca2+ 
responses is unrelated to greater mRNA levels of CD24 (a negative regulator of CXCR4) in 
MDA-MB-468 breast cancer cells, but may be related to higher levels of CXCR4 in MDA-
MB-231 cells. 
 TRPV4 is differentially expressed in MDA-MB-231 and MDA-MB-468 cells with higher 
mRNA TRPV4 levels in MDA-MB-468 cells and augmented Ca
2+ 
responses to the TRPV4 
activator GSK1016790A. 
 TRPV4 siRNA-mediated silencing reduced GSK1016790A-induced Ca2+ influx in both 
MDA-MB-231 and MDA-MB-468 cells, indicating that TRPV4-mediated Ca
2+ 
influx is a 
feature of some basal-like breast cancer cells. 
 Pharmacological activation of TRPV4 using GSK1016790A significantly reduced cell 
viability and induced caspase-independent cell death in MDA-MB-468 cells. These findings 
suggest that breast cancers overexpressing TRPV4 channels may be therapeutically targeted 
using TRPV4 activators. 
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6.1.4 Future research directions 
Although these studies suggest that TRPV4 may be a therapeutic target in some breast cancers, 
further work is still required. Key future experiments to gain insight into the potential for TRPV4 as 
a therapeutic target in breast cancer include the examination of TRPV4 mRNA and protein in breast 
(cancer and non-cancer derived) cell lines and in clinical breast cancer samples and also the 
identification of the TRPV4 splice variants expressed in breast cancer cells. Further work should 
also assess the ability of TRPV4 activation to induce MDA-MB-468 breast cancer cell death in 
vivo. The ability of TRPV4 activators to promote the sensitivity of breast cancer cells to agents 
whose efficacy is promoted by the TRPV2 agonist cannabidiol in glioblastoma cells (392), such as 
temozolomide, carmustine and doxorubicin should also be assessed. Moreover, given that TRPV4 
activation has been shown to inhibit the migration of GN11 neuroendocrine cells (393) but enhance 
the migration of pulmonary arterial smooth muscle cells (363), future studies should also 
characterise the possible role of TRPV4 in the migration and invasion of basal-like breast cancer 
cells.  
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8.0 Appendix 
8.1 Appendix I: Chemicals 
Chemical Catalogue number Supplier 
96-well CellBIND (FLIPR) 
plates 
3340 Corning 
96-well clear, round-bottom 
(FLIPR) reagent plates 
3797 Corning 
96-well FLIPR
 
Tetra black, 
non-sterile pipette tips 
9000-0762 Molecular Devices 
96-well imaging 
(ImageXpress) plates 
353219 BD Biosciences 
ABT-263 S1001 Selleckchem 
Adenosine 5’-triphosphate 
(ATP) disodium salt hydrate 
A6419 Sigma-Aldrich 
Bovine serum albumin 
(BSA), essentially fatty acid 
free (for FLIPR) 
A3803 Sigma-Aldrich 
CaCl2 (2H2O) C7902 Sigma-Aldrich 
CellTiter 96
®
 AQueous One 
Solution Cell Proliferation 
Assay (MTS) 
G3580 Promega 
DharmaFECT 4 transfection 
reagent 
T-2004-01 
Dharmacon RNAi 
Technologies 
Dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
D6546 Sigma-Aldrich 
Epidermal growth factor 
(EGF) 
E9644 Sigma-Aldrich 
Ethylenediamine tetraacetic 
acid (EDTA) 
431788 Sigma-Aldrich 
Fetal bovine serum (FBS) 12003C Sigma-Aldrich 
Fluo-4 AM F14201 Invitrogen (now Life 
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Technologies) 
Glucose powder G7021 Sigma-Aldrich 
GSK1016790A G0798 Sigma-Aldrich 
HEPES H3375 Sigma-Aldrich 
Hoechst 33342  H3570 
Invitrogen (now Life 
Technologies) 
KCl P5405 Sigma-Aldrich 
L-glutamine 25030 
Invitrogen (now Life 
Technologies) 
MgCl2 M8266 Sigma-Aldrich 
MycoAlert Mycoplasma 
detection kit 
LT07-218 Lonza 
NaCl S5886 Sigma-Aldrich 
NaH2PO4 S5011 Sigma-Aldrich 
NaHCO3 S5761 Sigma-Aldrich 
Omniscript RT Kit 205113 Qiagen 
PBX Ca
2+ 
Assay Kit 640175 BD Biosciences 
Phosphate buffered saline 
(PBS), packaged in foil 
pouches 
P3813 Sigma-Aldrich 
Penicillin-streptomycin 
solution 
15140 
Invitrogen (now Life 
Technologies) 
Probenecid P8761 Sigma-Aldrich 
Propidium iodide P3566 
Invitrogen (now Life 
Technologies) 
Random primers C1181 Promega 
Recombinant human 
CXCL12 
350-NS-010 R&D Systems 
RN 1734 3746 Tocris Bioscience 
RNase inhibitor N2511 (previously N2111) Promega 
RNeasy
®
 Plus Mini Kit 74104 Qiagen 
siRNA buffer (5X) B-002000-UB 
Dharmacon RNAi 
Technologies 
158 
 
Taqman Universal PCR 
Master Mix 
4324018 
Applied Biosystems (now 
Life Technologies) 
Z-VAD-FMK ALX-260-020-M001 Enzo Life Sciences 
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8.2 Appendix II: Applied Biosystems TaqMan Gene Expression Assays 
Gene symbol Assay ID 
CACNA1C Hs00167681_m1 
CACNA1H Hs00234934_m1 
CD24 Hs02379687_s1 
CXCR4 Hs00237052_m1 
TACR1 Hs00185530_m1 
TREML1 Hs00698316_m1 
TRPC1 Hs00608195_m1 
TRPM3 Hs00257553_m1 
TRPV4 Hs01099348_m1 
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8.3 Appendix III: Dharmacon ON-TARGET plus SMARTpool siRNAs 
Gene Catalog number 
Non-targeting D-001810-10-05 
CD24 L-187156-00-0005 
TRPV4 L-004195-00-0005 
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8.4 Appendix IV: Suppliers and Distributors 
 
Applied Biosystems (now Life Technologies) 
30-32 Compark Circuit, Mulgrave 
Victoria 3170 
Australia 
 
BD Biosciences 
4 Research Park Drive 
Macquarie University Research Park 
North Ryde 
New South Wales 2113 
Australia 
 
Bio-Rad Laboratories  
446 Victoria Road 
Gladesville  
New South Wales 2111 
Australia 
 
Bio-Scientific Pty. Ltd. (Australian distributor for R&D Systems and Tocris Bioscience) 
PO Box 78 
Gymea  
New South Wales 2227 
Australia 
 
Bio-Strategy Pty. Ltd. (Australian distributor for Molecular Devices Corporation) 
PO Box 498, 
Balwyn North, 
Victoria 3104 
Australia 
 
Cryosite (Australian distributor for American Type Culture Collection (ATCC)) 
13a Ferndell Street 
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South Granville 
New South Wales 2142 
Australia 
 
Invitrogen (now Life Technologies) 
30-32 Compark Circuit, Mulgrave 
Victoria 3170 
Australia 
 
Life Research Pty. Ltd. (Australian distributor for Selleckchem) 
1b Dalmore Drive 
Caribbean Park, 
Scoresby, Victoria 3179 
Australia 
 
Lonza Australia Pty. Ltd. 
2
nd 
Floor, 541 Blackburn Road 
Mt Waverley, Victoria 3149 
Australia 
 
Millennium Science Pty. Ltd. (Australian distributor for Dharmacon RNAi 
Technologies)  
Unit 2/390 Canterbury Road 
Surrey Hills 
Victoria 3127 
Australia 
 
Promega 
Suite W3A, Level 3, Westside Building 
South Sydney Corporate Park 
75-85 O’Riordan Street 
(PO Box 7417) 
Alexandria, New South Wales 2015 
Australia 
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Qiagen Pty. Ltd. 
PO Box 169 
Chadstone Centre  
Victoria 3148 
Australia 
 
Sapphire Bioscience Pty. Ltd. (Australian distributor for Enzo Life Sciences) 
126 Cope Street 
Waterloo 
New South Wales 2017 
Australia 
 
Sigma-Aldrich (Australian distributor for Corning) 
PO Box 970 
Castle Hill 
New South Wales 1765 
Australia 
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8.5 Appendix V: Recipes for buffers and solutions 
Cell culture buffers and solutions: 
Freezing media 
 FBS (5 mL) 
 DMEM (4 mL) 
 DMSO (1 mL) 
PBS 
One pouch of PBS powder dissolved in 
deionised water (1 L) to yield 0.01 M PBS and 
autoclaved 
* According to the product specification sheet 
from Sigma-Aldrich, one pouch of PBS powder 
(P3813) when dissolved in 1 L of deionised 
water will yield 0.01 M PBS. The composition 
of this PBS solution contains 0.138 M NaCl 
and 0.0027 M KCl. 
PBS EDTA, pH 7.4 
 0.01 M PBS (1 L) 
 EDTA (0.2 g) 
 Adjust pH to 7.4 and autoclaved 
 Store at room temperature 
10 mM acetic acid solution 
 Glacial acetic acid (5.7 µL) 
 Sterile distilled water (10 mL) 
 Filter-sterilised 
 Store at room temperature 
1 mM EGF stock solution 
 10 mM acetic acid solution (200 µL) 
 EGF (0.2 mg) 
 Store at -20°C in 4 µL aliquots 
 Avoid repeated freeze-thawing 
 
FLIPR
TETRA
 buffers and solutions: 
2 M CaCl2 solution 
 Weigh 11.76 g CaCl2 (2H2O) powder 
 Bring up the volume to 40 mL with 
deionised water 
 Store at 4°C 
HEPES stock (10X) For 500 mL: 
165 
 
 KCl powder (2.199 g) 
 1 M MgCl2 solution (7 mL) 
 HEPES powder (11.915 g) 
 1 M NaH2PO4 solution (6 mL) 
 NaHCO3 powder (2.1005 g) 
 Bring up the volume to 500 mL with 
deionised water 
 Filter-sterilised 
 Store at 4°C 
Physiological salt solution (PSS), with 1.8 mM 
Ca
2+
, pH 7.2 
For 500 mL: 
 Add 50 mL of HEPES stock (10X) 
 NaCl powder (4.0908 g) 
 Glucose powder (1.03619 g) 
 2 M CaCl2 solution (0.45 mL) 
 Make up the volume to 450 mL with 
deionised water and adjust pH to 7.2 
with either HCl or NaOH 
 Bring up the final volume to 500 mL 
with deionised water 
 Store at 4°C 
PSS BSA, pH 7.2 
For 50 mL of PSS with 1.8 mM Ca
2+ 
(pH 7.2), 
add 0.15 g of fatty-acid free BSA on the day of 
FLIPR 
 
 
